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1 Table of Abbreviations 
 
Abbrevation Meaning 
% Percent 
°C Degrees celcius 
µCT Micro computed tomography 
AB Aortic banding 
ABCC6 ATP-binding cassette sub-family C member 6 
ACE Angiotensin-converting enzyme 
ActR Activin type receptors 
ALK Activin receptor-like kinase 
ANF/ANP Atrial natriuretic peptide 
ANG Angiopoietin 
APJ/ APLNR Apelin receptor 
APLN Apelin 
A-V Arterial-venous 
AVM Arteriovenous malformation 
BAC Bacterial artificial chromosome 
BF Blood flow 
BMP Bone morphogenetic proteins 
BMPR Bone morphogenetic protein receptor 
BNP Brain natriuretic peptide 
BP Blood pressure 
BSA Bovine serum albumin 
BV Blood velocity 
cAMP Cyclic adenosine monophosphate 
CCV Common cardinal vein 
cDNA Complementary DNA 
ChIP Chromatin immunoprecipitation 
cKO Conditional single knockout 
cm Centimetre 
CM Cardiomyocyte 
Co-SMAD Co-mediated SMAD 
cT Cycle threshold 
CVD Cardiovascular disease 
Cy2 Carbocyanin 
Cy3 Indocarbocyanin 
DA Dorsal aorta 
DAG Diacylglycerol 
DAPI 4',6-diamidino-2-phenylindole 
ddH2O Double distilled water 
DEPC Diethylpyrocarbonate 
DKO Double knockout 
Dll Delta-like 
DMEM Dulbecco’s modified Eagle's medium 
DNA Deoxyribonucleic acid 
dNTP Deoxyribonucleotides 
DTA Diphtheria toxin A 
DTT Dithiothreitol 
E Embryonic day 
EC Endothelial cell 
ECM Extracellular matrix 
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EDN-1 Endothelin-1 
EDTA Ethylenediaminetetraacetic acid 
EdU 5-ethynyl-2´-deoxyuridine 
EDV End diastolic volume 
EF Ejection fraction 
EFN Ephrin 
EGTA Ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid 
ELA Elabela 
ENG Endoglin 
eNOS Endothelial nitric oxide synthase 
ERK Extracellular-regulated kinases 
ESC Embryonic stem cell 
ESV End systolic volume 
EtOH Ethanol 
FBS Fetal bovine serum 
FCS Fetal calf serum 
FGF Fibroblast growth factor 
FIH Factor inhibiting HIF 
FLK Fetal liver kinase 
FRT Short flippase recognition target sites 
g Gram 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
GDF Growth differentiation factor 
GDP Guanosine diphosphate 
GI Gastrointestinal   
Gi Inhibitory G protein  
GOF Gain of function 
GPCR G-protein coupled receptor 
GSEA Gene Set Enrichment Analysis 
GTP Guanosine-5'-triphosphate 
h Hour 
H&E Hematoxylin and eosin staining 
Hb Hemoglobin 
HB-EGF Heparin-binding egf-like growth factor 
HBSS Hank's balanced salt solution 
HCL Hydrochloric acid 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HF Heart failure 
HGF Hepatocyte growth factor 
HHT Hereditary haemorrhagic telangiectasia 
HIF Hypoxia-inducible factor 
HMVEC-d Human dermal microvascular endothelial cell 
HR Heart rate 
HRP Horse-radish-peroxidase 
HUVEC Human umbilical vein endothelial cell 
i.p Intraperitoneal 
IP3 Inositol 1, 4, 5-triphosphate 
i-SMAD Inhibitory SMAD 
JAG Jagged 
JNK c-jun N-terminal kinase 
JP Juvenile polyposis 
KD Knock down 
KLF Kruppel-like factor 
KO Knockout 
L Litre 
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LAD Left anterior descending artery 
L-NAME NG-nitro-L-arginine methyl ester 
LOS Loss of function 
loxP Locus of cross-over (x) of the bacteriophage P1 
LVM Left ventricular mass 
M Molar 
MAPK Mitogen-activated protein kinase 
MCP Monocyte chemoattractant protein 
MEF Myocyte enhancer factor 
MES 2-(N-morpholino)ethanesulfonic acid 
mg Milligram 
MHz Megahertz 
MI Myocardial infarction 
min Minute 
mL Millilitre 
mM Millimolar 
mm Millimetre 
mmHg Millimetre of mercury 
MMP Matrix metalloproteinases 
MRI Magnetic resonance imaging 
mSMC Mouse smooth muscle cell 
mT/m Millitesla per meter 
neg Negative 
ng Nanogram 
nm Manometers 
NO Nitric oxide 
NOS Nitric oxide synthase 
NRP Neuropilin 
O/N Overnight 
O2 Oxygen 
P Postnatal day 
P/S Penicillin/ streptomycin 
PA Plasminogen activator 
PAH Pulmonary arterial hypertension 
PAI Plasminogen activator inhibitor 
PBS Phosphate-buffered saline 
PCA Phase contrast angiography 
PCR Polymerase chain reaction 
PDGF Platelet-derived growth factor 
PECAM Platelet-endothelial cell adhesion molecule 
PFA Paraformaldehyde 
PH Pulmonary hypertension 
PHD Prolyl Hydroxylase Domain 
PI3K Phosphatidylinositol 3’-kinase 
PKC Protein kinase C 
PLC Phospholipase C 
PlGF Placental Growth Factor 
pos Positive 
PP Pulse pressure 
PTX Pertussis toxin 
PXE Pseudoxanthoma elasticum 
qRT-PCR Quantitative reverse transcription PCR 
RNA Ribonucleic acid 
R-SMAD Receptor-regulated SMAD 
rSMC Rat smooth muscles cell 
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RT Room temperature 
RV Right ventricle 
RVH Right ventricle hypertrophy 
s Seconds 
SC Stem cell 
SDS Sodium dodecyl sulfate 
SDS-PAGE Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
shRNA Short hairpin RNA 
SKO Single knockout 
SMA Smooth muscle actin 
SMAD Mothers against DPP homolog 
SMC Smooth muscle cell 
SMURF Smad-mediated ubiquitin regulatory factor 
STAT Signal Transducer And Activator Of Transcription 
SV Stroke volume 
T Tesla 
TAC Thoracic aortic constriction 
TBST Tris buffered saline / tween-20 
TE Tris-EDTA 
TEM Transmission electron microscope 
TEMED Tetramethylethylenediamine 
TGF  Transforming growth factor 
TIE TEK receptor tyrosine kinase 
TIMP Tissue inhibitors of metalloproteinase 
TKO Triple knockout 
TMX Tamoxifen 
TOF Time of flight 
V Volts 
VE Vascular endothelial 
VEGF Vascular endothelial growth factor 
vSMC Vascular smooth muscle cell 
WT Wild type 
x g Times gravity 
ZFN Zinc-finger nuclease 
αSMA Alpha smooth muscle actin 
μg Microgram 
μl Microliter 
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4 Summary 
 
 Bone Morphogenetic Proteins (BMPs) are members of the well-known Transforming 
Growth Factor (TGF) superfamily, consisting of TGFβ proteins, Activins and Growth 
Differentiation Factors (GDFs). These factors play an essential role in numerous different 
aspects of embryonic development and physiological organ function. BMP9 and BMP10 are 
members of this superfamily; however their role, especially in the cardiovascular system, is 
still poorly characterised. 
BMP9 is produced by and is secreted from the liver and is proposed to act as a major 
circulating vascular quiescence factor. BMP10, however, has a more limited expression 
where it is expressed during embryonic development in the ventricles from embryonic day 
(E) 9.0 to 13.5. After E14.5, expression of BMP10 declines in the ventricles, but is 
maintained in the right atria of postnatal and adult hearts. BMP9 and BMP10 bind with high 
affinity to ALK1, an endothelial specific receptor as well as to endoglin (ENG), a TGFβ  
co-receptor.  
Since both of these ligands bind with very high affinity to the ALK1 receptor and 
soluble ENG receptor, it was suggested that BMP9 and BMP10 are important mediators of 
cardiovascular development and homeostasis. So far it has been shown that mutations in 
ALK1, ENG and SMAD4 genes can result in hereditary haemorrhagic telangiectasias (HHT), 
which is a disease that results in vascular abnormalities. BMP10 along with ENG has been 
shown to be involved in pre-eclampsia, a disease resulting in high blood pressure (BP), thus 
strengthening the argument that these BMP family members are involved in cardiovascular 
homeostasis.  
The aim of this project was to elucidate the role of BMP9 and BMP10 in the adult heart 
and their role in cardiovascular homeostasis. Constitutive BMP9 knockout mice were 
generated, with a conditional heart-specific BMP10 deletion under the control of ANF Cre. 
Results demonstrated that the loss of BMP9 and BMP10 leads to vessel defects which 
caused disruption in vascular tone and altered cardiac function. In summary, these results 
have identified an essential role for BMP9 and BMP10 in postnatal cardiac remodelling and 
vascular homeostasis. 
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5 Zusammenfassung 
 
Die knochenmorphogenetischen Proteine (engl.: bone morphogenic proteins, BMPs) 
sind Bestandteil der intensiv erforschten TGF-β Superfamilie (engl.: Transforming Growth 
Factor), hierzu zählen TGF-β Proteine, Activine, Wachstums- und Differenzierungsgene 
(engl.: Growth and differentiation factors, GDFs). Diese Proteine spielen eine essenzielle 
Rolle in zahlreichen Aspekten der Embryonalentwicklung und in physiologischen 
Organfunktionen. BMP9 und BMP10 sind Teil dieser Familie, deren Rolle im 
kardiovaskulären System weitgehend unbekannt. 
BMP9 wird in der Leber produziert und über das Blut im Organismus verteilt, wo es als 
zirkulierender Faktor an der vaskulären Ruhe beteiligt ist. Im Vergleich dazu ist die 
Expression von BMP10 strenger reguliert. Während der Embryonalentwicklung wird BMP10 
ab Tag 9 (E9) in den Ventrikeln exprimiert. Ab E14.5 verlagert sich die Expression in die 
Atrien, wobei BMP10 im adulten Organismus nur noch im rechten Atrium exprimiert wird. 
BMP9 und BMP10 binden mit hoher Affinität an ALK1, einem endothelspezifischen 
Rezeptor, als auch an Endoglin (ENG), einem TGF-β-Korezeptor. Diese gemeinsamen 
Bindeeigenschaften sind ein Anzeichen dafür, dass BMP9 und BMP10 wichtige Mediatoren 
der kardiovaskulären Entwicklung als auch der vaskulären Homöostase sind. Bisher konnte 
gezeigt werden, dass Mutationen in den Genen für ALK1, ENG bzw. Smad4 verantwortlich 
für die Entstehung der sogenannten hereditären hämorrhagischen Teleangiektasie (HHT) 
sein können, eine Krankheit, die durch eine Erweiterung des Gefäßsystems gekennzeichnet 
ist. Des weiteren wurde gezeigt, dass BMP10, zusammen mit ENG, an der Entstehung der 
Präeklampsie beteiligt ist, was noch einmal zusätzlich darauf hindeutet, dass BMP9 und 
BMP10 in der vaskulären Homöostase involviert sind. 
Das Ziel dieses Projektes ist es, die Rolle von BMP9 und BMP10 im adulten Herzen 
und deren Funktion in der vaskulären Homöostase näher zu untersuchen und besser zu 
verstehen. Dazu wurde eine konstitutive BMP9-Knockoutmaus generiert, in welcher BMP10 
mittels einer konditionellen Cre-Rekombinase herzspezifisch (ANF-Cre) deletiert werden 
kann. Unsere Versuche zeigten, dass der Verlust von BMP9 und BMP10 zu 
Gefäßveränderungen führt, welche die vaskuläre Homöostase negativ beeinflussen und die 
Herzfunktion beeinträchtigen. Darüber hinaus konnte gezeigt werden, dass BMP9 und 
BMP10 eine essentielle Funktion im postnatalen Herzumbau und der vaskulären 
Homöostase haben. 
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6 Introduction  
 
 To this day, cardiovascular disease (CVD) is still the most common cause of death, 
with approximately 15.6 million people affected worldwide 1. Even though over the last two 
years previous statistics and publications have shown a decrease in CVD mortality 2,3, more 
than 4 million Europeans still die annually as a result of CVD. Although CVD is the most 
prominent killer worldwide, treatment of these diseases is lacking and current treatments 
only delay the onset of CVD rather than curing or reversing its affects. Obviously, further 
intensive research in this area is critical 4. CVDs cover a range of heart conditions from 
blood vessel diseases like  coronary artery disease; heart rhythm problems, also known as 
arrhythmias; and heart defects from birth (congenital heart defects), to name but a few 5. 
With such a wide range of differing diseases, herein lies the problem and difficulty of finding 
specific biomarkers as well as preventing and treating each individual condition. Ultimately, 
any untreated CVD will result in death simply due to the fact that, in the end stages, the flow 
of blood to or away from the heart is blocked or hindered resulting in insufficient oxygen 
availability whereby the cardiac tissue will begin to die and all cardiac function will be lost. 
The fact that it is very difficult to treat CVD long term or to cure these conditions due to the 
hearts inability to repair or regenerate itself, it is essential to focus on improving diagnosis 
and early detection methods to combat against further cardiac deterioration, which is 
characteristic of CVD.  
 Throughout my thesis I will outline the role of two understudied proteins, BMP9 and 
BMP10, and their function in maintaining vascular homeostasis and therefore in turn, cardiac 
function. These proteins could have the potential to be used therapeutically as well as being 
possible biomarkers for cardiac dysfunction.  
 
6.1 Outline of cardiovascular diseases, their causes and current 
therapies 
 There are many different types of heart disease that are covered by the term CVD as 
shown in Table 1. They result from electrical problems, such as arrhythmias, or problems 
with the heart structure itself including cardiomyopathies and congenital heart defects. 
Additionally, many of these diseases result from disruption to the circulatory system, where 
vascular homeostasis is essential for normal cardiac function, as is the case with elevated 
BP or coronary artery disease.  
  Introduction        
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 As seen in Table 1, many of these CVDs can only be treated by either alleviating the 
condition, via medication or changes in lifestyle, or by assisting the heart, via implantable 
devices, but never curing or removing the primary defect. Due to the fact that most CVD 
mechanisms are unknown and that the symptoms are detected when irreversible damage 
already exists, it is therefore essential to fully understand the underlying mechanisms 
involved to be able to fully reverse or cure these diseases, as well as establishing early 
detection methods to act as a preventive measure. As mentioned previously, all CVDs will 
eventually lead to heart failure (HF) and sudden death, whereby the heart loses its ability to 
pump blood and ceases to function. The consequence of CVD is the loss and death of 
cardiomyocytes (CMs) 4. Loss of CMs due to a myocardial infarction (MI) results in a 
decrease in the overall function of the heart. As CMs cannot replace themselves 6, there is 
an invasion of immune cells accompanied by myofibroblasts, which causes scar formation 
further impairing the hearts ability to pump 7. Over the past decade many different groups 
have focused on CMs and their proliferative capacity 8, cardiac stem cell therapy 4, reduction 
of scar formation and survival of CMs in damaged areas 7 and the importance of the 
epicardium in cardiac repair 9. Current focus is based not only on cardiac repair but also on 
the possibility of cardiac regeneration, where the heart can return back to its normal, full 
function. However, none of these treatments will be of significant benefit or even possible 
unless vascular homeostasis is maintained. If this is not the case the heart will again be put 
under huge strain, cardiac function will again diminish over time leading to severe cardiac 
disease 9. In the following section the development, maintenance and function of the 
vascular system as well as its significance and role in CVD development, and its prevention 
and treatment of such diseases will be discussed.  
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Table 1:  Cardiovascular diseases and description 
 
Condition Damage Caused by Treatment 
Rheumatic Heart Disease (results from attacks of rheumatic fever which causes damage to the heart, particularly the heart valves) 
Rheumatic Heart Disease Heart valves Streptococcal bacteria Surgical replacement of damaged 
valves 
Stenosis Narrow valves Birth defect, rheumatic fever, 
medication 
Valvuloplasty, surgical replacement 
 
Regurgitation Leaky valves Birth defect, rheumatic fever, 
medication 
Intra-aortic balloon pump, surgical 
replacement 
 
Prolapse Valves won't close properly Birth defect, rheumatic fever, 
medication 
Medication, surgical replacement in 
extreme cases 
 
Hypertensive Heart Disease (result of high BP that strains the heart and blood vessels) 
Aneurysm Bulge in blood vessel wall, can grow 
and rupture 
Hypertension, Atherosclerosis Graft is added to strengthen wall, 
surgical removal 
 
Atherosclerosis Artery walls become thick and stiff 
due to fatty deposits (plaques) which 
restricts BF 
High BP, high cholesterol, smoking Healthy lifestyle, medication, surgical 
removal, 
angioplasty and stent placement 
High BP (hypertension) Excessive force of blood pumping 
through your blood vessels 
Smoking, weight, high salt diet, 
stress, age, genetics, kidney disease, 
thyroid disorders 
Healthy lifestyle, medication 
Peripheral arterial disease (PAD) Narrowing and / or blockage of the 
blood vessels in the legs 
High BP, high cholesterol, high sugar 
intake, smoking 
Healthy lifestyle, medication, surgical 
removal, angioplasty and stent 
placement 
Ischemic Heart Disease (result due to narrowing of coronary arteries which decreases blood supply to the heart) 
Angina Reduced blood supply to the heart Atherosclerosis, coronary heart 
disease 
Healthy lifestyle, medication, 
angioplasty, coronary artery bypass 
grafting 
Atherosclerosis Artery walls become thick and stiff 
due to fatty deposits (plaques) which 
restricts BF 
High BP, high cholesterol, smoking Healthy lifestyle, medication, surgical 
removal, 
angioplasty and stent placement 
Coronary artery disease Narrowing/blockage of blood vessels 
that supply heart 
High BP, high cholesterol, high sugar 
intake, smoking, blood vessel 
inflammation 
Healthy lifestyle, medication, 
angioplasty, coronary artery bypass 
grafting 
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Condition Damage Caused by Treatment 
Coronary heart disease Disease of the arteries to the heart High BP, high cholesterol, high sugar 
intake, smoking, blood vessel 
inflammation 
Healthy lifestyle, medication, 
angioplasty, coronary artery bypass 
grafting 
Heart attack (MI) Heart’s supply of blood is stopped Coronary heart disease, 
atherosclerosis 
Healthy lifestyle, medication, 
coronary artery bypass grafting 
Sudden death (cardiac arrest) Abrupt loss of the heart's ability to 
pump blood 
Heart attack, abnormal heart rhythm None 
 
Cerebrovascular Heart Disease (result of vascular problems, usually impeded blood supply, within the brain) 
Atherosclerosis Artery walls become thick and stiff 
due to fatty deposits that restricts BF 
High BP, high cholesterol, smoking Healthy lifestyle, medication, surgical 
removal, angioplasty, stents 
Cerebral vascular disease Effects BF to vessels in the brain Atherosclerosis Healthy lifestyle, medication, carotid 
stent placement 
Stroke When BF to the brain the hindered or 
reduced 
Atherosclerosis, atrial fibrillation, 
coronary artery disease 
Healthy lifestyle, medication, 
angioplasty, arteriovenous 
malformation repair, surgery 
Transient ischemic attacks Due to a temporary blot clot or small 
amount of haemorrhaging 
Vascular injury, age, smoking, 
diabetes, high cholesterol, atrial 
fibrillation 
Healthy lifestyle, medication, surgery 
Inflammatory Heart Disease (due to inflammation within the different layers of the heart tissue) 
Atherosclerosis Artery walls become thick and stiff 
due to fatty deposits (plaques) which 
restricts BF 
High BP, high cholesterol, smoking Healthy lifestyle, medication, surgical 
removal, 
angioplasty and stent placement 
Idiopathic dilated cardiomyopathy Heart enlargement and dilation 
(thinning) of ventricle walls 
Unknown Healthy lifestyle, medication, heart 
transplant 
10
 
Ischemic dilated cardiomyopathy Heart enlargement, weakening and 
dilation (thinning) of ventricle walls 
Coronary artery disease, heart 
attack, mainly due to lack of blood 
supply 
Healthy lifestyle, medication, 
implantable devices, angioplasty, 
stents, bypass surgery, transplant 
Dilated cardiomyopathy Decreased ability to pump blood and 
the left ventricle (LV) becomes 
enlarged and weakened 
Coronary heart disease, heart attack, 
high BP, diabetes, thyroid disease, 
infections 
Medication, implantable devices, 
transplant 
Hypertrophic cardiomyopathy Thickening of the heart muscle, 
making it difficult for the heart to 
pump blood 
Genetic, secondary effect due to BF 
impediment 
Medication, surgery, implantable 
devices 
 
Pericardial disease Abnormal amount of blood between 
the heart and the sac surrounding the 
heart, the pericardium 
Viral infections, autoimmune 
disorder, heart attack 
Medication, removal of excess fluid, 
removal of pericardium 
  Introduction        
16 
 
Condition Damage Caused by Treatment 
Arrhythmias (results from problems in the electrical system of the heart) 
Bradyarrythmia When the HR is too slow and not 
enough blood is being circulated 
Heart attack, underactive thyroid, 
chemical imbalance that effects the 
electrical system 
Medication, pacemaker, surgery 
Tachyarrhythmia (tachycardia) When the HR exceeds the normal 
resting rate, problems with electrical 
connections 
Heart attack, high BP, coronary heart 
disease, HF, rheumatic heart disease 
Medication, pacemaker, surgery 
Atrial Fibrillation An irregular HR that leads to atrial 
contraction that is too fast and 
irregular 
High BP, coronary heart disease, 
age, inflammation 
Medication, pacemaker, 
Ventricular Fibrillation Disorganized electrical signals that 
make the ventricles quiver instead of 
pump blood 
Heart attack Defibrillation 
Other 
Congenital heart disease Defects with the heart's structure 
from birth 
Genetic, smoking during pregnancy, 
most reasons unknown 
Surgery 
Heart failure Heart's inability to pump enough 
blood for the whole body 
Coronary heart disease, diabetes, 
high BP, other heart diseases, 
alcohol abuse 
Healthy lifestyle, medication, surgery, 
implantable devices, transplant 
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6.2 The network and function of the cardiovascular system 
 In the vertebrate, the cardiovascular system is a closed system that is comprised of 
the heart, blood and blood vessels. This system is the first organ to function during 
embryogenesis, with numerous vital functions that are needed for embryogenesis and 
postnatal survival. The cardiovascular system is used to transport oxygenated blood 
throughout the whole organism along with essential metabolites and nutrients for normal 
cellular function and is also important for removal of waste products. Furthermore, the 
system facilitates hormonal communications between distant organs and also allows for the 
development of the organisms immune response. For a fully functioning closed circulatory 
system, that continually re-circulates blood to and from peripheral tissues, a system with two 
distinct networks is needed. Although these two vascular networks are separate from each 
other in structure and function they need to be interconnected and interlaced with each other 
to be to fully operational. Arteries, veins and capillaries are the blood vessel structures that 
make up this very complex system and differ in structure to deal with the different pressure 
systems and functions involved as shown in Table 2.  
Table 2: Comparison of arteries, capillaries and veins 
 
 Artery Capillary Vein 
Function Carry blood away from 
the heart 
Delivers needed 
products and removes 
waste products 
Carry blood to the 
heart 
Wall structure Thick, strong with 
muscles, elastic fibres 
and fibrous tissue 
Thin, only one cell thick Thin, mainly fibrous 
tissue with less muscle 
and elastic tissue 
Lumen diameter Narrow Very narrow Wide 
Valves None None Present 
Why structure 
needed for function 
Strength and elasticity 
needed to deal with 
pulsing blood, prevent 
rupturing, maintain high 
BP 
High BP ensures no 
back flow of blood 
Thick walls not needed 
due to low BP 
Thin walls and narrow 
lumen bring blood 
close to tissue for 
optimum diffusion 
 
Thick walls not needed 
due to low BP 
Wide lumen decreases 
resistance to BF 
Valves present to 
prevent back flow due 
to low pressure 
 
Arteries are the blood vessels that take oxygenated blood away from the heart to the 
rest of the body and have to deal with a high-pressure blood flow (BF) while the veins are 
blood vessels that bring deoxygenated blood back to the heart from the whole body under a 
low pressure system. Capillaries are the tiny vessels that mediated the change of different 
pressure systems and where diffusion of oxygen, nutrients and waste products can occur 
shown in Fig. 1. 
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Figure 1: Artery, vein and capillary structure 
Difference in structure between arteries and veins allow for different pressures and functions of this 
vascular system. Arteries develop into smaller arterioles before merging into the capillary bed while 
veins develop into venules which also run into the capillary bed. The capillary bed, which is only one 
cell thick, is where exchange of nutrients and removal of waste occurs 
11
.  
 
6.3 Vasculogenesis 
 Development of the vascular system starts not long after gastrulation accompanied 
by somite formation. It is comprised of different vessel types and occurs via two distinct 
mechanisms, vasculogenesis, de novo vessel formation, and angiogenesis, vessel formation 
from pre-existing vessels. In 1988, Risau first used the term vasculogenesis to describe de 
novo blood vessel formation in embryoid bodies 12. It has been long hypothesized, based on 
the close relationship between the development of the cardiovascular and the hematopoietic 
system that endothelial and hematopoietic cells are derived from a common precursor, 
known as the hemangioblast 13,14. As seen in Fig. 2a, these multipotent stem cells give rise 
to both pluripotent hematopoietic stem cells that produce all blood cell lineages, as well as 
the pluripotent stem cell of the endothelial lineage, the angioblast 13,15. The embryonic 
mesoderm, extra embryonic yolk sac, allantois and placenta have been discovered as 
sources of hematopoietic and endothelial progenitor cells and are also sites of 
vasculogenesis 16. 
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Figure 2: Origin of hematopoietic and vascular stem cells and extra embryonic 
vascular formation 
(A) Mesodermal stem cells (SCs) are able to give rise to mesenchymal SCs, which go on to be a 
number of possible cell types, or hemangioblasts. Hemangioblasts can give rise to hematopoietic 
cells or vascular cells. (B) During vascular formation hemangioblasts migrate and cluster to form 
blood islands. These cells within the blood island differentiate into to hematopoietic cells or vascular 
cells to form blood cells or the vascular tube respectively.  Modified from 
15,17
 
 
 During mouse development at E7.5, within the yolk sac, there is already evidence of 
separate lineages, the hematopoietic and endothelial lineage which results in the 
development of blood islands 13. These blood islands consist of an outer layer of endothelial 
cells (ECs) and an inner cluster of primitive hematopoietic cells which then extend and fuse 
together, allowing a primordial vascular network to develop in the extraembryonic region, 
seen in Fig. 2b 17,18. It is important to state that in this case the structure of the yolk sac blood 
islands in the human embryo is similar to that of the mouse embryo 19. The main function of 
vasculogenesis in the yolk sac is to generate the primitive vascular plexus 17.  
 During embryonic development, seeing as blood vessel formation is initiated in the 
extraembryonic regions, it was proposed that the extra embryonic vessels contributed to the 
formation of the blood vessels in the embryo itself, as these appear later in development via 
in-growth from the extraembryonic region 20. However this was subsequently shown to not 
be the case. Instead, it was shown that vessels found within the developing embryo itself are 
formed independently via vasculogenesis 21,22. In the case of the embryo itself, the primitive 
vascular network is also formed from angioblasts, although unlike the extra-embryonic 
angioblasts, they can develop and differentiate unaccompanied by hematopoietic progenitor 
cells 23. Major embryonic vessels are formed by large aggregates of angioblasts, that then 
form vesicles and cords of attached vascular ECs and then undergo morphogenesis to 
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create epithelial tubes as seen in Fig. 3 14,24. In the embryo, vasculogenesis is essential for 
the formation of capillaries in the head mesenchyme and endocardium and by E8.5 both the 
intra- and extra-vascular system have anastomosed where the plexus continues and 
connects to the developing heart before the initial heartbeat is initiated 25,26. Even though 
vasculogenesis is mainly associated with early embryonic development, it is also essential in 
the vascularisation of other organs such as the lungs, liver and spleen and so it is possible 
that angioblasts could arise de novo during later stages of development and arise from other 
mesodermal tissues such as the paraxial/ somitic mesoderm, mesodermal mesenchyme, 
and possibly even hematopoietic progenitors 14,27,28. 
 
Figure 3: Vasculogenesis 
The procedure of de novo vessel formation where a group of progenitor cells, angioblasts also known 
as vascular SCs, aggregate and differentiate into an immature epithelial tube which then undergo 
differential gene expression to give rise to distinct vascular identities. Modified from 
24
 
 
 In comparison to angiogenesis, there is still little known about the signalling pathways 
involved during vasculogenesis and specification of vessel identity. In Table 3 is a list of 
critical factors known to be necessary for vasculogenesis as well as artery and vein 
specification, outlining the complex network of signalling pathways necessary to orchestrate 
such an essential process. For a long time it was hypothesized that hemodynamic forces, 
like BF and BP, were key players in driving vessel fate. However is has now been shown 
that arteries and veins contain distinct molecular markers that distinguish their identity from 
an early stage, even before circulation has been initiated. Table 3 demonstrates a number of 
known pathways involved in establishing, as well as maintaining the different vessel 
identities; however much is still unknown in regards to other pathways potentially involved in 
this process or how the synergistic or antagonistic effect of these pathways functions. 
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Table 3: Signalling pathways important for vasculogenesis and vascular identity 
 
Signalling Pathway Vascular Effect 
Molecules controlling endothelial cell development and tube formation 
FGF2 Mesodermal induction and induction of angioblasts from the mesoderm 
29
 
IHH Formation of blood island in yolk sac and endothelial tube in embryo 
30,31
 
NRP Yolk sac vasculogenesis and formation of the primary vascular plexus 
32,33
 
VEGFα/VEGFR2 Blood island assembly and for their precursor cells 
34–36
 
TGFβ1 Yolk sac development 
37
 
TGFβR1/ TGFβR2 Vasculogenesis in yolk sac and embryo 
38,39
 
Cadherin/Connexins Formation of  EC-EC junctions 
40,41
 
Molecules involved in vascular identity 
Notch Focuses vessel fate toward arterial identity 
42
 
EFNB2 Involved in arterial specialization 
43
 
EFNB4 Involved in venous specialization 
43
 
NRP1 Expressed in arterial endothelium 
44
 
NRP2 Expressed in venous endothelium 
44
 
 
The main initial players that have been identified in artery and vein identity are ephrin 
B2 (Efnb2) and ephrin B4 (Efnb4) respectively. Expression of both can be detected early on 
in development. Efnb2 is expressed in the developing endothelium of arteries while EFNB4, 
its receptor, is specifically expressed in the developing endothelium in veins 43. Knockout 
studies in mice showed mice lacking Efnb2 (Efnb2-/-) died embryonically due to defects in 
vasculogenesis, with problems in vascular patterning in both the yolk sac as well as the 
embryo itself. Further, EFNB2 and EFNB4 play a major role in the development of 
arteriovenous anastomoses by inhibiting vascular endothelial growth factor A (Vegfa) and 
angiopoietin 1 (Angpt1, also known as Ang1) induced EC proliferation and migration 43,45. 
The Neuropilin signalling pathway was also shown to be a key regulator of vessel identity 
where neuropilin1 (Nrp1) is specifically expressed in arterial endothelium while neuropilin2 
(Nrp2) expression is restricted to venous endothelium 44. Subsequent expression pattern 
studies showed that neuropilins are expressed in the early stages of vasculogenesis, even 
before Efnb2 and Efnb4, suggesting that they are primary identity markers. This suggests, 
that the primitive vessels of the extraembryonic vascular plexus already possess the 
necessary information to  initiate vein and artery identity 46. Knockout of both neuropilins 
leads to embryonic lethality in mice, where the developing yolk sac is avascular and the 
primary vascular plexus fails to develop 32. Lastly, Notch signalling components, such as 
NOTCH3, delta-like 4 (DLL4) and Hes related family BHLH transcription factor with YRPW 
motif 2 (HEY2), have been described to be involved in the remodelling of the primary 
vascular plexus to develop a hierarchy of mature vascular beds and to maintain arterial fate 
47,48. For example Dll4 heterozygous mice (Dll4+/-) show reduced Efnb2 expression but an 
increased Efnb4 expression, indicating a failure in arterial differentiation implying that Dll4 
and their downstream targets are vital for promoting arterial fate 49. The initial vascular 
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network has been established once the ECs have connected and formed primitive 
interconnecting vessels. The vasculature then undergoes a sequence of events to expand 
and mature the network which involves sprouting, proliferation and migration of ECs and 
recruitment of other cell types allowing the next phase of vascular development. 
 
6.4 Angiogenesis 
Angiogenesis is defined as the formation of vessels from pre-existing vessels and is 
essential for the expansion and remodelling of the vascular network  24, 50.  Angiogenesis can 
be separated into three distinct phases; quiescence, where the vessel is at normal or resting 
conditions; activation, whereby cues have been given to start branching; and resolution, 
where at the end the vessel must stabilize and mature to return back to the initial phase of 
quiescence 51. 
Under normal conditions, ECs form a robust, quiescent monolayer of phalanx cells 
that possess a long half-life and are protected by autocrine signals such as VEGF, NOTCH, 
ANG1 and fibroblast growth factors (FGFs) 51. Phalanx cells are a type of EC with a specific 
characteristic, they have few filopodia extensions and low migration potential in response to 
VEGF, have tight barrier formation and vascular lumen and they also express higher levels 
of molecules such as vascular endothelial-cadherin (VE-cadherin, Cdh5) 52. These phalanx 
cells are what allows the monolayer, along with pericytes, to form such tight cell-cell 
junctions as they express VE-cadherin as well as claudins 51. Pericytes are a cell type that 
display a set of characteristics consistent with muscle-cell activity and have been shown to 
express contractile smooth-muscle actin, however it is still unclear whether these cells are 
indeed smooth muscle cells (SMCs), cells with smooth-muscle-cell features or if it's possible 
that they can turn into SMCs when required 53. Pericytes encase the EC vessel which allows 
them to maintain quiescence in a mature vessel by suppressing EC proliferation as well as 
releasing protective signals such as VEGF and ANG1 as mentioned previously and together 
these form the basement membrane as shown in Fig. 4a.  
 Once a vessel senses angiogenic signals, such as VEGF, FGF, ANG2 or 
chemokines, within the vicinity, the activation phase begins as seen in Fig. 4b. Environments 
such as hypoxia, inflammation, the presence of tumour cells or vascular occlusions can 
induce such angiogenic signals to be released 51. Firstly pericytes, detach from the vessel 
wall due to the presence of ANG2 and free themselves from the basement membrane by 
proteolytic degradation via matrix metallopeptidases (MMPs) 54,55. Next, ECs loosen their 
junctions and the budding vessel begins to dilate. This in turn allows the increased VEGF 
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signal to increase permeability of the EC layer allowing plasma proteins to be released which 
go on to form a extracellular matrix (ECM) scaffold 51. The next signalling cascade of 
integrins promotes ECs to migrate along the ECM surface towards to the angiogenic signals. 
On top of this, further protease factors increase the local concentration of angiogenic 
molecules contained within the ECM, remodelling the ECM and making it a more pro-
angiogenic environment 51. At this point ECs take on different characteristics and roles to 
allow one cell type to migrate further and move towards the angiogenic signal, while the 
other cell type remains behind to form a lumen structure that will become a lumen vascular 
structure pictured in Fig. 4c. These different ECs are known as tip and stalk cells 
respectively.  
 
Figure 4: Tip cell selection and sprouting vessel elongation 
(A) Under normal conditions ECs form a quiescent monolayer, strengthened by a basement 
membrane and covered with SMCs and pericytes. (B) Upon the detection of angiogenic factors, such 
as Vegf, the sprouting vessel begins to dilate allowing for EC tip cell selection via angiogenic factor 
gradient. To enable further invasion into the surrounding area degradation of the basement 
membrane, detachment of SMCs and pericytes and loosening of the other neighbouring EC junctions. 
Lastly an increase in permeability allows for extravasation of plasma proteins which go on to deposit a 
makeshift matrix layer. Proteases are also secreted to remodel the former interstitial matrix to allow 
cell migration. (C) Tip cells continue to move in response to further guidance signals and adhere to 
the newly laid down ECM. Stalk cells proliferate and elongate to form a lumen and pericytes and 
SMCs as well as depositing the basement membrane to stabilize the newly formed vessel. Myeloid 
cells are recruited and can produce pro-angiogenic factors as well as proteolytically liberate 
angiogenic factors from the ECM. Modified from 
51
 
 
Tip cells, stalk cells, phalanx cells and mural cells are the different cells groups that 
comprise a sprouting vessel, seen in Fig. 5a. Tip cells constitute a small number of ECs that 
take on a more motile and sprouting characteristic at the front of the sprouting vessel. These 
cells are able to respond to the pro-angiogenic signals, via their filopodia, where then act in 
accordance to positive or negative signals allowing directionality whilst preventing 
unorganized and random vessel growth56.  Stalk cells on the other hand produce fewer 
filopodia but are instead highly proliferative, work to establish adherent, tight junctions for 
vascular stability and form the necessary lumen 57. For a long time it was understood that tip 
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cells respond to angiogenic stimuli, such as VEGF, which is presented as a gradient and is 
important in controlling tip cell guidance, via the receptor VEGFR2 located on ECs 58. Tip 
cells contain high levels of DLL4, unlike stalk cells, and are activated by VEGF signalling 
which in turn activates Notch signalling in neighbouring ECs. This signal pushes them 
towards a stalk cell characteristic 58. NOTCH is then able to inhibit tip cell behaviour in these 
neighbouring stalk cells by decreasing levels of VEGFR2 and VEGFR3, which is needed for 
VEGF binding, and by increasing VEGFR1 58,59. VEGFR1, which is upregulated in stalk cells, 
binds left over VEGF to prevent tip cell formation 59. In stalk cells, another Notch ligand, 
jagged1 (JAG1), is highly expressed due to its pro-angiogenic influences and is required for 
stalk cell maintenance 60. JAG1 also targets DLL4 instead, thereby blocking Notch signalling 
allowing the tip cell to remain as such which is described in Fig. 5b 24.  
 
Figure 5: Sprouting cell composition and signalling mechanism 
(A) In a sprouting vessel the tip cell migrates along the ECM and is guided by numerous different 
signals while the stalk cells proliferate to allow the sprouting vessel to move and form a lumen. 
Phalanx cells and mural cells are required for vascular quiescence and stability. (B) Tip cells (white) 
are activated via VEGF signalling which goes on to regulate Notch signalling in neighbouring stalk 
cells (grey) via DLL4. Notch suppresses VEGFR to allow for stalk cell behaviour. (C)  Modified by 
24,61,62
 
 
In summary, tip and stalk cell specification is known to be regulated by Dll4/Notch 
signalling, where cells deficient for or activated by Notch signalling are either tip cells or 
excluded from the tip cell position respectively, and that ECs compete for the tip cell position 
via differential VEGFR levels under the control of Dll4/Notch signalling 59,63–65. Recently BMP 
/ SMAD family member 1/5 (SMAD1/5) signalling was also shown to affect tip/stalk cell 
specification, where inhibition of activin A receptor type II-like 1 (ACVRL1, as known as 
ALK1) or EC specific deletion of SMAD1 and SMAD5 results in hyper sprouting 62. 
Transforming growth factor beta (TGFβ) is also known to block sprouting angiogenesis but 
this is highly context dependent and relies on which type I receptor is involved, ALK1 or 
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ALK5 66–69. Until recently the identity of the signal needed to switch off BMP/ALK1 signalling 
in tip/stalk specification was largely unknown and the link between Notch and SMAD 
signalling pathways had yet to be discovered. Aspalter et al. described a role for ALK1 and 
ALK5 in controlling vascular sprouting which they suggested to be downstream of Notch. As 
mentioned previously, NRP1 was shown to be differentially expressed and was found in 
arterial endothelium, tip cells included 70–72. NRP1 is a transmembrane receptor and co-
receptor to several structurally and functionally unrelated groups of ligands and signalling 
complexes like VEGF family members, class 3 semaphorins and TGFβ 73–76. Nrp1 deficient 
cells cannot obtain the tip cell position even when Notch is inhibited indicating that Nrp1 
operates downstream of Notch 62. In another paper it had been shown that Nrp1 is 
quantitatively regulated by Notch activity 77, therefore these results further identify Nrp1 as 
the critical downstream effector of Notch that is needed for tip/stalk cell specification. Loss of 
tip cell ability and sprouting was due to the over activation of SMAD2/3 which remained 
consistent with the model that in stalk cells Notch is able to inhibit Nrp1 and allow 
downstream activation of SMAD2/3 giving rise to stalk cell behaviour, while in tip cells NRP1 
inhibits SMAD2/3 signalling allowing for tip cell response to VEGF as shown in Fig 5b and 5c 
62. How NRP1 directly inhibits SMAD2/3 or the differential roles TGFβ/ALK5 and BMP/ALK1 
play still needs to be determined and better understood.   
 If a vessel is unable to be perfused correctly or angiogenesis has led to the 
overproduction of unnecessary blood vessels, then vessel pruning occurs.  Vessel pruning is 
the trimming of a vascular network whereby regression of unwanted vessels occurs within a 
growing vasculature 78. Initial triggers for regression of selected branches and the outcome 
of the regressing ECs are still not fully understood. EC apoptosis could be the first 
mechanism that results in vessel regression due to the removal of survival factors, such as 
VEGF, or due to activation of apoptotic signalling pathways 79,80. One case in which this 
happens is in the case of pupillary membrane vessel regression and hyaloid vessel 
regression 81,82. However, this has also been shown to not always be the case where even 
though apoptosis is involved it is not the primary, but rather the secondary effect, like during 
a reduction in blood-flow mediated survival signals in areas of vascular pruning 78. 
Alternatively, detachment of ECs from a network as a result of migration away from an area 
of regression and later disassociation from the basement membrane can also lead to EC 
apoptosis 83,84. Franco et al. used the postnatal mouse retina model to analyse vascular 
pruning at a high resolution and proposed a model for regression shown in Fig. 6. Firstly the 
branch for pruning is selected, either due to BF problems or lack of survival signals, where it 
constricts until occlusion has occurred and BF ceases (Fig. 6a-c). The ECs either, detach 
and undergo apoptosis or they migrate and reintegrate somewhere else on a neighbouring 
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vessel, choosing their course of action depending on the vessel involved and the context of 
the vascular pruning (Fig. 6d). Finally, resolution occurs when the selected vessel has fully 
regressed and leaves behind a collagen IV and empty basement membrane sleeve (Fig. 6e) 
85. Taken together this data would suggest that full removal and regression of a vascular 
network is primarily due to EC apoptosis whereas pruning of a certain vascular bed in certain 
conditions may be due to a combination of EC migration, redistributing and apoptosis.  
 
Figure 6: Vascular pruning, regression and quiescence 
(A) BF can be used to select a section of a vessel for vascular regression. (B) Firstly the vessel 
restricts (C) until it closes and BF is blocked. (D) ECs in a regressing vessel retract and either 
undergo apoptosis or can reintegrate elsewhere in the vessel. Removal of these cells leaves behind 
an empty collagen positive basement membrane sleeve (grey area). (E) The final step in the 
resolution of this new vessel ends in the regression of the vessel. (F) After fusion of sprouting vessels, 
the lumen is formed and perfusion of the neovessel can occur. Vascular quiescence is achieved by 
promoting a quiescent phalanx phenotype, re-establishing EC junctions, depositing ECM, allowing 
maturation of SMCs and pericytes and secreting vascular maintenance signals. Modified by 
51,78
 
 
Lumen formation, depending on the type of vascular bed or the type of vessel 
formation, occurs via clustering of intracellular vacuoles that interconnect with vacuoles from 
neighbouring ECs and then go on to form a lumen known as cell hollowing or where ECs 
adjust their shape and junctions to allow a lumen to form known as cord hollowing 24. Once 
BF is initiated into the new lumen, the vessel is able to shape and remodel its connections 
and respond to hemodynamic forces. Hemodynamic forces play a huge part in remodelling 
arteries and are essential for vessel maintenance, vessel identity and collateral vessel 
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expansion. It is known that non-perfused vessels are susceptible to vascular pruning and 
regression and that this process can be influenced by alterations in BF. Supporting this 
hypothesis is the need for the first heart beat to initiate BF to allow remodelling of the 
vascular plexus 26. Vascular remodelling is the structural changes of vessels that involves 
cell growth, cell death, cell migration, and ECM synthesis or degradation and BF itself can 
initiate downstream effects via different signalling pathways 85. Shear stress is the force 
emitted onto the endothelial layer of a vessel due to BF. High shear, like laminar flow, 
promotes EC survival, quiescence, alignment and secretion of vasodilation substances 
whilst low shear, like turbulent flow, promotes EC proliferation, apoptosis, shape change and 
secretion of vasoconstrictive substances 86. Shear stress can induce AKT signalling which in 
turn leads to kruppel-like factor 2 (Klf2) activation and further upregulation of nitric oxide 
synthase (NOS), promoting EC survival and NO-mediated vessel dilation 83,87. Reduction of 
shear has the opposite effect where this induces vasoconstriction 88. BF itself is also able to 
direct EC migration during regression and its incorporation into the remaining vasculature. In 
quiescent vasculature ECs are known to align against the flow and this is determined by the 
axial polarity of the ECs golgi and nucleus 85.Though the full mechanisms of vascular 
pruning are not understood, in recent years, pathways such as signal transducer and 
activator of transcription 1 (STAT1)/ c-Jun N-terminal kinase (JNK3) and non-canonical WNT 
ligands have been implicated in  controlling these events 89,90. Downregulation of VEGF 
promotes EC apoptosis therefore inducing vascular regression, whilst DLL4/NOTCH 
signalling has been shown to activate pruning by altering the expression of vasoactive 
genes, inducing vessel occlusion, BF cessation and EC apoptosis 88. Ang2 is known to 
promote EC death and regression in the absence of VEGF and that shear stress is able to 
also control transcription of Klf2, which establishes a quiescent phenotype 54.  
 A major and very important step in vessel stability and maturation is the recruitment 
of pericytes and SMCs that will surround the newly formed vessel. Pericytes form direct 
contact with ECs but only in capillaries and immature vessels while SMCs and pericytes 
cover arteries and veins but are separated from ECs by a matrix. TGFβ signalling is needed 
during vessel maturation as it stimulates SMC induction, differentiation, migration and 
proliferation and also promotes ECM production 91. Mural cell recruitment is controlled by a 
number of factors, one being platelet-derived growth factor (PDGF) and its receptor platelet-
derived growth factor receptor beta (PDGFRβ) where PDGFβ is secreted from ECs that 
signals to PDGFRβ expressed by mural cells, effecting their migration and proliferation 24. 
Loss of either the ligand or the receptor results in pericyte deficiency, vascular dysfunction 
and blood vessel rupturing and specifically loss of PDGFβ leads to insufficient pericyte 
coverage 92. Other factors such as ANG1 are also important for recruitment of pericytes. 
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ANG1 is produced by mural cells and activates the endothelial-specific receptor tyrosine 
kinase (TEK, also known as TIE2) receptor in endothelial cells which stabilizes vessels by 
promotion of pericyte adhesion and firming the connection by tightening endothelial junctions 
54,93. These cells also require EFNB2 for association around ECs as well as Notch signalling 
for maturation and differentiation of arterial vSMCs  94,95. 
Many steps are important for returning a vessel into a quiescent and stable 
environment as seen in Fig. 6f. Perfusion of vessels delivers oxygen and nutrients needed 
which in turn reduces VEGF expression and inactivates endothelial oxygen sensors, 
allowing the vasculature to switch from an active to quiescent state. For a vessel to fully 
function it is essential that the vessel must stabilise and mature which is achieved by 
deposits of ECM, recruitment of SMCs and pericytes, reduction in EC proliferation and 
increased cell junctions. Contact of tip cells with other tip cells from other sprouting vessels 
will interact with their filopodia and will fuse to bridge the new sprouting vessels together. 
Atastomosis of these vessels is established and VE-cadherin junctions allow the solidifying 
of these new connection. Downregulation of the tip cell behaviour will occur as a result but 
also the reduction in pro-angiogenic signals will contribute to the ablation of a pro-angiogenic 
environment allowing vascular fusion 24,51. In addition, tissue inhibitor of metalloproteinase 
(TIMP) and plasminogen activator inhibitor 1 (PAI1) are circulated to allow deposition of the 
basement membrane where tight cell junctions can reform 96,97.  
 
6.5 Hemodynamic forces and vascular structure in vascular 
homeostasis 
Many different factors, such as genetic, mechanical and environmental (such as 
hypoxia) factors, are able to effect and alter vascular structure making this system a very 
complicated and dynamic system. Hemodynamics describes the fluid dynamics of blood and 
BF and explains these effects using physical laws that govern BF within the vessel. Our 
circulatory system is regulated by hemodynamic responses and mechanisms that are 
constantly monitored and adjusted to our body’s environment. The heart is the main pump in 
the circulatory system where it delivers blood to the whole body through timed contractions 
and relaxations. There are many different factors that determine and effect hemodynamic 
forces that are outlined in Table 4 and shown in Fig. 7. The terms mentioned below are able 
to regulate gene transcription, leading to direct alterations in vascular structure which can 
ultimately lead to disease conditions or compensate for transient and unfavourable 
conditions. 
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Table 4: Hemodynamic terms 
 
Term Definition 
Afterload The pressure in the left ventricular wall during ejection 
Blood flow Volume of blood that passes through a vessel with respect to time 
Cardiac output Total blood volume pumped out of the heart in one minute 
Circumferential stress The force exerted circumferentially in both directions of a vessel 
Heart rate The number of times the heart beats per minute  
Preload The stretching pressure on CMs before contraction 
Pressure Pressure exerted from pumped blood on walls of blood vessel 
Resistance Opposition to BF within a vascular network 
Shear Stress A stress state where the stress is parallel to the vessels surface 
Velocity  The distance blood travels in a vessel with respect to time 
 
Shear stress and BP are two of the main exogenous mechanical forces that alter ECs 
and SMCs respectively. The endothelial layer is organized into a monolayer which acts as a 
barrier between the blood and the vessel but also acts as a sensor to hemodynamic forces 
and factors within the blood.  These factors include regulators of vascular tone, recruitment 
of immune and mural cells and formation of new vessels. ECs are able to sense changes in 
their environment due to their mechanosensitive ability which allows for recognition of 
mechanical stimuli and coupling of these stimuli into a signalling event. Stimuli can be 
recognized by specific sensors on the surface of ECs and changed into a cellular signal via 
specialized proteins called mechanotransducers. Initial evidence indicated a role for 
cytoskeletal elements in transmitting signals due to shear forces throughout the intracellular 
network via ion channels, G-protein coupled receptors (GPCRs), the cytoskeleton, cell–cell 
adhesion molecules, and focal adhesions molecules 98,99. Recent evidence now indicates 
that the cytoskeleton probably does not have a direct role in transmitting these signals but 
rather works in conjunction with other signalling mechanisms. New studies suggest that 
these direct signals could begin due to the appearance of multiple sensor sites on the 
surface of ECs, as a result of structural changes in the presence of flow causing 
conformational alterations in proteins or protein complexes that trigger downstream 
pathways. Another explanation could be due to shear stress where it is directly sensed by 
sensor complexes that activate specific signalling pathways that trigger downstream targets. 
Evidence for direct detection due to shear stress was propose when results showed that 
platelet/endothelial cell adhesion molecule (PECAM) acted as a direct monitor and signal 
transducer in response to shear stress 100,101. PECAM can elicit a number of different 
responses when exposed to shear stress, such as alterations in cell shape via actin 
assembly, restructuring of cell adhesion complexes and adjustments in cell polarity. Further, 
PECAM was shown to interact with other molecules necessary for cell-cell adhesion such as 
CDH5 and VEGFR2. This signalling interaction evokes activation of downstream pathways, 
such as integrins, mitogen-activated protein kinases (MAPK) and extracellular-regulated 
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kinases 1/2 (ERK1/2), indicating that adhesion molecules, rather than the sensor, 
transmitted the transduction signal 100–102. Application of shear stress on ECs can cause 
several different responses in varying timescales. For example, in a matter of seconds, 
activation of potassium channels, SRC family kinases and VEGFR2 occurs along with the 
release of NO, while within a matter of minutes GTPases, integrins, Mapk and Rho family 
members are activated 103. Flow patterns were also shown to affect specific differential EC 
profiles.  For example in a high shear stress environment, normal in arteries, gene 
expression induces an anti-proliferative, -inflammatory and thrombotic environment whereas 
in a  low shear stress situation, hallmark of veins, gene expression increases cellular 
proliferation and apoptosis in a pro-inflammatory and –thrombotic setting 99,104.  
Cell alignment has also been suggested as being important in transmitting the 
pressure from shear stress in the EC, where cells that are perpendicular to the force, defined 
by the cells shape and organization of its cytoskeleton, strongly increase the activation of the 
NF-κB pathway while cells that are parallel to the force do not strongly activate the NF-κB 
pathway but rather activate the eNOS-NO pathway 105,106.  
SMCs act as the mechanical support for the vessel, allowing the vessel to contract or 
dilate according to the pressure being exerted. Many results have shown that mechanical 
stretch of SMCs due to BP and stress is able to regulate proliferation, apoptosis, and 
migration these cells as well as synthesis, degradation, and reorganization of the ECM 107.  
 
Figure 7: Role of hemodynamic forces on vascular structure 
Different hemodynamic forces that are exerted upon the vascular network in response to various 
stimuli and factors that can alter vascular structure. Modified from 
108
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6.6 BMP9 and BMP10 signalling pathway 
 BMP9 and BMP10 are members of the TGFβ superfamily of growth factors which 
include other factors such as the activin/inhibin family, GDFs, TGFs and other BMPs 109. 
Members of this family regulate many different processes during early stages of 
development, such as induction of the three germ layers, left/right asymmetry and 
maintenance of pluripotency along with induction of embryonic stem cell (ESC) 
differentiation, and later stages of development, like haematopoiesis and organ development 
109. These growth factors have an essential role in organ development due to the role they 
play at a cellular level in proliferation, differentiation, apoptosis, migration and adhesion 109. 
 BMP9 and BMP10 are close family members that share 65 % sequence identity at a 
protein level although they are distantly related to other family members as seen below in 
Fig. 7. Both BMP9 and BMP10, as is also the case with other protein family members, are 
synthesised as large precursors which contains a large pro-domain needed for proper 
folding and a C-terminal region consisting of the active ligand 110. Furin, an enzyme, or other 
proprotein convertases act to release the mature, dimeric ligand 111,112. In the case of BMP9 
it has been shown to circulate as an active ligand and this could be the case too for BMP10 
although normally it circulates in its inactive form 113–115. BMP9 is produced mainly in the liver 
but has also been shown to be expressed at low levels in the lungs and brain. BMP10 is 
expressed in the developing embryonic myocardium and is then secreted after development 
from the right atria of the heart through to adulthood 112,116–118. Both BMPs have been 
detected in both mouse and human plasma and circulate at approximately 0.5–15 ng/mL 
which is necessary to bind and stimulate their receptors in the endothelium 112–114,119,120. 
 Interest in BMP9 and BMP10 gained attention when it was shown that both of these 
proteins bind with high affinity to the TGFβ type I receptor, ALK1 113,121. In vertebrates there 
are seven type I receptors, five type II receptors and two co-receptors and these receptors 
pair up in a number of different combinations which allows them to propagate the signals for 
all the TGF superfamily members shown in Fig. 8 109. When ligands bind to their specific 
type I receptor at the cell surface membrane, the receptor dimerizes and recruits their 
required dimeric type II receptor. Type II receptors are considered to be constitutively active 
and when brought into close proximity of the type I receptor, it phosporylates the type I 
receptor. The phosphorylation of this complex enables the recruitment of the receptor-
regulated SMADs (R-SMADs) which are phosphorylated by the type I receptor. The 
phosphorylated R-SMAD forms a complex with the co-mediated SMAD (co-SMAD), SMAD4, 
which subsequently translocates to the nucleus  where it accumulates and positively or 
negatively regulates target gene transcription 122. BMP9 and BMP10 bind to their type I 
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receptor, ALK1. However when recruiting the type II receptor there is a difference in binding 
affinity between BMP9 and BMP10 with three possible receptors, Bone morphogenetic 
protein receptor II (BMPR2), Activin type receptor II A (ActR2A), and ActR2B 
123. BMP9 or 
BMP10 binding results in the recruitment and phosphorylation of Smad1/5/8 112,113. ENG, 
one of the co-receptors, has been shown to facilitate the binding of these ligands to ALKs 
which is displayed in Fig. 8 113,121. To date, BMP9 and BMP10 are the only ligands in this 
superfamily that have been shown to be able to bind directly to ENG 124. Within this 
signalling pathway there is a negative feedback loop whereby the initiation of this signalling 
pathway induces the inhibitory SMADs (I-SMADs), SMAD6 and SMAD7. Initial studies of 
these I-SMADs showed they target type I receptors and are able to interact with them 
ultimately inhibiting further signalling and additionally have been shown to recruit SMAD-
mediated ubiquitin regulatory factor (SMURF) with E3 ubiquitin ligase activity that degrade of 
the activate receptor complex 125.  
 
 
Figure 8: TGF tree, receptors and signalling pathway 
(a) Phylogenetic tree of the TGF protein superfamily which shows the high degree of sequence 
similarity between BMP9 and BMP10 and that also these two proteins are not as highly related to the 
other family members. (b) Binding of ligands to their specific type II receptors and recruitment of the 
type I receptors allows for high combinatorial complexity allowing for regulation of numerous different 
downstream targets. Ligands from this signalling pathway are normally categorized into two groups, 
ones that activate SMAD 2/3 via ALK4, ALK5 or ALK7 or ones that activate SMAD1/5/8 via ALK1, 
ALK2, ALK3 or ALK6. Once these SMADs have been phosphorylated they form a complex with 
SMAD4 which then translocates into the nucleus. Once in the nucleus gene transcription can be 
directly regulated in conjunction with transcription factors, chromatin remodelling complexes and 
histone modifying enzymes. (c) Chart of ligands, receptors and SMADs involved in the TGF signalling 
pathway. Modified by 
126,127
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6.7 BMP9 and BMP10 in disease and their role in vascular 
homeostasis 
In humans hereditary haemorrhagic telangiectasia (HHT), also known as Osler-Weber-
Rendu syndrome, is an autosomal dominate group of disorders that are characterized by the 
development of arteriovenous malformations (AVMs) in the skin, mucous membranes, 
and/or in internal organs such as the brain, lungs, and liver 128. Under normal conditions, an 
artery feeds into a smaller sized network of arterioles which feeds into a capillary bed that 
are drained into venuoles that are connected to a vein as seen in Fig 9. However, in AVMs, 
the capillary bed is completely unorganised which leads to the situation where arteries shunt 
blood directly into a vein without the intervening capillary bed 129. Therefore draining veins 
fail to remodel to have an arterialized characteristic and they keep their venous structure and 
identity which leads to rupturing and bleeding. If these AVMs are located in large organs like 
the brain, rupturing of these vessels can lead to seizures, a stroke or even severe and life-
threatening haemorrhaging. The etiology of these AVMs is still largely unknown; however, 
genes that have a loss of function mutation in them have been uncovered. Most cases of 
HHT are congenital and develop over time due to mutations within a number of genes, 
however there is still approximately 15 % of patients who don't have a mutation in these 
known genes 130 Mutations in receptors and binding partners, for example ENG, ALK1, 
SMAD4 and BMPR2, have been shown to develop into different forms of HHT 128,129,131. 
Although HHT is mainly congenital and was believed it was the only way AVMs could 
develop it is now understood that certain conditions or environments, like inflammation, 
trauma, stimuli promoting angiogenesis or even alterations in hemodynamic, can favour and 
initiate AVM formation spontaneously 132. For example the Notch and Ephrin family members 
that are important in artery and vein identity, are misregulated in AVMs and it has also been 
shown the AVMs overproduce angiogenic factors like VEGF, ANG-2 and MMP9 but 
downregulate inhibitors of EC growth or vascular stabilization factors such as ANG1 95,129. 
Understanding if changes in a certain settings can initiate AVM formation and how AVMs 
develop is vital.  
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Figure 9: Arteriovenous malformations 
In normal conditions areas of high pressure (dark) and low pressure (light) run into the capillary bed. 
Capillaries form a network of thin; one cell thick, vessels where gases and nutrients are exchanged 
and metabolic waste is removed. An arteriovenous malformation is when there is an abnormal 
connection between arteries and veins is formed, bypassing the capillary bed. In these cases vessels 
become dilated, fragile, and tortuous, and eventually end up rupturing. Modified from 
133
 
 
 Loss of Alk1 (Alk1-/-) leads to embryonic lethality by E11.5 and histological analysis 
showed that before E9.5, Alk1-/- mice were indistinguishable from their WT littermates 134,135. 
At E9.5 the yolk sac from these Alk1 mutant mice possess a lack of mature vessels resulting 
in an interconnected knot of similar sized endothelial tubes 134,135. The mutant embryos 
displayed smaller heads, were retarded in their growth and by E10.5, embryonic 
development was arrested 135. At E10.5 the Alk1-/-  yolk sac was avascular with few vessels 
showing severe signs of vascular dilation 134,135. Two papers addressing the loss of Alk1 
during embryonic development also noted at early stages the cardiac tube was contracting in 
these KO embryos but that blood circulation was aberrant while at E9.5 the endocardium 
and myocardium were dilated and by E10.5 the pericardium was enlarged 134,135. Urness et 
al. showed that between E7.5 – E8, angioblasts coalesced normally to form the primitive 
tube network with no differences between Alk1-/-  embryos and WTs 134. This was supported 
by Oh et al. that used an EC specific lacZ reporter line in the Alk1-/-  background and showed 
the normal formation of the primary capillary plexus and that vasculogenesis was not 
affected 135.  Taken together, both groups hypothesis that vascular defects seen in these 
Alk1-/-  embryos came directly after de novo formation of the central vascular network and 
that vasculogenesis was not affected, where vascular defects after E9.5 included multiple 
AV shunts, dilation of major vessels and excessive vessel and capillary fusion 134,135. 
Expression of vSMC markers, αSMA and SM22α, were also shown to be markedly reduced 
in areas known to have high expression, such as the dorsal aorta (DA), heart and somites, 
and one SMC reporter line showed SMCs were mislocalised and not present in the 
perivascular region 134,135. Urness et al. attributed the drastic loss of SMC to the 
downregulation of arterial specific marker, EFNB2. They concluded that loss of arterial 
identity lead to a reduced recruitment of SMCs which allowed for vascular dilation leading to 
fusion of vessels causing multiple AV shunts 134. Oh et al. showed a dramatic increase in 
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plasminogen activator (PA), urokinase-type PA (uPA) and PAI1 in Alk1 mutant mice, which 
are genes known to be expressed in perivascular matrix proteolysis 136. uPA is also known to 
be a marker for actively migrating ECs and VEGF has been shown to increase its expression 
137–139. This increase in VEGF and uPA in Alk1-/-  embryos was hypothesized to increase 
vascular permeability, due to perivascular proteolysis, which could allow for excessive EC 
migration and proliferation and this in turn results in loss of SMCs, which also cannot inhibit 
EC proliferation, resulting ultimately in vascular dilation and vessel fusion 135.  
Seeing as early deletion of Alk1 led to embryonic lethality, a later stage Cre was used 
to KO ALK1 (Alk1 L1 Cre) 140. Deletion of Alk1 after E13.5 resulted in no mutant fetuses after 
E18.5 but between E15.5 – E17.5 Alk1 L1 Cre embryos were already distinguishable from their 
WT littermates 140. Yolk sac analysis showed that loss of Alk1 resulted in an increase in 
diameter and decrease in wall thickness of the vitelline artery, similar characteristics to the 
vitelline vein, suggesting the artery had lost its arterial specification as previously debated 
140. The mutant yolk sacs also showed dilated, torturous vascular networks with the presence 
of AVMs 140. When analyzing the vascular network within the lung between E16.5 - E17.5, 
Alk1 L1 Cre lungs also displayed an irregular mesh of dilated, fused vessels and when stained 
with αSMA showed a reduction in the SMC layer 140.  
To further investigate the role of ALK1 in the neonatal mouse, Alk1-/-  mice were 
crossed with an EC specific Cre (Alk1 EC) 141. Deletion of Alk1 in ECs led to postnatal lethality 
at P5 as a result of severe hemorrhaging in various organs and as seen previously in all the 
other Alk1 embryonic models, these Alk1 EC pups displayed severe dilation and tortuous 
vessels with the presence of numerous AV shunts as well as an uneven and depleted SMC 
layer which resulted in permeable and leaky vessels 141. To achieve a better understanding 
of the role of Alk1 in the adult mouse, after establishment of the vascular system, Park et al. 
generated an inducible, global deletion of ALK1 (Alk1 iCre) via tamoxifen injection. Alk1 iCre 
were injected once with tamoxifen at the age of 2 months which resulted in lethality 9 – 21 
days after the injection. These mice again showed similar phenotypes to all the previous 
Alk1 KO models; hemorrhaging, dilation of the pulmonary vessels, increased vascular 
permeability and the development of AVMs 141. Inducing wounds in these Alk1 iCre mice 
allowed for the real time monitoring of de novo AVMs after vessel formation. Control animals 
had normal arterial branches after wounding while Alk1 iCre mice developed AVMs in the 
wounded area showing that this is a local response 141. These results concluded that 
environmental factors, like wound healing, can induce AVM formation in adults de novo 141. 
To address the question of how these AVMs are formed, Park et al visually monitored the 
process of vascular remodeling during wound healing in these Alk1 iCre mice. During vascular 
remodeling, control mice formed large numbers of growing microvessels that grew towards 
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the center of the wound 141. In contrast the mutants developed fewer vessels and continued 
remodeling at the periphery of the wound 141. Hb (O2) saturation levels in the controls stayed 
constant in the venous vessels while in the mutants Hb (O2) levels were highly elevated in 
the veins, evidence of A-V shunts and lastly minor changes were made in the major arterial 
and venous branches of the controls during healing, while in the mutants there was an 
obvious and progressive dilation of vessels 141. Taken together these papers all indicated the 
importance ALK1 has as an EC receptor in maintaining vascular identity and stability during 
embryonic and adult angiogenesis.  
The involvement of BMP and TGF signalling in the maintenance of vascular 
homeostasis was reiterated in the discovery of the role of ENG, a co-receptor in the TGF 
signalling pathway, in the development of HHT in humans 142. Similar to the Alk1-/-  embryos, 
loss of Eng leads embryonic lethality by E11.5 due to defective angiogenesis and both KO’s 
shared similar phenotypes 143. At E8.5 ENG KO (Eng -/-) embryos were indistinguishable to 
WT littermates where both possessed a primary vascular network but by E10.5 Eng -/-
embryos were smaller in size, lacked vascular organisation and possessed cardiac defects; 
extra fluid was in the pericardial space, failed closure of the lumen, dilated endocardium and 
defects in valve formation and heart septation 143,144. EC impairment was first detected in 
Eng -/- embryos between E9.5 – E10.5, where major vessels such as the DA, CA and BA, 
were highly disorganised and the same was clear in the yolk sac of these embryos which 
possessed an immature vascular plexus and undefined, disorganised vessels 143. Although 
problems with EC organisation were detected around E9.5, defects with SMC coverage and 
differentiation were detected as early as E8.5 up till E10.5 143. Eng -/- yolk sacs possess 
endothelial tubes lacking SMC coverage by E8.5 which does not progress by E9.5 and 
αSMA staining confirmed fewer SMCs between the endoderm and endothelium 143. SM22α 
staining at E9.5 also confirmed an inhibition in SMC development in both the yolk sacs and 
embryos lacking Eng 143. Studies of adult mice with a heterozygous KO for Eng showed 
development of ear telangiectasia’s with recurring nose or mouth bleeds, recapitulating sign 
in patients with HHT 144. To understand the role of Eng in a cell specific context, an Eng EC 
inducible line was generated (Eng iKO). The retinas of  P4 Eng iKO mice showed a denser 
capillary plexus and a reduction in vascular outgrowth, suggesting a delay in remodelling 
and a reduction in migration, which persisted until P9 145. AVMs were also detected at a high 
frequency in Eng iKO retinas and numerous AVMs had ruptured and were bleeding, possibly 
due to the increase in venous calibre and AVM enlargement 145. There was an increased 
number of ECs lining the diameter of AVMs and the arteries in these AVMs had a high 
number of proliferating cells, where normally arteries contain non proliferating cells. 
Additionally αSMA expression was detected in veins in these AVMs, where αSMA is 
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normally only expressed in arteries. These results concluded that  loss of vascular identity 
could play a major role in AVM development and progression 145. Taken together these 
groups propose that loss of Eng leads to vascular instability which can lead to cardiac 
defects or develop diseases such as HHT and that ECs are needed to induce SMC 
differentiation, while SMCs are important in regulating EC organisation 143–145.  
 As mentioned above, BMPR2 and SMAD4 have also been implicated recently with 
HHT syndromes in humans 131,146,147. Loss of Bmpr2 leads to embryonic lethality by E9.5 and 
is known to  be essential for gastrulation and early development due to its regulation of many 
different signalling ligands 148. To overcome embryonic lethality, a knock down (KD) of 
Bmpr2 was generated and showed that KD of Bmpr2 lead to an insufficient coverage and 
sometimes a complete loss of SMCs in pulmonary arteries and the large intestine. The 
pericyte marker, PDGFRβ was also reduced in lung extracts of these KD mice. KD of Bmpr2 
in ECs also lead to an impaired angiogenic response and analysis of alterations in gene 
expression showed a downregulation of major components needed for vascular patterning 
and maturation 149. Loss of Smad4 also results in embryonic lethality at E7.5 in mice, where 
these mice showed a reduction in size, due to an impairment in cellular proliferation and with 
a poor definition between the embryonic and the extraembryonic regions of the embryo 150. 
This group discovered a problem with mutant ESCs lacking Smad4 during in vitro 
differentiation of the visceral endoderm and mesoderm explaining the gastrulation defects in 
these mutant embryos 150. To date not much is known as to why some SMAD4 mutations 
can cause HHT as well as JP but in other cases it doesn't. However a possible correlation 
has been made where SMAD4 mutations in JP-HHT patients all have mutations clustered in 
one  domain of the protein and this could explain a molecular mechanism for the different 
phenotypes 151. 
 To date, research has been carried out on the receptors and signalling components 
in the TGF signalling pathway while the ligands, BMP9 and BMP10, haven’t received as 
much attention. BMP9 was first described as being involved in ectopic bone formation and 
later was shown to have a role in osteoblast differentiation as well as inducing and 
maintaining the neuronal  cholinergic phenotype in the central nervous system 152–154. Once it 
had been discovered that BMP9, along with BMP10, were the functional ligands of the ALK1 
receptor, research shifted and focused on the role these two BMPs play in modulating 
angiogenesis 113. Using human dermal microvascular ECs (HMVEC-d) it was shown that 
BMP9 binds and activates ALK1, where ENG overexpression was shown to increase this 
response. Stimulation with BMP9 leads to phosphorylation of SMAD1/5/8 via either BMPR2 
or ACTR2A, where loss of either receptor results in a compensatory overlap from the other. 
Although these receptors can compensate for each other there were different cellular 
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responses 113,155. Here they showed that BMP9 was able to inhibit both migration and growth 
of HMVEC-d's via ALK1 and this was also as the case with BMP10 113. BMP9 which is 
produced in the liver, is an active circulating factor and is found to be present in human 
serum that acts on ALK1 and a vascular quiescent factor in vivo as well as BMP10 which is 
produced in the right atria 112,119. In another animal model, the zebrafish, it was shown that 
bmp10 is able to limit EC number via alk1 115,117,120,156. 
 Loss of BMP9 in mice is not lethal as shown by Ricard et al as well as described in 
this thesis with hardly any obvious effects on angiogenesis. In contrast, loss of BMP10 leads 
to embryonic lethality in mice around E10.5 where cardiac defects are already observed at 
E9 118,120. Not only is BMP10 involved in maintaining vascular quiescence and homeostasis 
during development but it also has a unique function in cardiac development 114. During 
cardiac development, BMP10 expression is detected around E8.5 and is transiently 
expressed in the ventricular trabecular myocardium and is involved in the process of 
trabeculation between E9.0 - E13.5. After this process BMP10 is no longer detected in the 
ventricles at E16.5 - E18.5 and is only detectable in the right atria 117,118. In contrast, 
upregulation of BMP10 expression, as seen in FKBP12 deficient mice, leads to 
hypertrabeculation and non-compaction showing a needed for a balance in expression 
118,157. The cardiac-specific role of BMP10 is likely not restricted to its specific location but 
also because of its ability to regulate other important cardiac factors such as NKX2.5 and 
MEF2C in controlling normal cardiac function 118. It has been hypothesized that BMP9 and 
BMP10 have overlapping functions during embryonic and postnatal angiogenesis. To 
understand the role of BMP9 and BMP10 in neonates one group used BMP9 KO (BMP9-/-) 
mice and injected them with BMP10 monoclonal antibody. Here they showed that that loss of 
BMP9 together with reduced BMP10 levels in a neonate leads to more drastic vascular 
abnormalities in the retina where expansion of the vascular plexus was significantly delayed, 
vascular density was noticeably increased, vessel diameter was enlarged and  affected 
blood vessels have reduced coverage of mural cells 114,120. To address the question of 
overlapping functions during development, another group checked whether Bmp9 can 
substitute Bmp10 and fulfil its developmental role in cardiac development and angiogenesis 
112,114. Chen et al created a mouse line where the coding region of Bmp10 was replaced by 
the coding region of Bmp9, Bmp109/9. At E16.5, Bmp109/9 embryos did not display any major 
developmental angiogenic defects which was observed in Bmp10-/- embryos by E9.5 114. 
Bmp109/9 embryos displayed distinct DA and cardinal veins and lacked AVMs that were 
detected in Bmp10-/- embryos. These results indicated that BMP9 and BMP10 are 
functionally able to overlap to allow normal early vascular development via ALK1. However 
by E14.5 Bmp109/9 hearts were hypoplastic with thin ventricular walls and showed pericardial 
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edema and by E17.5, the hearts had grown in size, altered in shape and a majority of them 
also had ventricular septal defects which were all similar to previous results in Bmp10-/- 
embryos 114. Around E16.5 Bmp109/9 embryos were also affected by haemorrhages and 
edema, which increased in severity as the embryos developed. Seeing as early vascular 
development in Bmp109/9 embryos was mostly normal they hypothesized that the late 
vascular phenotype may be a secondary effect due to defects in heart development. Taken 
together these results clearly show that BMP9 is able to compensate for loss of BMP10 
during vascular development but BMP10 has a very specific role in cardiac development that 
cannot be replaced and impairment in cardiac development leads to later vascular 
abnormalities.  
 
6.8 Thesis aim and overview 
 To date, little is known about the role of BMP9 and BMP10 in the adult 
cardiovascular system and how they maintain vascular quiescence. The aim of this thesis 
was to use different mouse models and in vitro analysis to study the role of both BMP9 and 
BMP10 individually as well as their possible overlapping roles and how they affect vascular 
homeostasis. To achieve this, a constitutive BMP9 single knockout line (SKO) was 
generated along with a conditional BMP10 single knockout line (cKO) which was under the 
control of ANF Cre, to bypass the embryonic lethality. These two SKO lines were then 
crossed to generate a BMP9/BMP10 double knockout line (DKO). Using these two SKO 
lines and DKO line I have investigated overall cardiac function and structure by using 
techniques such as magnetic resonance imaging (MRI) and micro computed tomography 
(µCT) to determine if cardiac function was compromised. Vascular structure and changes in 
vascular homeostasis was measured by using numerous different hemodynamic factors as 
read outs, such as BF, blood velocity (BV), heart rate (HR) and BP. Along with structural and 
functional readouts I was able to use these different lines to decipher and understand the 
changes and alterations in gene and protein expression that shed light onto the mechanisms 
that can lead to CVDs, as well as vascular diseases such as HHT, and an overall view on 
how vascular homeostasis is maintained. 
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7 Materials and Methods 
 
7.1 Animal Experimentation 
 
7.1.1 Isolation of mouse embryos from the uterus 
Breeding female mice were checked for a vaginal plug formation, indicating mating 
has usually occurred. When this plug is formed, it is counted as E0.5. Embryos at E14.5 and 
E16.5 were required and these developmental stages were calculated by counting from the 
positive plug formation to these final time points. 
Pregnant female mice were killed via cervical dislocation as anaesthetics can have 
unwanted effects on the embryos. The abdominal cavity was opened and the uteri were 
removed and placed in to cold PBS. A small part of the embryo, usually the tail, was used for 
genotyping.  
 
7.1.2 Magnetic Resonance Imaging 
MRI was used for cardiac functional analysis and was carried out by our in house 
service group. A Bruker Pharmascan 7.0 T machine, fitted with a 300 mT/m gradient system 
and a custom-built circularly polarized birdcage resonator, was used for analyzing our 
samples. An Early Access Package for self-gated cardiac imaging was used (Intragate, 
Bruker, Ettlingen, Germany) and all data were analysed via the Qmass digital imaging 
software (Medis, Leiden, the Netherlands). 
Before analysis mice had to be anaesthetized using 5 % Isofluorane /O2 to ensure a 
reduction in movement during measurements. The mice were then fixed in a dorsal 
orientation in a specialized mount to further ensure a more permanent position during 
measurement. The mice were then placed into a magnetic field where they were, kept at a 
constant temperature of 37 °C, via the systems thermostatic regulatory system and 
continually anaesthetised with a mask that produced 2 % Isoflurane/O2. 
We wanted to understand the cardiac function of our DKO mice in comparison to 
their littermate controls and both the SKO mice over an extended period of time. Therefore 
we began measurements at 1 month of age and then measured the same mice again at 3, 6, 
9 and 12 months from all groups. By using MRI we were able to determine cardiac wall 
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thickness, ejection fraction (EF), stroke volume (SV), left ventricular mass (LVM) as well as 
end diastolic (ED) and end systolic (ES) volume over a long period of time.  
 
7.1.3 Magnetic Resonance Angiography 
Two angiography techniques based on physical properties of flowing blood are most 
commonly used: The Time Of Flight method is based on the principles of in-flow of the fresh, 
unsaturated blood into the imaging plane and on the other side the Phase Contrast 
Angiography uses alternating flow encoding gradients to produce an angiogram. Both 
techniques provide an insight into morphology, but PCA additionally allows a mapping of the 
average blood velocities (PC-MRA). 
3 and 6 month old mice were measured under anesthesia (1.2 – 1.8 % Isoflurane in 
0.5 L/min O2 and 0.5 L/min air) in the 7.0 T superconducting magnet (Bruker Biospin, 
Pharmascan, 70/16, 16 cm; Ettlingen, Germany) equipped with an actively shielded imaging 
gradient field of 300 mT/m, and, after an upgrade, of 760 mT/m respectively. The frequency 
for the 1H isotope is 300.33MHz. The body temperature was maintained at 37 °C by a 
thermostatically regulated water flow system during the entire imaging protocol. 
For a rough positioning in the magnetic field a spinecho sequence, for exact 
positioning RARE-(Rapid acquisition with relaxation enhancement) sequences in coronal, 
sagittal and axial orientation was used. The interesting blood vessels are subsequently 
presented in an axial orientation with the 2D TOF-MRA: TE (echo time) = 2.9 ms, TR 
(repetition time) = 25 ms, FOV (field of view) =3.7x3.7 cm, MTX (matrix size) = 256x256, 
slice thickness = 0.8 mm, slice overlap = 0.5mm and 150 slices. Subsequently a three-
dimensional reconstruction (MIP) was calculated with the imaging software Paravision 5.1 
(Bruker, Ettlingen, BRD). 
For the following flow quantification via velocity mapping  it is important to set the 
slice orientation  strictly perpendicular to the target vessel, using an in-house-developed 
program 158. For the PC-MRA we use the following parameter: TE= 4.0ms; TR= 35 ms; 
Venc= 60 cm/sec, FOV = 4.0x2.5x2.0 cm, MTX =256x256x40 and slice thickness = 20 mm. 
The quantitative flow values are obtained by integrating across manually drawn regions of 
interest (ROI) that enclose the vessels (Paravision 5.1, ROI Tool, Bruker, Ettlingen, 
Germany). For the increase of accuracy magnitude images are used to define vessel walls 
and for a reduction of the influence of possible segmentation errors a velocity threshold is 
defined: Only pixels with a velocity >0 in the direction of flow are used. 
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7.1.4 Micro computed tomography 
µCT was performed at the Vascular Research Centre, Frankfurt am Main by Dr. 
Christoph Schürmann 159. Mice were killed and perfused with vasodilation buffer (4 mg/L 
Papaverine, 1 g/L Adenosine in PBS, Sigma-Aldrich, Taufkirchen, Germany) for 5 min, 
followed by fixation for 15 min with 4 % PFA. After PFA fixation, the mouse was perfused 
with the radiopaque contrast agent MicroFil (Flow Tech, Carver, MA, USA) with a pressure 
of 100-120 mmHg until the silicon polymer had set. Mice were stored overnight in 4 % PFA 
at 4 °C and scanned using a Skyscan 1176, Bruker micro-CT (Kontich, Belgium). Data 
reconstruction was done using the NRecon/InstaRecon CBR Server – Premium software 
(Skyscan, Kontich, Belgium/ InstaRecon, Champaign, Illinois, USA) and image analysis, 
segmentation of µCT data and quantification of vessel lumen area was performed with the 
Imalytics Preclinical Software (Gremse-IT, Aachen, Germany).  
 
7.1.5 Retina Assay and Immunofluroescence Histochemistry 
The protocol for mouse retina extraction was described by Stahl et al. 2010 160. To 
begin to process the eyes, they were firstly fixed in 4 % PFA for 1 h on ice. The eyes were 
then transferred to cold PBS where they were dissected and processed. Retinas were then 
blocked for 1 h in C-Buffer (1 % BSA, 3 % FBS, 0.5 % Triton, 0.5 % Tween-20, 0.01 % 
Sodium-Deoxy-Cholate in PBS) before antibody staining. Primary antibody was diluted in 50 
% C-Buffer/PBS and incubated overnight (O/N) at 4°C. Retinas were then washed in PBSA 
(PBS with 1 % BSA) + 0.1 % Tween-20, 3 times for 10-15 min each time. Secondary 
antibody is diluted in 50 % C-Buffer/PBS and incubated for 1 h at room temperature (RT) 
rotating in the dark. Retinas were again washed in PBSA + 0.1 % Tween-20, 3 times for 10-
15 min each time.  
For lectin staining retinas were washed in pBLEC (1 % Tween-20, 0.1 mM CaCl2,  
0.1 mM MgCl2, 0.1 mM MnCl2 in PBSA at pH 6.8) for 30 min. Isolectin B-4 antibody was 
diluted at 1:100 in pBLEC and incubated at RT for 2 h. Retinas were washed one in pBLEC 
for 30 min, then once in PBSA-Tween-20 for 30 min and lastly in PBSA for 30 min.  
To check for cellular proliferation, 5-ethynyl-2´-deoxyuridine (EdU) was injected at 50 
µg/g body weight i.p into P5 pups and the pups were left for 3 h, to allow for EdU 
incorporation. The P5 pups were killed via decapitation, as cervical dislocation is not 
possible. When staining for EdU incorporation, retinas were washed twice with 3 % BSA in 
PBS. Each retina was then incubated at RT for 20 min in 500 µL 0.5 % Triton-X100/PBS to 
permeabilize the samples. Retinas were then washed again twice in 3 % BSA/PBS. The 
EdU reaction cocktail was prepared according to the company’s protocol and 100 µL of this 
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reaction cocktail was added to each retina and left at RT for 30 min rotating. The samples 
had to be protected from the light. The retinas were finally washed once with 3 % BSA/PBS 
and further staining’s were then performed. 
For nuclear staining, DAPI was used at a 1:1000 dilution in PBSA and incubated for 
15 min while rotating at RT. Retinas were finally washed twice with PBSA for 10 min each. 
Retinas were mounted onto cover slides using MOWIOL and stored at 4°C. 
 
7.1.6 Blood Pressure Measurements 
BP of the control and DKO mice was determined using implantable telemetric 
transmitters (DSI, TA11PA-C10). Firstly the mice must weigh a minimum of 27 g before the 
catheter of the transmitter is inserted into the left carotid artery. Data was set to record every 
30 min for 180 s and this lasted for 7 days per treatment. The first recordings are performed 
7 days after implantation of transmitter to allow the mice time to recover after the surgery 
and reach basal levels.  
Two different chemical compounds we used to invest potential alterations in BP were 
Captopril and L-NAME at a concentration of 600 µg/mL and 500 µg/mL, respectively. These 
compounds will be administered by dissolving them in the drinking water where the mice 
drank them ad libitum, as a non-invasive method. The water was changed on a daily basis to 
ensure the chemicals were still present and effective. One week’s period was given between 
each treatment to make sure the mice had recovered and returned to their normal basal 
levels before the next set of measurements.  
Data was sampled with Dataquest A.R.T. 4.0 with a sample rate of 500 Hz and with a 
filter cut-off of 100 Hz. Data reduction is performed by Dataquest A.R.T. 4.0 by calculating 
the reduced mean for the sampled signals. From these devices diastolic, systolic, pulse 
pressure (PP), activity, BP and HR were measured. The mean of these values were then 
calculated separately for day- and night-time.  
 
7.2 Molecular Biology 
 
7.2.1 Genomic tail and tissue DNA Isolation 
Tail cuts or small pieces of embryonic tissue were digested in 500 μl TENS Buffer 
(100 mM EDTA pH 8.0, 100 mM NaCl, 50 mM Tris-hydrochloric acid (HCl) pH 8.0 and 1 % 
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SDS), together with 200 μg/mL Proteinase K at 56°C O/N. The next day, the samples were 
spun at 12,000 x g for 10 min and 500 μl Isopropanol was then added to precipitate the 
DNA. Samples were left to stand for 10 min before being centrifuged again at 12,000 x g for 
15 min. The DNA pellet was then washed with 700 μl 70 % Ethanol (EtOH) and centrifuged 
further. The pellet was then let dry for 5-10 min before adding 100 μl of ddH2O. To elute and 
re-suspend the DNA, the samples were left to shake O/N at 56°C. This extracted DNA was 
then used for genotyping. 
 
7.2.2 Polymerase Chain Reaction and Genotyping Protocols 
Polymerase chain reaction (PCR) was performed to determine mice genotypes as 
well as determining optimal primer conditions. For each setup PCR buffer (20 mM Tris/HCl 
pH 8.4, 50 mM KCl), 2 mM MgCl2, 10 mM dNTP´s (0.2 mM per nucleotide), 10 mM forward 
primer, 10 mM reverse primer and 0.2 units Taq DNA-polymerase were added to 1 μl 
genomic DNA. The total volume of each reaction was 25 µL and the difference in volume 
was made using ddH2O. The primers (Table 5) and protocols (Table 6) used for each 
genotype are mentioned below.  
Table 5: Mouse genotyping primers 
 
Genotype Forward Primer Reverse Primer 
Apelin Mutant 
ATG TCT GGG TGT AGG TCC ATA 
AAG G 
GAC AGT TTC TCT AAC TCA AAG 
GGC C 
Apelin Wild 
Type 
ATG TCT GGG TGT AGG TCC ATA 
AAG G 
GCT TCC TTC TTC TAG TCC TGT 
TCC A 
BMP10 AAC AGG CCC GCA TCA TTT AT TGG CCC AGG GGC CTA TTC TTT G 
BMP9 Mutant CTG TGG TCC ACC AGG ATA CG ACA CCG GGA TTC TCC CAA TC 
BMP9 Wild 
Type 
GTC ACT GTT CCC CCA CTA GC GAA AGG GGA AGT CCT CCG TG 
General Cre 
CCA GGC TAA GTG CCT TCT CTA 
CA 
AAT GCT TCT GTC CGT TTG CCG 
GT 
 
Table 6: Specific genotyping protocols 
 
Apelin BMP10 BMP9 Mutant BMP9 Wild Type General Cre 
94°C – 5 min 95°C – 5 min 95°C – 5 min 95°C – 5 min 95°C – 4 min 
94°C – 10 s 95°C – 30 s 95°C – 30 s 95°C – 30 s 95°C – 1 min 
58°C – 10 s 58°C – 30 s 50°C – 30 s 65°C – 30 s 67°C – 1 min 
72° - 40 s 72°C – 1 min 72°C – 45 s 72°C – 40 s 72°C – 1 min 
Go to 2 repeat 40x Go to 2 repeat 40x Go to 2 repeat 35x Go to 2 repeat 35x Go to 2 repeat 30x 
72°C – 5 min 72°C – 5 min 72°C – 5 min 72°C – 5 min 72°C – 10 min 
4°C - ∞ 4°C - ∞ 4°C - ∞ 4°C - ∞ 4°C - ∞ 
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7.2.3 RNA isolation 
Trizol (Invitrogen) was used to extract RNA from both tissue and cells in accordance 
with manufacture’s protocol. To obtain homogenous tissue samples, the samples were 
ground with sterile steel balls and then processed using a tissue homogeniser.  
Tissue samples were normally suspended in 1 mL Trizol, whereas cells collected 
from smaller plates were placed in 500 µL Trizol (in this case the other components volume 
though out the protocol were also halved). 200 µl of chloroform was added to allow for 
separation of RNA from unwanted components such as, proteins. The samples were 
centrifuged at 4°C for 5 min at 12,000 x g. Once each aqueous phase had been separated 
clearly the top layer containing the RNA was removed and placed in 500 µL of cold 
Isopropanol. The samples were mixed and left on ice for 5-15 min to allow for the RNA to 
precipitate. Samples were centrifuged at 12,000 x g for 15 min, the pellet was collected, 
supernatant removed and the pellet was washed twice with 1 mL 75 % EtOH. After the 
samples had been washed they were dried carefully, so as not to dry out the pellet, and the 
pellets were then resuspended firstly in 25 µL of DEPC water (0.1 % v/v DEPC in ddH2O). 
DEPC is used because it inactivates RNAses and autoclaving before it’s used is necessary 
to deactivate the DEPC. To determine the concentration of each sample, a Nanodrop 
photospectrometer was used. 
 
7.2.4 Reverse Transcription and (semi)Quantitative Reverse Transcription PCR 
For Quantitative Reverse Transcription PCR (qRT-PCR), reverse transcription of 
RNA into cDNA is first needed. RT-PCR was performed using the Superscript II kit according 
to the manufacture’s protocol. 
To begin 1 μg, in a total of 10 µL DEPC H2O, of isolated RNA was incubated with 1 
µL Oligo(dT)T15 and 1 μL 10 mM dNTP at 65°C for 5 min. Samples were then put on ice and 
in each sample a mixture was added. This mixture contained 4 μL 5x First strand buffer, 2 
μL 1 M DTT, 1 μL RNAsin and 1 μL SuperScript™ II reverse transcriptase. The samples 
were then heated at 42°C for 60 min and then at 70°C for 15 min. Samples were then put on 
ice and then diluted at 1:4 using ddH2O. 
To be able to measure the differences in differential gene expression, SYBR®Green 
I (Thermo Fisher) was used, and RT-PCRs were performed using a iCycler Multicolor Real 
Time PCR machines. The setup up used was according to manufacturing suggestions with 
the majority of PCRs run at an annealing temperature of 60°C. All setups used 25 μL 
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reaction mix which contained 5.5 μL ddH2O, 12.5 μL 2x SYBR®Green, 1 µL 2.5 mM primers, 
both forward and reverse, and 5 μL of cDNA that had been further diluted at 1:10.  
To calculate the relative expression of each sample, the cT values quantified by the 
PCR machine were used. Samples then had to be individually normalised by using the 
expression of the housekeeping genes, such as acidic ribosomal protein (Arp) for the mice 
samples or Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) for the human samples.  
Table 7: qRT-PCR protocol 
 
Temperature (°C) Duration (s) Cycles 
95 30  
95 07  
60 20 max. 40 
72 03  
50 10 100 (+0.5 °C per step) 
 
Table 8: qRT-PCR primers 
 
Gene 
Name 
Specie
s 
Forward Reverse 
ALK1 Mouse GAG GAT TAC AGG CCA CCT 
TTC 
GGA TTG TGA CTG AGC TTC TGC 
ANP Mouse GGA TTT CAA GAA CCT GCT AG TGC TTT TCA AGA GGG CAG AT 
αSMA All GTG CTA TGT CGC TCT GGA CTT 
TGA 
ATG AAA GAT GGC TGG AAG AGG 
GTC 
APLN Mouse GAG GAA ATT TCG CAG ACA GC GGG ACC ATC AGC AGC TAG AA 
APLN Human AAG GGA CCC ATG CCT TTC CAC TGG TGG CTA CAG CAG GT 
APLNR Mouse TGG CCA CAG CAG TCT TAT GG AGG TCA CTA CAA GCA CCA CG 
APLNR Human CCT GCA TCA GCT ACG TCA 
ACA 
GGG ATG GAT TTC TCG TGC ATC T 
ARP Mouse AAG CGC GTC CTG GCA TTG 
TCT 
CCG CAG GGG CAG CAG TGG T 
BMP10 Mouse GCT AAC ATC ATC CGG AGC 
TTC 
CTC TGT TGA TAC TAA GAC CAG C 
BMP9 Mouse CTC CCA GGA CAA AAC CAG AG TGT GCT TCT GAA AGG GGA AG 
BNP Mouse GCA ATT CAA GAT GCA GAA GC AAG AGA CCC AGG CAG AGT CA 
CCNA2 Mouse GCC TTC ACT CAT TGC TGG AG TGA CTG TTG GGC ATG TTG TG 
CD34 Mouse GGT AGC TCT CTG CCT GAT 
GAG 
TGG TAG GAA CTG ATG GGG ATA 
TT 
CD34 Human GCA AGC CAC CAG AGC TAT TC TGC ATG TGC AGA CTC CTT TC 
GAPDH All ACC ACA GTC CAT GCC ATC AC CAT GCC AGT GAG CTT CCC GT 
HEY1 Human TGC GGA CGA GAA TGG AAA 
CTT GAG 
CGG CTT TTT CTA GCT TAG CAG 
ATC CCT 
PECAM Mouse AGT GAC AGC GGG GAG TAC AG TAC TGG GCT TCG AGA GCA TT 
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7.2.5 Gene Array Protocol 
The gene array was performed according to the manufacture’s manual from 
Affymetrix.  
 
7.3 Biochemistry 
 
7.3.1 Protein isolation from tissue 
Samples, which had been snap frozen and kept at -80°C, were crushed using a 
chilled mortar and pestle and were ground into a fine powder. The fine sample powder was 
then added to a new tube and 300 µL protein extraction buffer (0.1 M Tris/HCl pH 8.0, 0.01 
M EDTA, 10 % SDS and protease and phosphatase inhibitors 4 μg/mL aprotinin, 500 μg/mL 
benzamidine, 4 μg/mL leupeptin, 1 mM Na3VO4, 20 mM NaF and 2 mM PMSF) was added. 
The samples were then sonicated for 20 s for 5 cycles and afterwards were 
centrifuged. At this stage samples should not be viscous. If that was the case, more sample 
buffer was added and samples were again sonicated. 
To determine the concentration of the samples, to allow for equal loading on a 
Western Blot, a small amount of sample was removed and a Bio-Rad assay was performed. 
Before loading onto a gel, 0.04 M DTT was added to the samples. The samples were 
then heated at 98°C for 5 min and then centrifuged before loading. Samples could be stored 
at -20°C or -80°C for long term storage. 
 
7.3.2 Protein isolation from cell culture 
Adherent cells were washed once in PBS and protein extraction buffer was added. 
The samples were scrapped into a new tube, sonicated and centrifuged for 10 min at 20,000 
x g. The supernatant was placed into a new tube, 0.04 M DTT was added and the samples 
were incubated at 98°C for 5 min and centrifuged again before use. 
 
7.3.3 Protein concentration measurement 
To measure the protein concentration of each sample, the DC™ protein kit (BioRad) 
was used. A standard curve was prepared by using known, different concentrations of 
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bovine serum albumin (BSA). The samples were prepared according to the company’s 
protocol. The samples were then measured by using the Flurostar and the concentration 
could be measured via an absorption measurement at 750 nm. 
 
7.3.4 Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis 
Gels for sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
were self-made according to Table 9 below. To begin an empty 1 mm gel chamber was filled 
three quarters fill with the resolving gel mixture and left for about 30-40 min until they had 
set. Once dry the chamber was then filled with the stacking gel and a comb was inserted at 
the top of the chamber. When the stacking gel had set the complete gel could then be used 
for gel electrophoresis. The chamber was then fixed into a western blot chamber, SDS 
running buffer was poured in (2.5 mM MES, 2.5 mM Tris, 0.05 % SDS, 50 mM EDTA) and 
the prepared protein samples were loaded. At the beginning electrophoresis was at 60 volts 
(V) until the samples had passed though the stacking gel and then the volts were increased 
to 140 V until the samples were separated accordingly.  
Table 9: Resolving and stacking gel for SDS-PAGE  
 
Resolving Gel (10 mL)     Stacking Gel (10 mL)  
Components 8 %  10 %  12 %  15 %  Components 5 %  
Water  4.60 4.00 3.30 2.30 Water 6.80 
30 % acryl-bisacrylamide  2.70 3.30 4.00 5.00 30% acryl-bisacrylamide 1.70 
1.5 M Tris-HCl (pH 8.8)  2.50 2.50 2.50 2.50 1.5M Tris-HCl (pH 8.6) 1.25 
10 % SDS 0.1 0.1 0.1 0.1 10% SDS 0.1 
10 % APS 0.1 0.1 0.1 0.1 10% APS 0.1 
TEMED 0.006 0.004 0.004 0.004 TEMED 0.01 
 
7.3.5 Western Blot Image Processing and Analysis 
Wet transfer was used to transfer the proteins from the gel onto a nitrocellulose 
membrane. The transfer chamber was lined with sponges that had been soaked in transfer 
buffer (12.5 mM Bicine, 12.5 mM Bis-Tris, 0.8 mM EDTA, 20 % Methanol). Next Whatman 
filter paper was placed followed by the gel and then the membrane. Lastly another Whatman 
filter paper and then soaked sponges were added. This chamber was loaded and filled with 
transfer buffer and run at 30 V for 2 h. To check for equal loading and a proper transfer, the 
blots were later stained with Ponceau S red staining solution.  
To stain the membrane for the specific antibody, the membrane was firstly blocked 
with 5% skim milk powder in TBST at 4°C O/N. This was followed by the primary incubation 
step at RT for approximately 5 h with the first required antibody (Table 10). Next the 
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membrane had to be incubated with a horse-radish-peroxidase (HRP-) coupled secondary 
antibody (Table 10). If it was necessary to use a membrane twice for the detection of two 
different proteins, then the membranes were stripped with RestoreTM PLUS Western Blot 
Stripping Buffer (Thermo Scientific, 46430) for 10 min and then washed 3 times with TBST 
(20 mM Tris, 140 mM NaCl, 0.1 % Tween-20) and blocked again O/N using 5 % skim milk 
powder in TBST at 4°C before the next antibody was used. 
To detect the protein signal, chemiluminescence was used with the SuperSignal™ 
Femto kit (Pierce) and imaged using a VersaDoc™ 3000 Imaging system. To quantify the 
protein signal, the software “Quantity One” was used. 
Table 10 Antibodies and working dilutions used for western blotting 
 
Name Dilution IgG Source 
Actin 1:1000 rabbit Sigma, A2668 
ANP 1:1000 rabbit Novus Biologicals, NBP2-14873 
pSMAD1/5/8 1:1000 rabbit Cell Signalling Technology, 9511 
pSMAD2 1:1000 rabbit Cell Signalling Technology, 3101 
α-rabbit (HRP) 1:300 goat Pierce, 31460 
 
7.4 Histochemistry 
 
7.4.1 Cryosectioning and Paraffin Sectioning 
For immunohistological analysis cryosectioning was performed. To prepare for 
cryosectioning tissues were fixed by O/N incubation in 4 % PFA/PBS. They were then 
transferred into 15 % sucrose/PBS O/N and then 30 % sucrose/PBS O/N respectively. 
Samples were then placed into moulds and embedded in Tissue-Tek® O.C.T. Polyfreeze™, 
and frozen using dry ice. Samples were kept long term at -80°C. Sections were made using 
a cryostat-microtome (Leica) and sectioning was performed at between -20 and -25°C. The 
cryostat was set to cut at a thickness of 8 μm. The sections were placed on microscope 
slides and stored at -20°C. 
Paraffin sections were used for histochemical staining. To prepare organs for paraffin 
sectioning, the mice were first perfused with PBS and then secondly with 4 % PFA. The 
organs were excised from the mouse and kept O/N at 4°C in 4 % PFA. Next they were 
washed twice in 1x PBS and then added to 70 % EtOH O/N at 4°C. Following this they were 
put into 80 % EtOH followed by 90 % EtOH and twice 100 % EtOH for 2 h at each point at 
RT. Next the samples were put into isopropanol O/N at RT and then were placed in a 1:1 
mixture of isopropanol/Paraffin O/N at 65°C. The samples were left in 100 % Paraffin at 
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65°C all day and then were placed in a vacuum oven at 65°C for 2 h. After this the samples 
could then be embedded. Sections were performed on a Leica RM2125RT microtome at RT. 
and samples were placed in a water bath at 42°C before putting them on a slide. Slides were 
dried O/N on a hot plate at 42°C and sections were then kept at RT. 
 
7.4.2 Hematoxylin and Eosin Staining 
Firstly the paraffin sections had to be deparaffinized by placing the samples twice in 
Xylol for 5 min each time. The samples were then passed through 100 % EtOH, 90 % EtOH, 
80 % EtOH and 70 % EtOH for 2 min each time. The sections were then placed in ddH20 for 
2 min followed by Meyer’s Hematoxylin for 10 min. Next the sections were twice dipped and 
quickly passed through ddH20 before being put into normal, running water for 10 min. 
Samples were then dipped 10 times in HCl and again placed into normal water for 10 min. 
Samples were added to Eosin for 10 min and the sections passed through 70 %, 80 % and 
90 % EtOH. Samples were left for 10 min in 100 % EtOH and xylol twice for 5 min each time. 
The slides were mounted using Entellan.  
 
7.4.3 Masson’s Trichrome Staining 
Paraffin sections were deparaffinised by placing the samples twice in Xylol for 5 min 
each time and then by passing them through 100 % EtOH, 90 % EtOH, 80 % EtOH and 70 
% EtOH for 2 min each time. The slides were placed in ddH2O for 2 min before they were 
placed into preheated Bouin’s Solution at 56°C. They were left in the Bouin’s solution at 
56°C for 15 min. The slides were washed in running tap water for 20-25 min until the yellow 
colour was removed as much as possible. 
The slides were rinsed in ddH2O briefly before they were put into Mayer’s 
Hematoxylin for 5min. Again the sections were rinsed in running tap water for 5 min and then 
dipped briefly in ddH2O. The sections were then stained in Biebrich Scarlet-Acid Fuchsin 
solution for 5 min and rinsed again briefly in ddH2O. A solution with 
Phosphotungstic/Phosphomolybdic acid/ ddH2O at a ratio of 1:1:2, respectively, was 
prepared and the slides were placed in the solution for 5 min. Next the slides were further 
stained by adding them to Anilin Blue solution for 5 min. The slides were added to 1 % 
Acetic Acid for 2 min and then washed in ddH2O before they were dehydrated. Dehydration 
of the slides was performed by dipping the sections in 96 % EtOH and then placing them in 
twice in 100 % EtOH for 2 min each time. Slides were then placed in Xylol twice for 10 min 
each time and then mounted with Entellan. 
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7.4.4 Toluidine Blue Staining 
Firstly 0.1 g of toluidine blue powder was dissolved in 100 mL of water and filtered. 
Sections were then stained for 2-3 minutes with toluidine blue dye and washed 3 times in 
water before mounting with Mowiol.  
 
7.4.5 Immunoflurosecence Antibody Staining  
Sections were fixed using 4 % PFA for 15 min and to permeabilize 0.2 % Trition X-
100 in PBS was added for 5min. Sections were washed three times in PBS before they were 
incubated for 1 h with Blocking Solution (5 % FCS, 1 % BSA, 1x Gold Buffer [20 mM Tris, 
0.155 M NaCl, 2 mM EGTA, 2 mM MgCl2 at pH 7.5]) at RT. After blocking, the primary 
antibody (Table 11) was diluted in 1 % BSA and 1x Gold Buffer and incubated O.N. at 4°C. 
Following that the sections were washed 3 times in PBS and incubated with the correct 
corresponding secondary antibody in 1 % BSA/1x Gold Buffer at RT. for 1 h. Slides were 
again washed 3 times in PBS and mounted using a glass cover and Mowiol. Sections were 
left to dry O.N. and then stored at 4°C. 
Table 11 Antibodies and working dilutions used for immunofluorescence 
 
Name Dilution IgG Source 
αSMA 1:1000 Mouse Sigma, C6198 
ERG1/2/3 1:1000 Rabbit Santa Cruz, sc-353 
Ki-67 1:1000 Rabbit Abcam, ab15580 
MF20 1:50 Mouse Hybridoma Bank, MF 20 
PECAM 1:500 Rabbit Abcam, ab28364 
 
7.4.6 Electron Microscopy 
Mice were perfused and the tissues were fixated in fixation buffer (1.5 % 
Glutaraldehyde and 1.5 % Paraformaldehyde in 0.15 M HEPES Buffer at pH 7.3) for 24 h at 
4°C. The tissue was that contrasted using 1 % osmium tetroxide followed by washing in 
distilled water and embedded in hypoxic resin. Next the samples were contrasted using 
uranyl acetate and dehydrated by placing the samples in an increasing percentage of 
alcohol. Finally the samples were embedded in agar100 and ultra-thin slices were made with 
an ultra cyrotome and analysis was performed using a transmission electron microscope 
(TEM, Zeiss EM 902).  
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7.5 Cell Culture 
 
7.5.1 Adult Mouse Cardiomyocyte Isolation 
The adult CM Isolation protocol was based and modified from a previous publication 
161. To begin the mice were killed and the hearts were directly removed from them. In the 
aorta a cannula was placed and fixed to allow for perfusion and finally was arrested and then 
perused with approximately 20 mL Calcium-Free Buffer (113 mM NaCl, 4.7 mM KCl, 0.6 mM 
KH2PO4, 0.6 mM Na2HPO4, 1.2 mM MgSO4x7H20, 12 mM NaHCO3, 10 mM KHCO3, 10 mM 
Hepes, 30 mM Tarin, 10 mM 2,3-Butanedionemonoxime, 5.5 mM Glucose). To dissociate 
the CMs, 20 mL Enzyme Buffer (0.25 mg/mL Liberase DH, 0.14 mg/mL Trypsin, 12.5 µM 
CaCl2) was used. The heart turned pale and swelled slightly to indicate that perfusion was 
carried out properly and was complete. The aorta was then removed from the heart and then 
the ventricles were separated from the rest of the heart and chopped into small pieces. 
These small ventricle pieces were then added to 5 mL Stop Buffer 1 (Enzyme Buffer, 10 % 
FCS, 12.5 µM CaCl2). The pieces were continuously resupsended by pipetting up and down 
with a wide-mouth pipette. The cell suspension was then moved into a 50 mL falcon tube 
and the cells were allowed to settle down to the bottom of the tube. The supernatant was 
removed and placed into a new tube which was then centrifuged for 1 min at 300 x g. Both 
pellets, one from the cells that has settled and two from the cells that had been spun down, 
were then resuspended in 5 mL of Stop Buffer 2 (Enzyme Buffer, 5 % FCS, 12.5 µM CaCl2), 
combined and then filtered using a 100 µm cell strainer. 
An important note to remember was to keep the Ca2+ levels at a final concentration of 
1 mM. Again the samples were centrifuged for 1 min at 300 x g and the supernatant was 
finally removed, leaving the CMs in the pellet. The CMs were resuspended in the appropriate 
cell culture medium (M199 medium from Gibco, 5 mM Creatinine, 2 mM L-carnitine in HCl, 5 
mM Taurin, 25 mM Hepes, 1% Penicillin/streptomycin, 5 % FCS, 1 % Its supplement from 
Sigma) and then plated on laminin-coated slides. They were left to attach for 4 h and then 
were fixed and stained with MF20 and DAPI (Table 11). Adult CMs were then analysed, 
firstly by taking images on a Zeiss Z.1 Axio Imager 2 microscope and then the area of 200 
CMs was calculated using ImageJ. 
7.5.2 Adult Mouse Smooth Muscle Cell Extraction, Culturing and Stimulation 
A 6 well plate should be coated in 1% Gelatin for at least 30min before plating the 
cells. For mice to be able to plate 1 well in a 6 well plate, between 6-8 mice were needed at 
approximately 8-10 weeks of age. Mice were killed via CO2 as cervical dislocation could 
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destroy the aorta. Once the mice were dead the aorta was removed and put into a dish with 
ice cold HBSS. The adventitia was removed by using two serrated bent forceps and by 
gently pulling it away from the aorta. Each aorta was then immersed and gently moved 
through 70 % EtOH for 2-3sec. The aortas were then washed three times in HBSS before 
mincing them into small pieces. The aortas were then digestion according to the following 
instructions three times. Firstly they were digested in 10ml Digestion Buffer (1 mg/ml 
Collagenase, 0.5 mg/ml Soybean trypsin inhibitor, 0.3 mg/ml BSA) for 40-60 min in a 
shaking water bath at 37°C. Every 15-20min the pieces were pipetted a number of times to 
ensure no clumps formed and to allow for more efficient digestion. After each digestion step, 
the pieces were let settle to the bottom of the flask and the supernatant was centrifuged at 
120xg for 5min. Then 10ml new Digestion Buffer was added to the cell pieces and the 
second digestion step was carried out while the cell pellet was then resuspended in SMC 
medium (Glutamax (Invitrogen, 10569010), 1 % P/S, 10 % FCS, 10 % mouse serum, 0.5 % 
Amphotericin) and plated into one gelatin coated well. This process was carried out three 
times and on the third time the supernatant was passed through a 100 µm filter before 
plating and all cell mixtures were combined in 1 well. The cells were then left untouched for 
one week before the first medium change was performed.  
To starve these mouse SMCs the media had to be switched down over a couple of 
days. Firstly in the morning of the first day the medium was changed to Glutamax with 2% 
FCS and 2 % mouse serum and then in the evening the media was again changed to 
Glutamax plus 2 % FCS. The next day the medium was exchanged for Glutamax without 
any serum and then finally the next day the cells were stimulated in Glutamax without any 
serum.  
Cells were stimulated with BMP9 (R&D 5566-BP-010) or BMP10 (R&D 6038-BP) or 
both together, at 1 ng/mL and 25 ng/mL respectively. 
 
7.5.3 Adult Rat Smooth Muscle Cell Extraction, Culturing and Stimulation 
Rat smooth muscles cells (rSMCs) were isolated according to the protocol described 
by Owens et al 162. A 60 mm plate was coated in 1 % Gelatin for at least 30min before 
plating the cells. 4-5 Sprague-Dawley rats approximately 150-175 g in weight were used. 
Rats were killed via CO2 and the aortas were put into a dish of M199 media (ThermoFischer, 
12340-030) containing 1 % P/S. The loose fat and connective tissue was gently removed 
from the aorta and was then placed in a new dish with M199 and 1 % P/S. The aortas were 
placed in the enzyme solution (25 ml per 5 aortas, 1 mg/ml Collagenase II, 1 mg/ml Soybean 
trypsin inhibitor, 0.25 mg/ml Elastase and 1 % P/S made up to 25 ml Hank’s HBSS at a pH 
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of 7.2) and preincubated for 20 min at 37 °C. Aortas were then placed into M199 and 1 % 
P/S and the enzyme solution was rinsed away and then the adventitia was removed from the 
media. A longitudinal incision was made along the aortas where pieces with adventitia still 
attached were removed and the intimal surface of the aorta was gently scraped. The aortas 
were rinsed to wash off the intimal cells and then placed in the above enzyme solution and 
cut up into small pieces and then incubated at 37 °C for 1 h. Free cells were collected and 
rinsed in M199 and 1 % P/S to remove the excess enzyme solution and then passed through 
a filter for plating. Media containing 10 % FBS is needed to inactivate the enzyme solution 
and the cells are then centrifuged, counted and plated according to the needed cell density. 
Media should be changed after about a week and cells shouldn’t be passaged until cells are 
subconfluent to allow for proper cell growth and expansion. Cells were grown in SMC growth 
medium plus supplements (Provitro, 200 0601 – prf) containing 1 % P/S and 0.1 % 
Amphotericin-B (rSMC media). For splitting and before stimulation the smooth cells were 
kept in a media mixture at a 1:1 ratio of rSMC growth media and Media199 with 1 % P/S, 10 
mM HEPES, 0.1 % Amphotericin-B and 10 % FBS. 
To starve rat SMCs the medium is changed to Medium 199 and 10 % FBS on the 
first day, the next day the medium is changed to Medium 199 without FBS and the following 
day the cells were stimulated in Medium 199 only. They were stimulated with BMP9 (R&D 
5566-BP-010) or BMP10 (R&D 6038-BP) or BMP9 and BMP10 together, at a concentration 
of 1 ng/mL and 25 ng/mL respectively or with Apelin-13 (Bachem, H-4568) at 1mM and 
FGF2 at 20ng/mL used as a positive control. When rSMCs were directly stimulated with 
BMP9 and BMP10 they were stimulated after starvation O/N in M199 or M199 with 1 % FCS. 
 
7.5.4 Smooth Muscle Cell Proliferation and Migration Assay 
To determine the effects of BMP9, BMP10 and Apelin (APLN) on rSMC proliferation, 
cells were plated at a density of 5,000 cells in a 96 well plate. To test for cellular proliferation 
an MTT assay (Vybrant® MTT Cell Proliferation Assay Kit, ThermoFisher V13154) was used 
and performed according to the company’s manual. The medium from the cells was 
removed and replaced it with 100 µL of fresh starvation medium.  A stock solution of 12 mM 
MTT had been made and 10 µL was added to each well. As a negative control 10 µL of the 
MTT stock solution was added to 100 µL of the starvation medium alone. The cells were 
incubated at 37°C for 4 h. Next 100 µL of the SDS-HCl solution was added to each well and 
mix thoroughly. The cells were further incubated at 37 °C for 4 h before each sample was 
mixed the absorbance read at 570 nm.  
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To understand the migratory effects these different compounds have on rSMCs, the 
cells were first plated in a 24 well plate and let grow till fully confluent. The cells then 
underwent the starvation process mentioned before. When in starvation media a small 
scratch was made down the center of each well, the cells were then washed once or twice 
before starvation media containing the difference compounds being tested was added. 
Photos were made of the scratched area which was then taken again after 24 h of 
stimulation. Brightfield images were taken as were immunofluorescent pictures of Dapi 
stained.  
 
7.5.5 Human Umbilical Vein Endothelial Cell Culturing and Stimulation 
Human Umbilical Vein Endothelial Cell (HUVECs) were obtained from Lonza (CC-
2519) were cultured in Endothelial Basal Medium (CC-3121) combined with 10% FCS and 
EGM™ SingleQuots™ (CC-4133), which contained growth factors, cytokines, and 
supplements.  
Cells were plated in T75 cell culture flasks for maintenance at 37 °C and 5 % CO2. 
When needed for stimulation the cells were split maximum 1:6 onto 15 cm cell culture plates. 
To starve the HUVECs, the media was switched to Endothelial Basal Medium without FCS 
and the EGM™ SingleQuots™ but just contained 0.1 % BSA for 6 h. 
After HUVECS were starved for 6 h, they were stimulated with BMP9 (R&D 5566-BP-
010) or BMP10 (R&D 6038-BP) or BMP9 and BMP10 together, at a concentration of 1 
ng/mL and 20 ng/mL respectively. TGF-β was used at a concentration of 5 ng/mL. 
Cells were stimulated for 6 h before the media was changed or cells were collected for 
further experiments.  
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7.6 Analysis Programs 
 
7.6.1 Statistical Analysis 
All graphs and data are shown as mean ± standard error (mean ± SEM). To calculate 
the difference between each of the groups and to determine their P values, the two-tailed 
student’s t-test was performed using the statistical analysis program from GraphPad Prism 
version 6.07 (GraphPad Software, La Jolla California USA, www.graphpad.com). From the 
program the P values were defined as *p<0.05, **p<0.01, p***<0.001, ****p<0.0001, non-
significant (ns) p>0.05.  
 
7.6.2 Gene Ontology Term Analysis 
To determine changes in global gene sets of the different arrays performed, a Gene 
Ontology enRIchment anaLysis and visuaLizAtion tool (GOrilla) was used 163. This program 
gave an overview into biological processes that were both up- and down-regulated when 
comparing DKO to WT samples or stimulated and none stimulated samples. 
 
7.6.3 Gene Set Enrichment Analysis  
Another program used to analysis gene sets from the array data was Gene Set 
Enrichment Analysis (GSEA) 164,165. This program was used to give insight into global 
changes happening within the different gene set samples. 
 
7.6.4 Venn Diagram Generation 
To determine overlapping genes within the various gene array sets, Venn diagrams 
were generated using an online tool 166.  
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7.7 Generation of Mouse Lines 
 
7.7.1 BMP9 SKO Line 
Bmp9 (also known as GDF2) targeted ESCs were bought from EUCOMM (MGI: 
1321394, project: VG10018) and upon homologous recombination the entire coding region 
of Bmp9 was replaced with a lacZ cassette, resulting in targeted deletion of Bmp9 shown in 
Fig. 10. These targeted ESCs were then injected into blastocysts of fertilized female mice 
and backcrossed for 5 generations to generate the Bmp9-/- SKO (BMP9 SKO) line.  
 
 
Figure 10: BMP9 SKO mouse line schematic 
BMP9 was generated by inserting a cassette, containing a lacZ reporter and neo
r
 selection, into the 
coding region of BMP9 via homologous recombination, therefore generating a constitutive knockout 
mouse. Arrows indicate general location of the genotyping primers used. 
 
7.7.2 BMP10 cKO Line 
The Bmp10 heart specific conditional knockout mice (BMP10 cKO) were generated 
and described by Bücker 167. A BAC containing 61.5Kb (87339721-87401265) genomic DNA 
of chromosome 6 was obtained from BACPAC Resources Center (BPRC) (bMQ438f03). A 
12.4 kb fragment (BamHI-HindIII) was subcloned into pKODTA vector by homologous 
recombination in SW102 cells. 5’ and 3’ recombination arms were inserted into pL451 vector 
containing a FRT flanked Neomycin selection cassette with a single LoxP site. The 
XhoI/SacII digested fragment was introduced into the first intron by recombination. For 
insertion of a second LoxP site, 5’ and 3’ recombination arms were inserted into pL452 
vector containing a Neomycin selection cassette flanked by two LoxP sites. A KpnI/SacII 
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fragment was introduced into intron 5 by homologous recombination. For gene targeting, 20 
μg of NotI-linearized BMP10 cko-targeting vector DNA was electroporated into 129/Bl6 F1 
hybrid ES cells. Targeted clones were selected for neomycin resistance and were confirmed 
by Southern blotting (EcoRI digest: WT, 18.8 Kb; mutant, 8.9 Kb) and PCR with primers 
surrounding the single loxP site in the long homolog arm. The same PCR reaction was used 
to genotype resulting recombinant mice after injection of selected ESCs into blastocysts of 
fertilized female mice and backcrossed for 5 generations. To remove the neomycin cassette 
these mice, carrying the targeted Bmp10 allele, were crossed with a Flp deleter mouse line. 
Once the neomycin cassette was removed there mice were then backcrossed for five 
generations to remove the Flp deleter. For heart specific conditional Cre-mediated 
recombination, Bmp10fl/fl mice were bred with Nppa Cre (also known as ANF Cre) transgenic 
mice as shown in Fig.11 168. 
 
 
Figure 11: BMP10 cKO mouse line schematic 
LoxP sites (triangles) were inserted into the area of interest via homologous recombination. These 
sites were excised and exon 2 of the gene was removed when in the presence of ANF Cre to give a 
heart specific conditional knockout line. Arrows indicate general location of the genotyping primers 
used. 
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7.7.3 BMP9 and BMP10 DKO Line 
BMP9 and BMP10 DKO mice were generated by crossing ANF-CreposBmp10fl/fl with 
Bmp9-/- mice on a C57/BL6 background to give ANF-CreposBmp10fl/flBmp9-/- (DKO) mice. 
These mice were then backcrossed for 5 generations.  
 
7.7.4 BMP9, BMP10, Apelin TKO Line 
Apelin KO (Apln-/-) mice described by Kuba et al 169. To remove Apln a targeting 
vector that replaced exons 2 and 3, the complete coding area of Apln, was constructed using 
the self-excision ACN-Neo cassette as seen in Fig. 12 below. The ACN-Neo cassette 
contained a testis-specific ACE promoter–driven Cre recombinase and a PGK promoter–
driven neomycin resistance gene which was flanked by loxP sites and in the mouse testis, 
the whole ACN-Neo cassette is excised through Cre-lox–mediated recombination. 
 
Figure 12: Apelin KO mouse line schematic 
Apln coding area, exons 2 and 3 were substituted with the ACN-Neo self-excision cassette via 
homologous. In the testis self-excision of the ACN-Neo cassette occurred, resulting in the removal of 
the ACN-cassette. Diphtheria toxin A (DTA) was used as a negative-selection cassette and the SacI 
(S) digestion sites are also shown. 
 
Bmp9, Bmp10, Apln triple knockout (TKO) mice were generated by crossing  
ANF-CreposBmp10fl/flBmp9-/- mice with Apln−/y males or Apln+/- (Apelin heterozygous) females, 
resulting in ANF-CreposBmp10fl/flBmp9-/-Apln−/y males or ANF-CreposBmp10fl/flBmp9-/-Apln-/- 
females.
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8 Results 
 
8.1 Loss of BMP9 and BMP10 does not result in embryonic 
lethality or developmental issues 
To ensure that Bmp9 and Bmp10 expression were depleted in their respective mouse 
models, qRT-PCR was used detect their expression patterns. Two different organs were 
analysed to ensure a systemic knockout of Bmp9 and Bmp10. The liver, where Bmp9 is 
secreted from, and the heart, which is Bmp10’s secretary organ, was analysed at 1 and 2 
months of age. Results showed that at both time points Bmp9 was clearly ablated in the liver 
of both BMP9 SKO mice and DKO compared to WT littermates (Fig. 13 A) and absent from 
the heart as expected (Fig. 13 C). Bmp10 expression was absent in the heart of BMP10 cKO 
and DKO mice (Fig. 13 B) as well as the liver (Fig. 13 C). This confirms successful targeted 
depletion of both Bmp9 and Bmp10. At 1 month of age, both SKOs and DKO mice did not 
display obvious postnatal growth problems, shown by their normal body weights (Fig. 13 D) 
and all groups survived with no noticeable problems for more than 1 year (Fig. 13 E). 
Since loss of Bmp10, Alk1 or Eng, results in embryonic lethality, it was important to 
determine if either SKOs or the DKO mice resulted in embryonic or postnatal lethality. Litters 
were counted to ensure that the number of each genotype was represented according to 
normal Mendelian ratios. Each breeding scheme set up is described below and showed that 
mice from all genotypes were born at the expected Mendelian ratios (Fig. 13 F). 
Loss of Alk1 or Eng leads to embryonic lethality due to severe vascular abnormalities 
during development. Therefore, E14.5 control and DKO embryos were collected and 
immunostained for PECAM and αSMA to determine the coverage of ECs and SMCs 
respectively. At E14.5 there was no obvious difference between PECAM and αSMA 
suggesting that the DKO mice do not suffer any vascular defects during embryonic 
development (Fig. 13 G).  
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Figure 13: Loss of BMP9 and BMP10 does not lead to embryonic or postnatal lethality 
or vascular abnormalities during development 
(A) RT-PCR shows Bmp9 expression in the liver at 1 month (L) and 2 months (R). (B) RT-PCR shows 
Bmp10 expression in the heart at 1 month (L) and 2 months (R). (C) Control RT-PCR shows specific 
tissue expression, where Bmp9 and Bmp10 are not expressed in the heart (L) and liver (R) 
respectively at 1 month. (D) Body weights of P21 pups reveal no difference between SKO and DKO 
mice compared to controls during postnatal development and (E) Survival curve showing the loss of 
BMP9 and 10 does not affect viability. (F) Calculations of the expected embryo Mendelian ratios also 
occur as expected. (G) Immunofluorescent staining’s showed no vascular abnormalities at E14.5, 
PECAM (red), αSMA (green) and DAPI (Blue). *p<0.05, **p<0.01, ****p<0.0001, non-significant (ns) 
p>0.05 
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8.2 DKO mice develop cardiac hypertrophy and impaired cardiac 
function 
Using MRI it is possible to determine cardiac function and structure using a number of 
different parameters. Each group was measured at different time points to determine if 
mutant mice displayed signs of age-dependent cardiac failure. 
Ejection fraction (EF) is the percentage of blood pumped out of the heart with every 
heartbeat. Normally a low EF is used as an indicator of HF, resulting from insufficient blood 
volume being pumped out of the heart. Functionally, the heart has to increase its contractility 
which can ultimately leads to HF. MRI analysis showed that the DKO mice had a significantly 
lower EF at 6 months of age. This was not evident at 1 month while both SKO mouse groups 
did not display any significant changes in EF (Fig. 14 A). This data showed that the loss of 
BMP9 and BMP10 leads to reduced EF indicating impaired cardiac function. 
SV is the amount of blood pumped out of the heart during each contraction and is 
calculated by measuring the difference between the ventricular end-diastolic volume (EDV) 
and the end-systolic volume (ESV). The EDV is the volume of blood in the ventricle at the 
end of chamber filling (diastole) and ESV is the volume of blood in the ventricle at the end of 
a contraction (systole). By 1 month, the DKO mice showed an increase in SV in comparison 
to the other groups which more than doubled in volume by 6 months of age (Fig. 14 B). This 
increase in SV showed an increase in blood volume in the heart and again demonstrated a 
change in cardiac function.  
It is also possible to measure the left ventricular mass (LVM) using MRI as well as the 
thickness of the LV wall during both diastole and systole phases. Again, by 1 month of age, it 
was already clear that the LVM of the DKO mice was significantly greater than the control 
mice as well as both SKO mice, although they displayed a slight increase in size in 
comparison to the controls (Fig. 14 C).  A significant two-fold increase in LVM was evident in 
the DKO compared to controls by 6 months whereas there was only a slight increase seen in 
the SKO mice (Fig. 14 C). This demonstrates that loss of BMP9 and 10 leads to cardiac 
hypertrophy.  
This was further verified when the ventricular wall thickness was calculated in the 
diastole phase where an increase in thickness was already evident by 1 month in the DKO 
and was more pronounced at 6 months in comparison to the other groups (Fig.14 D). Dilated 
cardiomyopathy is a condition whereby the heart becomes enlarged and cannot pump blood 
efficiently which normally leads to a thinning of the ventricular wall 170. Even though the DKO 
hearts were enlarged, this data clearly shows there was no sign of ventricular wall dilation, 
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as the wall thickness was increased in the DKO animals. Taken together, these results 
showed an increase in overall heart size of the DKO mice, already beginning at 1 month of 
age, with an increase in blood volume but an overall reduction in pumping and ejection 
efficiency. This overall increase in heart size, without cardiac dilation and the increase in 
blood volume could be an explanation as to why these DKO mice are able to survive and 
function normally although they have a reduction in EF.  
Hearts from each group were collected at 1 and 6 months of age to visualize the 
difference in heart size and overall structure. Hematoxylin and Eosin Staining (H&E) staining 
confirmed there was an overall increase in the whole heart size at 1 month of age in the 
DKO mice compared to the other groups (Fig. 14 E). At 6 months the difference in heart size 
of the DKO mice was still significantly larger than in the other groups, consistent with the 
MRI analysis (Fig. 14 F). Measurement of the heart weight to the tibia length further showed 
the hypertrophic phenotype of the DKO mice beginning at 1 month of age which was still 
seen at 6 months (Fig. 14 G).  
Cases of cardiac hypertrophy, even if just in specific areas, for example in the right 
atria due to valve stenosis or atrial septal defect, are normally correlated with cardiac 
dysfunction 171. This can be a result of an increase in ECM components which restricts CM 
contractility. Seeing as the DKO mice display cardiac dysfunction and hypertrophy it was 
essential to determine the extent of cardiac fibrosis, as this could have been a reason for 
cardiac impairment. At 1 month and 6 months, hearts from DKO mice did not display cardiac 
fibrosis (Fig. 14 E). This revealed that the lower EF in the DKO mice is not due to excess 
fibrosis but rather due to an overall increase in size (Fig. 14 F). It was recently published that 
in vitro BMP9 acts as a profibrotic factor and so lack of BMP9 in these mutant mice could 
also explain why there is no increased fibrosis 172. During HF, dilation can occur along with 
morphological changes such as increase in CM apoptosis and fibrosis 173. However this 
situation does not occur in the DKO mice meaning they may undergo compensatory 
hypertrophy where fibrosis is not necessary as the CM increases in size in response to an 
increase in work load 173. 
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Figure 14: DKO mice display cardiac impairment with an overall increase in heart size 
but do not exhibit significant fibrosis  
(A) The EF of each mouse group at 1 (L) and 6 (R) months shows a decrease in the DKO over time. 
(B) The SV of each mouse group at 1 (L) and 6 (R) months shows an increase over time. (C) The 
LVM of each mouse group at 1 (L) and 6 (R) months shows a major increase in size especially in the 
DKO. (D) The wall thickness was measured during the diastole phase at 1 (L) and 6 (R) months 
showing a thickening in the wall of the DKO. (E) H&E staining (top) and Trichrome (bottom) of all 
mouse groups at 1 month shows the overall increase in heart size of the DKO mice without the 
presence of fibrosis. (F) H&E (top) and Trichrome (bottom) staining of all mouse groups at 6 months 
show that over time there is no presence of fibrosis even though the heart increases in size.  (G) The 
heart: tibia ratio all mouse groups at 1 (L) and 6 (R) months shows the hypertrophic nature of these 
DKO hearts. *p<0.05, **p<0.01, p***<0.001, ****p<0.0001, non-significant (ns) p>0.05 
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To determine if cardiac hypertrophy was due to an increase in size or overall number 
of CMs, adult CMs were isolated and the area of CMs was calculated. CMs isolated from 
DKO mice had a higher % of larger CMs; approximately 60 % were between 2000-3000 µm2 
(Fig. 15 A), in comparison to the control and the SKO mice, where approximately 60 % were 
between 1500-2000 µm2 (Fig. 15 A). These results were further analyzed via 
immunofluorescence staining (Fig. 15 B) and the average size of CMs from each genotype 
was calculated showing that DKO CMs were significantly larger (Fig. 15 C). P5 hearts from 
each group, that were injected with EdU, were sectioned, stained and quantified for cellular 
proliferation, as EdU is a quantitate chemical that follows newly synthesized DNA via 
detection of the incorporation of a deoxyribonucleoside analog. EdU and DAPI positive cells 
were counted and compared to determine overall proliferation of cells within the heart. 
Analysis of these sections showed there was no significant change in proliferation in the 
DKO mice compared to controls (Fig. 15 D). 
During HF and adverse cardiac remodelling, CMs react to stress signals by activating 
pathways that induce pathological hypertrophy. These changes that occur during HF and 
remodelling are similar to the processes seen during fetal cardiac development where CMs 
must grow in size. Normally the heart responds by reactivating the fetal gene program where 
the heart switches expression of structural proteins from the adult form back to the fetal 
isoforms 174. Analysis of fetal gene expression were analysed by qRT-PCR and revealed an 
increase in both Anp (Nppa) and Bnp (Nppb) levels in DKO mice at 2 months as well as in 
the SKO mice, confirming reactivation of the fetal gene program under cardiac hypertrophy 
and stress (Fig. 15 E). 
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Figure 15: DKO adult CMs are larger but do not display increased proliferation 
(A) Calculation of the total area of adult CMs shows a shift in the DKO CMs towards a higher 
percentage of larger CMs. (B) Immunofluorescent staining with MF20 (green) and DAPI (blue) 
demonstrate CM an increase in size of the DKO CMs compared to controls. (C) The average area of 
adult CMs shows the significant increase in CM size of the DKOs. (D) Analysis of proliferating adult 
CMs using EdU shows there is no increase in proliferating CMs in any of the groups. (E). RT-PCR for 
Anp (L) and Bnp (R) levels at 2 months indicates an increased hypertrophic response in the DKO 
hearts. *p<0.05, **p<0.01, p***<0.001, non-significant (ns) p>0.05 
 
8.3 DKO mice show changes in vascular structure leading to 
changes in vascular homeostasis 
 As BMP9 and BMP10 are known to be involved in vascular homeostasis, µCT 
analysis was used to determine the vessel structure and dynamics. From the images taken it 
was again clear that the DKO mice were characterized by an overall increase in heart size 
compared to control mice (Fig. 16 A). Aside from the increase in heart size, it was shown 
that the DKO mice have an increase in vessel diameter of the coronary arteries (Fig. 16 B). 
This was determined by measuring the diameter of the main coronary artery from the aortic 
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valve until the first bifurcation process. This increase in vessel dilation was concomitant with 
an increase in the vessel volume in the DKO mice compared to controls (Fig. 16 C). 
Interestingly, it was also shown that there was an increase in branch numbers in the DKO 
mice compared to the control mice (Fig. 16 D). This increase in branch number could be due 
to the lack of BMP9 and BMP10, which are vascular quiescent factors, leading to a 
continuation of vascular expansion or due to the fact that there is an increase in vessel 
diameter meaning there is better perfusion for visualization.  
Due to changes in vascular structure of the DKO mice it was important to determine 
changes in vascular hemodynamics, as changes in vascular structure will ultimately affect 
hemodynamic forces and vice versa, with changes in both having adverse effects on the 
heart. Telemetric devices were implanted into adult mice for 1 month where the basal BP 
was measured, as was BP in response to stimulation with vasoconstrictive or vasodilative 
compounds. At basal levels, DKO mice displayed significantly reduced BP compared to the 
controls (Fig. 16 I) however there were no changes in HR in either of the mice groups (Fig. 
16 J) demonstrating bradycardia was not the cause of the hypotension seen in the DKO 
mice. 
 Captopril is an angiotensin-converting enzyme (ACE) inhibitor and is used to induce 
vasodilation via the angiotensin II pathway. After administration of Captopril the DKO were 
able to respond and further dilate resulting in a further reduction in their BP (Fig 16 H) similar 
to controls (Fig. 16 G). When compared with the control mice it was still clear that the DKO 
mice had a significantly lower BP even after Captopril administration meaning they still kept 
the dilated phenotype (Fig. 16 I) and this overall vessel dilation could explain the chronic 
hypotension seen in these DKO mice.  
 Nitric oxide synthases are a group of essential enzymes needed to catalyse NO 
production from L-arginine. NO is a cellular signalling molecule that is involved in vascular 
tone, angiogenesis and other important functions. NG-nitro-L-arginine methyl ester (L-
NAME) has been widely used to inhibit constitutive NOS which results in vasoconstriction. 
When L-NAME was administered to control mice, a significant increase in BP was observed 
(Fig. 16 G). In contrast, there was a slight increase in BP seen in the DKO mice compared to 
their basal BP (Fig. 16 H). When compared with control mice, DKO mice had a significantly 
blunted response to L-NAME administration indicating that these mice have a defect in their 
SMCs to respond to signals that induce vasoconstriction (Fig. 16 I). 
 Another method used to determine changes in hemodynamic forces was 
angiography imaging as it was possible to visualize the vascular network of adult mice in the 
tail region and to measure the BF and BV at 6 months of age (Fig. 16 E-F). This showed a 
consistent and significant change in both the BF and BV in the DKO mice when compared to 
the control mice.  
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Taken together these results show an overall change in hemodynamic forces due to 
a systemic increase in vessel diameter. Since there was no change in heart rate, it showed 
that this was not the main cause of hypotension seen in the DKO mice but that it was more 
likely due to vasodilation. Chronic vasodilation causes the BP to drop, which was seen in the 
DKO mice, and a decrease in BP effects vascular resistance therefore allowing for an 
increase in BV and BF.  
 
Figure 16: µCT analysis clearly shows a dilation of major coronary vessels in the 
heart with an increase in blood volume, velocity and flow in the DKO mice 
(A) µCT images of main coronary artery from the control (L) and DKO (R) mice where there is a clear 
dilation of the artery in DKO mice.(B) µCT analysis from the aortic valve till the first bifurcation point 
show an increase in lumen diameter of the DKO (black boxes) vessel in comparison to the control 
(white boxes). (C) Measurement of vessel volume of coronary arteries using µCT shows an increase 
in DKO mice. (D) Quantification of branch point numbers from the coronary artery clearly shows an 
increase in the DKO hearts. (E) Measurement using angiography analysis of BV and (F) BF shows an 
increase in both in the DKO mice at 6 months. (G) BP measurements of control mice under different 
conditions. (H) BP measurements of DKO mice under different conditions. (I) Comparison of control 
(white) and DKO (black) mice at basal levels and after captopril and  
L-NAME treatment shows the DKO mice had lower BP and are unable to respond fully to L-NAME. (J) 
HR of control (white) and DKO (black) mice at basal levels and after captopril and L-NAME treatment 
show no major changes. *p<0.05, **p<0.01, non-significant (ns) p>0.05 
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8.4 Retina assay shows changes in vascular network of DKO mice 
during postnatal development 
 To study vascular development and cellular migration and proliferation, the ex vivo 
retina assay model was used. The main advantage for using this model is that the retina of 
mice are avascular after birth which then becomes highly vascularized after a number of 
days. By collecting retinas at P5, early sprouting angiogenesis can be studied. During this 
time frame, vasculature development and EC migration and proliferation can be monitored. 
Using P21 retinas allows for the monitoring of later stages of development when vascular 
remodelling and maturation occurs. 
 Images from P5 retinas showed a clear difference between the DKO retinas and the 
other groups where there was a severely impaired outgrowth of the vascular network from 
the optic nerve to the periphery of the retina (Fig. 17 A). This could be due to problems and 
perturbations in chemical cues that guide ECs while proliferating and migrating. ERG is a 
member of the ETS family of transcription factors and is known to be expressed in the 
nucleus of ECs 175. Staining for ERG allowed for the visualization of ECs (green) in DKO 
retinas at P5. This revealed a clear increase in ERG positive cells (Fig. 17 A). When 
quantified the DKO retinas showed there was a trend in an increase in ERG/ EdU double 
positive cells at the vascular front compared to the other groups (Fig. 17 D). BMP9 and 
BMP10 are EC quiescent factors so in their absence, an increase in proliferating ECs would 
be consistent with their known proposed function. Not only was the outgrowth hindered but 
the vascular networks that had formed leaned towards a denser network in the DKO seen in 
the PECAM coverage in both the outer and inner areas of the retina (Fig.17 B). 
Quantification of numbers of protruding filopodia and branch points also showed an increase 
suggesting an active, immature network that was still proliferating and unable to switch to a 
mature and quiescent network (Fig. 17 C). Taken together these results indicate that BMP9 
and BMP10 play a role in endothelial tip cell migration which ultimately leads to prolonged 
proliferation resulting in a denser, unorganized network that causes vascular abnormalities. 
Two recent publications used two different methods showing the effects of the loss of BMP9 
and BMP10. Ola et al. injected postnatal pups from P2 to P4 with BMP9 and BMP10 
blocking antibodies and collected the retinas at P5 which clearly showed the presence of 
AVMs, an increase in vascular area and branching in retinas blocked for BMP9 and BMP10 
176. Meanwhile Ruiz et al demonstrated that immunoblocking of BMP9 and BMP10 via 
transmammary delivery also lead to an increase in vascular density and number of AVMs in 
P6 pup retinas 177. Taken these recent papers and the data shown in Fig. 19, loss of BMP9 
and BMP10 leads to vascular abnormalities where AVMs are formed and the retinal vascular 
has an increased density and branching points. 
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As it is known that ECs are able to recruit SMCs when in a quiescent phase, it was 
next investigated how the loss of BMP9 and BMP10 affected SMC coverage in the retina. 
Quantification of αSMA showed a declining trend in its overall expression in the DKO retinas, 
again highlighting the vascular defects seen in these DKO mice (Fig. 17 E). Retinas blocked 
with BMP9 and BMP10 antibodies, as well as endothelial specific ALK1 KO, were stained for 
αSMA showed a decrease in coverage of arteries and an increase in SMC coverage of veins 
involved in AVM formation 176. Taken together this indicates the need for EC quiescence to 
allow for the recruitment of SMCs and that impaired or improper coverage of SMCs could be 
involved in the development of vascular abnormalities such as AVMs.  
 
Figure 17: Loss of BMP9 and BMP10 disturbs vascular outgrowth during early 
vascular development and effects vascular quiescence in P5 retinas 
(A) P5 retinas stained with ERG (green) and PECAM (red) show a reduced outgrowth in the DKO 
retinas with an increase in vascular density at the periphery. (B) Quantification of PECAM in the outer 
(L) and inner (R) areas of the retina shows a trend towards an increase in DKO retinas. (C) In the 
DKO retinas there is a significant increase in both the number of filopodia and branch points. (D) 
Quantification of double positive cells for ERG and EdU shows an increase in proliferating ECs in 
DKO retinas. (E) Analysis of αSMA shows a reduction in coverage of the DKO retinas. **p<0.01, non-
significant (ns) p>0.05 
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 Around P21 the retinal vasculature responds to factors that suppress angiogenic 
sprouting leading to a mature, quiescent network. Proliferation and migration of ECs is 
suppressed, which in turn allows the recruitment of perivascular cells to stabilize and 
reinforce the vascular network. Once this has occurred and perfusion has begun, pruning is 
needed to remove regressing vessels that are not in use. In the DKO retinas at P21 it is 
clear that the retinas have a much denser network with higher levels of connecting vessels 
from PECAM (green) staining (Fig. 18 A). To quantify this, PECAM coverage was analysed 
at both the inner and outer part of the retinas where an overall increase was seen in the 
DKO retinas (Fig. 18 D). This result clearly demonstrates that the DKO retinas have not 
reached a quiescent state. Quantification of the total coverage of αSMA also indicated a lack 
of SMC coverage which would also account for an unstable environment (Fig. 18 C). 
Reduced SMC coverage and active ECs leads to weakened vessels that are not able to 
maintain their shape and rigidity. Measurements of the artery and vein diameter showed an 
increase in their size due to increased EC number that are not reinforced properly due to 
absence of SMCs (Fig 18 B). Alk1-/- and Eng-/- mice are known to lead to tortuous vascular 
beds that exhibit a higher degree of permeability leading to haemorrhaging and in these 
models, severe and lethal AVMs are present. Although our mice are viable, the presence of 
tortuous vascular beds was seen in the DKO retinas as well as misalignment of the veins, 
where the vein is no longer parallel to the arteries but perpendicular (Fig. 18 A, white arrow). 
The presence of AVMs was also present in the DKO retinas but never seen in the controls or 
SKOs, where an artery feeds directly into a vein (Fig. 18 A, white arrows). Although loss of 
BMP9 and BMP10 does not lead to lethality, unlike their receptor KOs, there are still AVMs 
and vascular abnormalities, although at a lower frequency, meaning other factors may bind 
to ALK1 in their absence in an attempt to maintain vascular homeostasis. 
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Figure 18: Absence of BMP9 and BMP10 leads to vascular abnormalities during 
vascular remodelling and maturation in P21 retinas 
(A) P21 retinas stained with PECAM (green) and αSMA (red) show the presence of AVMs and 
torturous vascular beds in the DKO retinas (white arrows). (B) Analysis of artery and vein diameter 
showed dilation in the arteries of the DKO retinas. (C) Quantification of total αSMA coverage shows a 
trend towards less coverage in DKO retinas. (D) Quantification of PECAM coverage at the inner (L) 
and outer (R) regions of the retina shows an overall increase in DKO mice. *p<0.05, **p<0.01, non-
significant (ns) p>0.05 
 
8.5 DKO mice lose SMC number and coverage resulting in dilated 
vessels 
Due to the obvious vascular defects seen in the DKO retinas together with the 
changes in hemodynamic forces it was important to determine how the loss of BMP9 and 
BMP10 affects the cellular structure and coverage of the vasculature. Already at 1 month of 
age there is a clear reduction in Acta2 (also known as αSMA) expression in the heart of 
DKO mice compared to control mice (Fig. 19 A). This reduction was still evident in DKO 
hearts at 2 months of age but had clearly not worsened over time (Fig. 19 A). In hearts from 
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DKO and SKO at 1 month of age, an increase in Pecam levels was observed however no 
significant increase could be detected at 2 months of age in any of the groups (Fig. 19 B). 
These results suggested that loss of BMP9 and BMP10 play an active role in EC quiescence 
which in turn allows for either direct or indirect SMC recruitment that establishes a quiescent 
mature vessel. To compliment the qRT-PCR expression data, immunofluorescent staining 
for PECAM and αSMA of control and DKO hearts at 2 months was performed. This 
confirmed a reduction of αSMA in the DKO mice in comparison to the controls with a slight 
increase in PECAM (Fig 19 E).  
To further investigate the vascular abnormalities resulting from the loss of BMP9 and 
BMP10, transmission electron microscope (TEM) was carried out on 6 month old hearts. 
Consistently, the images showed that DKO mice had reduced SMC numbers and that the 
SMCs instead of being “brick like” in appearance are very thin and appear to stretch around 
the vessel (Fig. 19 C). At higher magnification it was clear that the structure of the vessel in 
the DKO mice was disrupted and their SMCs had lost their size and structure in comparison 
to the controls (Fig. 19 D). Such a high loss of SMC number, as well as their overall 
coverage, explains why these DKO mice have such dilated vessels and that it is mainly due 
to the loss of vascular tone and stability. The level of dilation and the incapability of the DKO 
vessels to respond to vasoconstrictors explain why they have a lower BP and an impaired 
response. Due to a non-quiescent state, vital cross talk between the ECs and SMCs is likely 
inhibited preventing recruitment of SMCs and subsequent maturation. 
To quantify vessel diameter and wall thickness, control and DKO aorta’s were 
collected at P21 and stained with Toluidine Blue. Quantification showed that loss of BMP9 
and BMP10 leads to a clear increase in aortic diameter and that the DKO mice have a 
thinner aortic wall in comparison to the control and SKO mice (Fig. 19 F and G). 
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Figure 19: Loss of BMP9 and BMP10 leads to a reduction in SMC number and 
coverage, leading to changes in the vascular structure 
(A) RT-PCR of αSma in 1 month (L) and 2 month (R) old hearts shows a massive decrease in 
expression in DKO hearts. (B) RT-PCR of Pecam in 1 month (L) and 2 month (R) old hearts shows a 
slight increase in expression in the DKO samples at 1 month. (C) Electron microscope image on 6 
month old heart samples shows the reduction in SMC number and a thinner layer in DKOs. (D) Higher 
magnification of 6 month old heart samples shows the smaller SMCs and disruption of the vascular 
structure in DKOs. (E) Immunofluorescence of PECAM (green), αSMA (red) and DAPI (blue) on 2 
month old heart samples shows a clear reduction in αSMA in the DKOs. (F) Quantification of vessel 
diameter and wall thickness of P21 aortas shows the DKOs have a thinner wall and are more dilated. 
(G) Toluidine Blue staining of P21 aortas shows the DKO aortas are dilated and has a thinner wall. 
*p<0.05, **p<0.01, p***<0.001, ****p<0.0001, non-significant (ns) p>0.05 
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8.6 BMP9 and BMP10 effect endothelial cell proliferation and alter 
genes involved in differentiation and cell cycle 
BMP9 and BMP10’s primary receptor, ALK1, is known to be expressed in ECs. qRT-
PCR revealed that it was also expressed at high levels in SMCs but not CMs (Fig. 20 A). To 
date, ALK1 has been described mainly as an EC receptor. Intriguingly, this qRT-PCR data 
suggests BMP9 and BMP10 could potentially bind directly to SMCs .To date BMP9 and 
BMP10 are known to directly target ECs and induce their quiescence. To determine their 
functioning concentration on ECs in vitro, HUVECS were stimulated with different 
concentrations of BMP9 and 10 to confirm activation of SMAD1/5/8 occurs (Fig. 20 B). 
Stimulation of HUVECs with BMP9 and BMP10 showed the optimal concentrations, 1 ng/mL 
and 20 ng/mL respectively, were able to induce pSMAD 1/5/8 expression. Stimulation of 
HUVECs with TGFβ showed its optimal concentration to be 5 ng/mL and that TGFβ is able 
to stimulate both pSMAD 1/5/8 as well as pSMAD2. This result showed that other ligands, 
such as TGFβ, could activate SMAD 1/5/8 signalling in ECs in vitro in the absence of BMP9 
and BMP10, consistent with other publications 66,135,178. 
As a proof of principle experiment, EC proliferation was assessed on HUVECs 
stimulated with BMP9 and BMP10 (Fig. 20 C). TGFβ was also included because TGFβ has 
been shown to induce EC proliferation and functions with BMP9 and BMP10 to achieve a 
balance between EC proliferation and inhibition. Stimulation of HUVECs with BMP9 and 
BMP10, singularly and combined, resulted in a significant reduction in EdU incorporation, 
showing that these two factors do directly inhibit EC proliferation, reiterating that they are 
important quiescent factors (Fig. 20 C) While TGFβ had no significant effect on proliferation 
alone, when stimulated with BMP9 and BMP10 there was a slight increase in HUVEC 
proliferation compared to stimulation with BMP9 and BMP10 on their own (Fig. 20 C).  
In order to determine downstream targets of BMP9 and BMP10, RNA array analysis of 
HUVECs stimulated with BMP9 and BMP10 was performed and from this array two genes 
were validated using qRT-PCR (Fig. 20 D). HEY1, which is upregulated in HUVECs 
stimulated with BMP9 and BMP10, is known to be involved in Notch signalling and is 
important in angiogenesis and has been previously shown to be upregulated in the presence 
of BMP9 and BMP10 120,179. CD34 is thought to be a ECs progenitor marker and has been 
shown to be expressed in tip cells during active angiogenesis, therefore reduction in CD34 
would suggest activation of cellular quiescence (Fig. 20 D) 180. A previous publication also 
showed that BMP9 and BMP10 could affect APLN expression levels, therefore analysis of 
APLN expression following BMP9 and 10 stimulation at different time points was tested 120. 
The result in HUVECs revealed a dramatic and significant downregulation of APLN 
expression by 1 hour that was still evident after 4 hours that was maintained right through to 
overnight (Fig. 20 E). 
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This result suggested that BMP9 and BMP10 may directly inhibit APLN expression 
and that APLN could have an important role in vascular quiescence. Recent work by Kasai 
et. al showed that blocking Apln via siRNA lead to an increase in EC proliferation which in 
turn resulted in a reduction in pericyte recruitment, which is similar to what we observed in 
our DKO mice 181. To further understand APLN expression and its relationship to BMP9 and 
BMP10 expression, its expression was then further investigated in the hearts of the DKO 
mice. 
GOrilla analysis was performed to gain further insight into the global biological 
processes that were altered in HUVECs after BMP9 and BMP10 stimulation. Processes of 
interest that were upregulated in the presence of BMP9 and BMP10 included regulation of 
cell differentiation, regulation of pathway-restricted SMAD protein phosphorylation, BMP 
signalling pathway, regulation of cell migration and blood vessel morphogenesis (Supp. Fig 
A). Genes involved in regulation of cell differentiation overlapped with genes involved in 
SMAD protein phosphorylation and BMP signalling pathway. The genes included BMPR2 
and ENG, showing BMP9 and BMP10 signalling were activated, along with TGFβ2 and 
TGFβ1 and other receptors such as BMPR1A, ACVR2A and ACVR1. BMP9 and BMP10 
have been reported to work in concert or opposition with TGFβ under differing conditions to 
induce or inhibit EC proliferation and migration 182. BMP9 and BMP10 induce quiescence by 
activating stalk cell genes, via crosstalk with Notch signalling, such as JAG1, ID1, ID2, HEY1 
and VEGF, which was clearly seen in the gene sets involved in the regulation of cell 
differentiation and blood vessel morphogenesis 62,120,183. Another upregulated factor 
important in endothelial cell differentiation was TMEM100, which is also a known 
downstream target of BMP9 and BMP10 signalling, where loss of TMEM100 is able to 
recapitulate the Alk1-/- phenotype 184. Lastly, genes involved in cell migration, that were 
upregulated included PDGF, integrin’s, TGFβ, heparin-binding egf-like growth factor (HB-
EGF) and VEGF. Interestingly the majority of these candidates are essential for the 
migration and recruitment of SMCs 185,186. 
Gene processes downregulated in HUVECs stimulated with BMP9 and BMP10 mainly 
included cell cycle, cell division and DNA replication (Supp. Fig. B). Many genes overlapped 
in these processes, including CCNA1 and members of the KIF and CDC family’s. This result 
clearly backs the evidence that BMP9 and BMP10 are involved in inhibiting EC proliferation. 
Taken together gene analysis of HUVECs showed the involvement of BMP9 and 
BMP10 in differentiating ECs and induction of quiescence. This in turn would allow for stable 
interaction with neighbouring cells, such as SMCs and pericytes, shutting down cell cycle 
progression and enabling stabilization of the vascular network. 
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Figure 20: BMP9 and BMP10 directly reduce EC proliferation and decrease APLN 
expression 
(A) RT-PCR analysis of Alk1 shows it is expressed in ECs and SMCs but not in CMs. (B) Western blot 
analysis of HUVECs stimulated with different concentrations of BMP9, BMP10 and TGFβ after 30 
minutes. Activation of pSMAD1/5/8 was used to confirm the working concentrations of BMP9 and 
BMP10, while pSMAD2 was used for TGFβ signalling. (C) HUVECs stimulated with BMP9 and 
BMP10 overnight showing they are able to inhibit proliferation, while TGFβ does not. (D) RT-PCR 
validation of candidate genes from the array. (E) Time course of APLN expression in HUVECs when 
BMP9 and BMP10 are present shows they are able to reduce APLN expression after 1 hour. *p<0.05, 
**p<0.01, p***<0.001, non-significant (ns) p>0.05 
 
8.7 Loss of BMP9 and BMP10 in the heart of DKO mice leads to 
changes in vascular quiescent and response to stimuli 
ALK1 is not expressed on CMs (Fig. 20 A) making it very unlikely that BMP9 and 
BMP10 exert direct effects on CMs. Hence, it was more important to look for secreted 
factors that could affect the vasculature as well as CMs. Gene array analysis of the total 
heart was performed to gain a global insight into changes within the cardiovascular system 
of control versus DKO mice. Gain-of-function (GOF, where HUVECs were stimulated), and 
Loss-of-function (LOF, where heart and aorta of DKO mice were analysed) approaches were 
analysed to discover direct targets of BMP9 and BMP10 that are involved in cardiovascular 
homeostasis. GO analysis of processes upregulated in DKO hearts showed changes in 
biological processes such as GPCR signalling pathway, ECM structure organization, 
angiogenesis, epithelial cell migration and cell division (Supp. Fig C). Genes involved in 
GPCR signalling pathway, included Apln and endothelin-1 (Edn1), were upregulated in the 
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DKO hearts which are important factors regulating cardiac hypertrophy, vascular tone and 
blood pressure (Fig. 21 A) 187. This result was intriguing as upregulation of such potent 
factors could explain for the phenotype seen in the DKO hearts, making them interesting 
potential downstream targets. APLN levels were dramatically reduced in HUVECs stimulated 
with BMP9 and BMP10 (Fig. 20 E), the opposite of what was seen in the DKO hearts (Fig. 
22 A), while EDN1 remained unchanged in the absence or presence of BMP9 and BMP10 
making Apln a potential downstream target of BMP9 and BMP10.  
Many of these gene processes had overlapping players that are normally associated 
with active angiogenesis including Ccn2a, Cdk, Kdr and Vegf (Fig. 23 B-C). Genes such as 
Nos3 were also upregulated which could explain the excessive vascular dilation seen in the 
DKO hearts and higher levels of hypoxia-inducible factor 1α (Hif1α) would suggest these 
DKO mice have a slightly higher hypoxic environment as a result. Changes in the expression 
of genes important for ECM structure organization were also detected including collagen, 
Tgfβ and elastin. Upregulation of these genes is explained by the constant active angiogenic 
environment in the DKO hearts but also due to the fact that the DKO hearts have 
remodelled, become overall hypertrophic, so that it can remain functional and the mice 
viable. These findings altogether strengthen the role BMP9 and 10 in angiogenesis and 
cardiovascular homeostasis. 
Gene targets from the array that were involved in the various processes mentioned 
were validated by RT-PCR, for example Ccn2a, Cd34 and Apln (Fig. 21 A). Comparison of 
the HUVEC array and DKO heart array showed an overlap of 15,000 genes in the form of a 
Venn diagram (Fig. 21 B). From these 15,000 genes, significant targets from both sets with a 
fold change greater than 1.20 and lower than 0.80 were analysed. From these criteria 130 
genes were found and a comparison was made between genes that were highly expressed 
in the DKO hearts but lower expressed in stimulated HUVECs and vice versa to decipher 
direct downstream targets of BMP9 and BMP10. GO analysis of genes expressed at high 
levels in DKO hearts compared to HUVECs were analysed and shown to be mainly involved 
in cell cycle and division (Supp. Fig D). These results would suggest that even though a 
global analysis of the whole heart was performed the majority and most significant changes 
in gene transcription are all related to ECs proliferation and angiogenic processes.  
The effects of APLN as well as BMP9 and BMP10 on CMs are not clear. To further 
understand the role of APLN, BMP9 and BMP10, rCMs were isolated and stimulated in vitro 
for 1 week. As a positive control to induce a hypertrophic environment, FGF2 was used as it 
is a known inducer of CM hypertrophy, which was confirmed as seen in Fig. 21 C-E 188. 
Preliminary results show that BMP9 stimulation alone has no significant effect on 
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cardiomyocyte hypertrophy seen by the same basal ANP expression as the control and the 
few number of cardiomyocytes with protruding filopodia (Fig. 21 C-E). When BMP9 is added 
along with FGF2, an increase in ANP expression and protruding filopodia is detected 
however this is just a response from FGF2, as FGF2 stimulation alone has similar results 
(Fig. 21 C-E). However when BMP10 was added separately to cardiomyocytes there was a 
clear reduction in ANP levels and this was also evident in the reduced number of extending 
filopodia compared with the control (Fig. 21 C-E). Moreover these initial results would also 
suggest that in a hypertrophic environment, BMP10 and FGF2 together, BMP10 is able to 
block cardiomyocyte hypertrophy as ANP expression is lower than in FGF2 alone (Fig. 21 C-
D). This result is also evident in bright field images where there is a clear reduction in 
filopodia extensions (Fig. 21 E). To date conflicting results for the role of APLN in 
cardiomyocyte hypertrophy makes it difficult to understand its direct function in the heart. 
However these first results also do not give a clear insight into the role of APLN because at 
basal levels APLN does not increase ANP expression nor does it exasperate FGF2 induced 
hypertrophy (Fig. 21 C-E). These findings support the ideas from different publications that 
BMP10 does play a specific role in the heart, which BMP9 does not, and higher expression 
levels of BMP10 blocks cardiomyocytes hypertrophy 114,189. Further work on APLN detailing 
its effects on cardiomyocyte hypertrophy is still needed.  
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Figure 21: BMP9 and BMP10 effect vascular stability and quiesence in DKO hearts 
resulting in an increase in APLN levels, along with changes in the hypertrophic 
response 
(A) RT-PCR analysis validating targets upregulated in DKO hearts. (B) Venn diagram comparing 
overlapping genes in the DKO heart and stimulated HUVEC array. (C) WB analysis for ANP on rCMs 
stimulated with different factors to check for the hypertrophic response (D) Quantification analysis of 
WB for ANP with different stimulation factors normalised to Actin. (E) Bright field images of rCMs after 
stimulation with various compounds.  **p<0.01, ****p<0.0001, non-significant (ns) p>0.05 
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8.8 Loss of APLN in the DKO mice does not rescue the 
cardiovascular phenotype 
Taken together, since loss of BMP9 and BMP10 led to an increase in APLN levels 
(Fig. 22 A) and HUVEC stimulation with both BMPs led to a drastic decrease in APLN 
expression (Fig. 20 E), it was postulated that loss of Apln (Apln-/-) in the DKO mice could 
lead to a rescue of the cardiovascular phenotype. TKO mice were generated by breeding 
DKO mice with APLN SKO mice (Fig. 12). qRT for Apln expression was then performed on 
the TKO mice to ensure deletion of Apln, where results showed that Apln expression was 
efficiently decreased in the TKO line (Fig. 22 A). The two parameters used to determine if 
loss of Apln in the DKO background could rescue these mice was the return of the 
hypertrophic heart to a normal size and secondly the return of SMCs to the vasculature 
allowing for the reduction of vascular dilation. qRT-PCR for αSMA performed on TKO hearts 
showed that there was no increase in αSma expression and that it was still significantly 
lower than the control mice, although not as low as the DKO samples (Fig. 22 B). 
Measurement of the heart: tibia ratio also showed there was no reduction in cardiac 
hypertrophy in the TKO and that they still resembled the DKO phenotype (Fig. 22 C). 
Histochemistry staining confirmed these hearts to be large in size, with an overall 
hypertrophy and no signs of fibrosis (Fig. 22 D). Aorta’s from TKO mice and control mice at 2 
months were collected and stained for Toluidine blue to determine if vascular dilation was 
still present and if they still presented a thinner aortic wall. Quantification of the aorta’s 
showed that the TKO mice have a tendency towards a more dilated vessel in comparison to 
the control mice (Fig. 22 E). Along with this finding the TKO’s also possess a thinner aortic 
wall when compared to controls (Fig. 22 F).  
Taken together initial results would suggest that loss of Apln does not rescue the DKO 
mice phenotype. In these circumstances loss of one gene alone may not be enough to 
account for all the phenotypes seen and therefore cannot rescue our DKO mice. As shown 
above many different factors are changed in our DKO mice which have a very complex 
system involved, with numerous different pathways cross talking and interacting together or 
in opposition to each other. One explanation could involve a second ligand that has been 
published that binds the APLN receptor, known as apelin receptor early endogenous ligand 
(Apela also known as Ela) 190. qRT-PCR and PCR for Ela was unsuccessful as it was 
undetectable in either PCRs which used both mouse and human samples. This could be due 
to the fact that Ela is located is a non-coding region which gives rise to a small hormone 
peptide that undergoes further cleavage making it hard to detect 191. Therefore it is not 
known whether this ligand’s expression is increased to compensate for the loss of Apln and 
cannot be ruled out. 
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Figure 22: Loss of Apelin in the DKO background rescues the SMC phenotype but not 
always the cardiac hypertrophy 
(A) qRT-PCR shows higher expression of Apln in the DKO hearts but no expression in the TKO 
hearts at 2 months. (B) Loss of Apln, Bmp9 and Bmp10 in TKO mice does not increase αSma 
expression at 2 months. (C) Calculation of the heart: tibia ratio of TKO hearts compared to control and 
DKO hearts at 2 months shows they are still hypertrophic with no reduction in size (D) H&E (upper 
panel) and Trichrome (lower panel) staining shows an overall increase in cardiac morphology in the 
TKO hearts and no sign of fibrosis at 2 months just like the DKO hearts. (E) Analysis at 2 months 
shows there is a slight increase in vascular diameter of the TKO aorta compared to the control. (F) 
Analysis at 2 months shows a decrease in the wall thickness of the TKO aorta compared to the 
control. (G) Toluidine blue staining of the aorta at 2 months for control and TKO samples. (H) Higher 
magnification of aortas from control and TKO mice show the difference in structure and thinner wall 
layer. *p<0.05, p***<0.001, ****p<0.0001, non-significant (ns) p>0.05 
 
8.9 BMP9 and BMP10 induce expression of contractile markers 
and are involved in SMC differentiation and recruitment  
 To date ALK1 is considered primarily an EC receptor, although others have reported 
its expression on other cell types, qRT-PCR analysis shows Alk1 expression in SMCs also 
(Fig. 20 A) 192.The expression of ALK1 in SMCs leads to question whether or not BMP9 and 
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BMP10 have direct effects on SMCs and this question was addressed in vitro with isolated 
SMCs. To therefore also determine whether the phenotype in the DKO mice was due to a 
problem in EC to SMC cross-talk, primary SMCs from the aorta of DKO mice were isolated 
and a gene array was performed to monitor global changes and co-cultures in vitro were 
also setup.  
Direct stimulation of mSMCs in vitro with BMP9 and BMP10 followed by IF staining 
showed a remarkable increase in αSMA (red) expression (Fig. 23 A). This was further 
quantified using qRT-PCR, where the expression of αSma was dramatically increased when 
compared to non-stimulated cells (Fig. 23 B). Normally when isolated and cultured, SMCs 
lose their contractile phenotype and αSMA is amongst a number of markers whose 
expression is dramatically downregulated 193. This data indicated that BMP9 and BMP10 
could be important in directly maintaining SMC contractility in vivo. In our lab it was 
published that loss of mir143 and mir145 results in a loss of contractility in SMCs 194. It was 
reported that loss of these two mirs led to a reduced contractile state in SMCs, where 
contractile markers were decreased and there was a reduction in media thickness of the 
femoral artery, as well as having low basal BP 194. Therefore to test how potent BMP9 and 
BMP10 were at increasing αSMA levels, SMCs from mice heterozygote for mir143 and 
mir145 were isolated and stimulated. Although not as extreme as in WT SMCs, stimulation 
of SMCs heterozygote for mir143 and mir145 showed BMP9 and BMP10 together were able 
to activate αSma expression, as this is not normally the case (Fig. 23 C), making these 
BMPs good candidates for promoting SMC contractility.  
To test the roles of BMP9 and BMP10 in SMC proliferation, rSMCs were isolated and a 
Vybrant assay was performed after 7h stimulation with BMP9, BMP10, Apelin-13 and FGF2. 
Stimulation of all compounds caused an increase in cellular proliferation, although 
stimulation with BMP9 and BMP10 gave the highest increase in proliferation along with 
Apelin-13 (Fig. 23 D). However stimulation with BMP9, BMP10 and Apelin-13 sees a 
reduction in proliferation compared to Apelin-13 or BMP9 and BMP10 alone, indicating that 
BMP9 and BMP10 are able to inhibit the proliferative effects of APLN in vitro (Fig. 23 D). 
This evidence was further supported as stimulation of both SMCs and HUVECS with BMP9 
and BMP10 leads to a dramatic decrease in Apln expression (Fig. 20 E, 23 E) along with its 
receptor, Aplnr (also known as Apj) (Fig. 23 F). 
As mentioned previously mentioned ECs receive signals from within the blood and 
then signal to SMC via secreted factors, such as PDGF, to recruit or differentiated SMCs 
195,196. To uncover potential secreted factors from ECs on SMCs that could affect SMC 
recruitment, co-culture experiments were performed where HUVECs were stimulated with 
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BMP9 and BMP10 and the stimulated media was then put onto mSMCs. This stimulated 
HUVEC media that was put onto mSMCs also induced a reduction in Apln expression (Fig. 
23 G). When αSma expression was analysed it was shown that upon reduced APLN levels, 
αSMA expression was increased (Fig. 23 H). Taken together, these results show that a 
reduction in APLN could lead to higher expression of contractile markers, such as αSMA, in 
SMCs.  
Recruitment of SMCs is needed for vascular maturity and stability to induce vascular 
quiescence. To understand the affects BMP9, BMP10 and APLN have on rSMC migration, a 
migration assay was performed. To date there are conflicting results as to whether or not 
APLN promotes or inhibits SMC migration 197,198. Results from the migration assay would 
suggest that BMP9 and BMP10 along with APLN are not potent factors involved in SMC 
migration, unlike FGF2 (Fig. 23 I).  
GSEA analysis of aortas from DKO mice showed an increase in genes expressed in 
regulation of respiration and metabolism (Fig. 23 J) while genes involved in cell division and 
maturation were downregulated (Fig. 23 K). Genes involved in aerobic respiration and 
cellular respiration included genes involved in the succinate dehydrogenase complex and 
ubiquinol-cytochrome c reductase genes. This upregulation in respiration could be due to 
higher mitochondria production or mitochondria number in SMCs, seeing as there is a loss of 
SMC coverage. Gene’s downregulated in DKO aortas were involved in cell division and 
maturation. This result is not surprising as these mice have a severe reduction in SMC 
coverage and number. Gene’s downregulated in cell division included Myh9, Myh10 and 
TGFβ. MYH9 and MYH 10 are non-muscle myosin proteins expressed in numerous cells in 
the heart and are important factors in the contractile properties of SMCs while TGFβ has 
been shown to been important for SMC differentiation 199,200. When looking at genes 
downregulated in cell maturation, genes such as Adam12 and Ereg were amongst some of 
the significant hits. Not much is known about these factors but recent papers have revealed 
the importance ADAM12 plays in inducing differentiation of mesenchymal SCs into SMCs via 
TGFβ signalling and how ADAM12 was able to induce αSMA expression 201. Recent findings 
have shown EREG to be a potent SMC mitogen, whose expression was controlled by factors 
such as ANG2 and EDN1, and may have an important role in SMC proliferation and 
remodelling 202. 
In vitro BMP9 and BMP10 are able to induce expression of αSMA in mSMCs while 
also being able to suppress APLN signalling. Co-culture experiments were able to confirm 
that factors secreted from ECs are important and capable of also re-expressing αSMA and 
suppress APLN signalling, although it is not as dramatic. BMP9 and BMP10 allow rSMC 
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proliferation in vitro and can also inhibit proliferation induced by APLN stimulation. This data 
was further supported by gene array analysis of aorta’s lacking BMP9 and BMP10, where 
genes involved in cell division and maturation are downregulated. Taken together these 
results would suggest that BMP9 and BMP10 play a role in SMC proliferation and 
maturation, where they also help to maintain the SMCs contractile phenotype. These results 
then lead to the question of whether BMP9 and BMP10 can directly affect SMCs in vivo and 
what role they play and to address this question an Alk1 SMC specific KO mouse line is 
needed.  
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Figure 23: BMP9 and BMP10 increases levels of αSMA in SMCs and inhibits APLN 
expression while also affecting SMC proliferation and migration 
(A) Immunofluorescence staining of mouse SMCs (mSMCs) with ki-67 (green), to monitor 
proliferation, and αSMA (red), to determine contractile phenotype. BMP9 and BMP10 together are 
able to induce re-expression of αSMA (B) qRT-PCR showed the higher level of αSMA in mSMCs 
stimulated with BMP9 and BMP10 (C) Heterozygous KO of mir-143 and mir-145 in mSMCs leads to 
the absence of αSMA, where stimulation with BMP9 and BMP10 is able to slightly increase its 
expression levels.  (D) Rat SMCs (rSMCs) were directly stimulated and a Vybrant assay was 
performed to test for proliferation. (E) qRT-PCR of stimulated mSMCs showed a significant decrease 
in APLN expression (F) qRT-PCR of stimulated mSMCs showed a significant decrease in APLNR 
expression. (G) Co-culture experiments, where HUVECs were stimulated with BMP9 and BMP10 and 
the media was put onto mSMCs, showed that APLN expression was decreased. (H) Co-culture 
experiments, where HUVECs were stimulated with BMP9 and BMP10 and the media was put onto 
mSMCs, showed that αSMA expression was increased. (I) Migration assay performed on rSMCs 
showed there was hardly a response to stimulation with BMP9 and BMP10 or APLN after 72 hr 
compared to the control group stimulated with FGF2. (J) GSEA analysis of DKO aortas showed an 
increase in genes related to cellular respiration and aerobic respiration. (K) GSEA analysis showed 
that loss of BMP9 and BMP10 in the aorta led to a decrease in genes involved in cell division and cell 
maturation. *p<0.05, **p<0.01 
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9 Discussion 
 
9.1  The role of BMP9 and BMP10 in cardiovascular homeostasis  
BMP9 and BMP10 are part of a complex and interconnected signalling pathway, the 
TGF-β superfamily signalling pathway, which control and modulate numerous important 
biological processes. To understand the specific role of each of these players in this pathway 
and their implications in human diseases, many different mouse models have been utilized 
203–205. Not only do they orchestrate a fine balance within their own signalling pathway to 
maintain homeostasis but TGF signalling family members are also known to interact with 
other signalling pathways such as MAPK pathway, PI3K/AKT, WNT and Notch signalling 
205,206.  
To date no research has been published on the loss of both BMP9 and BMP10 in a 
mouse model to address their role in cardiovascular homeostasis or how they may 
contribute or protect against disease development and progression. BMP9 and BMP10 are 
secreted from the liver and the right atria respectively and loss of these two ligands was 
confirmed via qRT-PCR 112,120. Loss of Alk1 and Eng, the binding receptors of BMP9 and 
BMP10, leads to embryonic lethality when constitutively knocked out 135,140,143,144,207. While 
Alk1 EC in ECs and Alk1 iCre KO in the adult leads to lethality after P5 and P21 respectively, 
Eng iKO KO results in vascular abnormalities but the mice are viable 141,145. These results 
reveal the complex role of BMP9 and BMP10 and their binding partners in angiogenesis and 
vascular homeostasis. The approach taken here allowed a systematic characterisation of the 
role of BMP9, BMP10 and their overlapping function as the main mediators of ALK1 
signalling. Loss of Bmp9 and Bmp10 did not result in embryonic lethality which strengthens 
the argument  that other ligands are able to bind ALK1, such as TGFβ1 and TGFβ3, and 
also work to maintain vascular homeostasis 192,208. This point was further supported by the 
fact that DKO embryos at E14.5 displayed no signs of abnormal PECAM or αSMA coverage 
unlike Alk1-/- and Eng-/- embryos that already have problems with EC and SMC coverage 
between E8.5 and E9.5 134,143. Further, loss of Bmp9 and heart specific deletion of Bmp10, to 
overcome embryonic lethality seen in constitutive BMP10 KO mice, does not result in any 
major developmental problems in either the SKOs or DKO suggesting that BMP9 and 
BMP10 have redundant functions in the adult. This is consistent with previous work revealing 
that Bmp9 can compensate for the loss of Bmp10 in modulating developmental 
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angiogenesis and maintaining vascular homeostasis but not BMP10’s specific role in early 
cardiac development 114. 
The comprehensive analysis of heart morphology and cardiac function revealed some 
intriguing insights into the role of BMP9 and BMP10. Cardiac failure can be defined by a 
decrease in SV, due to systolic or diastolic dysfunction, where the heart has problems with 
contractility (systolic dysfunction) or problems with chamber filling due to stiffness of the 
heart (diastolic dysfunction) leading to a decrease in EF 209. These changes result in an 
increase in ventricular end diastolic pressure. To normalize this increase in preload, the 
heart dilates which over time can lead to cardiomyopathy and ultimately HF 209. Although the 
DKO hearts show clear signs of cardiac hypertrophy, via MRI analysis, heart: tibia 
comparison and histochemistry, by 1 month of age they do not show a severe reduction in 
EF. However by 6 months of age these DKO animals display a higher increase in LVM and a 
significant reduction in EF but these symptoms did not progressively get worse, suggesting 
the system was able to stabilize and cope with these adverse effects hence why these mice 
survived. What causes the observed increase in LVM in the DKO mice can be explained by 
the increase detected in SV along with EDV, which in known to increase preload exerted on 
the heart 210. Preload is defined as the stretching of CMs before contraction and according to 
the Frank Starling mechanism, an rise in SV increases the volume of blood in the heart, by 
stretching the ventricles which expand during diastole 211. This increase in blood volume 
enhances the force of contraction and therefore also increases the blood pumped out during 
diastole 211. Normally a significant decrease in EF is a hallmark of cardiac failure. However in 
the case of the DKO mice, the reduction in EF did not significantly worsen over time 
suggesting that this adaptation was more physiological rather than pathological. Overall loss 
of BMP9 and BMP10 results in a decrease in EF and increases in LVM, SV and wall 
thickness. This concludes that although the EF is lower, the SV is higher and the heart 
functional as there are no signs of a thinner ventricle wall, though the LVM is significantly 
increased, meaning a sufficient amount of blood is being pumped around the system and is 
not detrimental to the animal.  
 Another hallmark of cardiac failure that leads to reduced EF is the presence of 
fibrosis, meaning the heart is no longer effectively pumping 212. The lack of fibrosis in DKO 
hearts at 1 month or at 6 months of age revealed these hearts do not suffer from contractility 
problems. These images of the DKO mice also showed that they did not suffer from specific 
areas of cardiac hypertrophy, i.e. right atria seen in PH, but rather the whole heart was 
enlarged in size 213. These images again argued for a lack of pathological hypertrophy, 
where an increase in interstitial fibrosis correlates with the degree and initiation of LV 
hypertrophy, but rather argue towards an adaptive response due to the changes in the 
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vascular system 214,215. Recently it was published that BMP9 is a profibrotic factor that, via 
ALK1 and ALK5 signalling, promotes ECM protein production meaning that under stress 
conditions loss of BMP9 is unable to elicit this response 172. However the more likely 
explanation is that the heart adapts to altered cardiac output and pressure in a physiological 
way, as seen in athletes who undergo different types of training 216. 
It has been long established and accepted that after birth, adult cardiomyocytes do not 
undergo proliferation but rather respond to injury or stress by increasing their area, which 
was the case for the DKO hearts 217. This hypertrophy could have occurred as a result of 
increased blood volume, which  is known to stretch CMs making them hypertrophic, or due 
to the secretion of hypertrophic stimuli under stress conditions  211. ANP and BNP are small 
peptide hormones that are important during development where they have been shown to be 
involved in many important biological processes such as regulation of blood pressure, 
monitoring salt and water balance, vasodilation to ensure proper blood supply to the embryo 
and cardiogenesis 218. Re-expression of ANP and BNP are common markers used to 
determine cardiac hypertrophy as these two peptides are secreted upon cardiac wall strain 
and are also known to play a role in preventing increased cardiac hypertrophy and fibrosis 
219–223. qRT-PCR confirmed an increase in these hypertrophic markers, Anp and Bnp, in the 
DKO and SKO hearts. These results suggested that hypertrophic stimuli, like ANP and BNP, 
play a role in the enlargement of the DKO hearts due to the increase in cardiac strain and 
may also contribute to vasodilation. Stimulation of cardiomyocytes with BMP9 and BMP10 
show that loss of BMP10, not BMP9, could also result in the increase in ANP expression 
resulting in cardiomyocyte hypertrophy.  
ALK1 is not present on CMs, but rather ALK3, suggesting that BMP9 and BMP10 do 
not cause hypertrophy directly but it is possible that the hypertrophy is a secondary effect 
due to changes in the vascular network or initiation via a different signalling pathway 189. Due 
to the fact BMP9 and BMP10 are quiescence factors, loss of both results in an increase in 
vascular dilation because of active ECs and a lack of SMCs. This hypothesis was addressed 
already in both papers studying the loss of Alk1 and Eng, where the vascular defect was 
developed first leading secondly to cardiac developmental defects 134,135,143. This is due to 
the important relationship between vessel diameter, BF, BV and BP which play an important 
role in vascular homeostasis and changes in any of these can have pathological effects 
156,224,225 . Arteries normally deal with higher BP than veins and as a result are surrounded by 
a thicker layer of SMCs that allow for support as well as adaptation to changes in BP, by 
initiating either vaso-dilation or -constriction 226. To determine the effects of vasodilation and 
vasoconstriction on the DKO mice, Captopril and L-NAME were administered respectively. 
Captopril intake resulted in a further drop in the BP of DKO animals, due to a dilative 
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environment already, as well as the controls. L-NAME treatment in the control mice 
increased BP and reduced HR, as a rise in BP coincides with a reduction in HR, so as not to 
stress and damage the heart 227. The DKO mice however responded with a slight increase in 
BP and a slight decrease in HR. This lack of response to vasoconstriction was due to the 
reduced number and coverage of SMCs in the DKO animals, which are vital in regulating 
vascular tone 228. Taken together these results suggest that changes in the vascular 
structure, i.e. an increase in vessel dilation, leads to changes in blood volume, which 
increases the force exerted on the heart during filling, causing the heart to increase in size. 
As previously reported in other studies, the DKO mice display  increases in blood volume 
and vascular dilation with reduced vascular resistance and BP, allowing an increase in BF 
and BV to ensure enough blood is pumped around the system 227. Loss of SMCs that result 
in hypotension and cardiac hypertrophy have been previously described by Schreier et al. 
229. Mice lacking vSMC Egfr display similar vascular and cardiac defects compared with the 
BMP9 and BMP10 DKO mice; increased cardiac hypertrophy, no fibrosis, reduced BP and 
reduced SMC coverage 229. They too hypothesise that loss of Egfr in SMCs results in a 
destabilisation of the vascular system which results in altered vascular function that ends in 
the loss of tissue homeostasis 229.  
To understand potential downstream targets that could affect primarily the 
vasculature as well as the cardiac system, ex vivo retina assays were performed to 
determine events during vascularisation without BMP9 and BMP10 while gene arrays for 
DKO hearts and in vitro stimulated HUVECs were used to determine global transcriptional 
changes. During angiogenesis an important balance between tip cell migration and stalk cell 
proliferation is needed for the correct development of the sprouting vascular network. As 
discussed previously it is known that Notch, BMP, VEGF and NRP signalling plays a major 
role in tip/ stalk cell selection. Gene array data from HUVECs stimulated with BMP9 and 
BMP10 show a downregulation of DLL4 and a major upregulation of genes involved in stalk 
cell behaviour such as JAG1, HEY1, HEY2 and ID1 which had also been reported previously 
120,230,231. Although not all genes were detected in the DKO heart array, Hey1 and Hey2 were 
downregulated and Apln, known to be more highly expressed in tip cells and induce EC 
proliferation, was upregulated indicating a more tip cell environment 62,231,232. It is essential to 
stabilize and mature a new vascular network to allow for recruitment of mural cells, therefore 
having a more sprouting and active network means there is interference with coordinated 
sprouting which results in hyperplasia and vessel enlargement 231,233. Quantification showed 
a denser network in PECAM levels of the DKO and SKO retinas with a reduction in SMC 
coverage at both early and late stages of vascularisation. One explanation could be VEGF, 
which is a known player in this process and its availability in the vascular plexus determines 
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the rate of cellular division 234. In a normal retina, where VEGF is limited to the periphery of 
the vascular plexus there is a significant proliferation rate in ECs directly behind the 
sprouting front where administration of VEGF results in widespread proliferation throughout 
the whole vascular plexus 234. Within the growing plexus, levels of VEGF differ according to 
location and vessel type. In the avascular region of the retinas it is considered a hypoxic 
environment where VEGF levels are higher than in the vascular plexus where O2 levels are 
normal and therefore has lower VEGF signalling 234. The vein is also considered hypoxic, 
with high VEGF, and arteries normoxic, with lower VEGF, leading to lower levels of migration 
and more stalk cell proliferation or an increase in migration and less proliferation, 
respectively 234. Taken together these data would suggest that VEGF has a dual role and 
can act as a mitogen and chemotactic factor on ECs in vivo,  where they have to choose to 
either proliferate or migrate in the presence of VEGF. Results suggest if VEGF levels are 
high around an actively growing vessel, then ECs seem to react by proliferating to increase 
the vessel calibre, while if VEGF is lower at the cell but higher at a distance, then ECs 
polarize and extend filopodia to migrate towards the VEGF source 235. Changes in O2 levels 
are also known to affect other factors such as vasodilation and SMC differentiation where 
hypoxic conditions were shown to create a less dense and patchier SMC coverage in 
arteries at P6 236. Although it was not fully proven that the DKO mice suffer from an increase 
in VEGF expression or hypoxic environment, it is clear that at P5 loss of BMP9 and BMP10 
leads to a reduction in network extension and SMC coverage and an increase in PECAM 
density, proliferating ECs, protruding filopodia and branch points. These findings support the 
theory that ECs do not undergo quiescence resulting in a lack of SMC coverage, weakening 
the vessel and creating are environment for developing vascular abnormalities. 
AVM’s can form de novo under certain conditions, such as wounding or during 
angiogenesis, and have been suggested to develop due to a lack a vascular identity and 
vascular dilation 134,141. This could explain why AVM’s are not seen as early as P5 in DKO 
mice, but need time to develop, and are formed during active angiogenesis in the post-natal 
retina and are therefore seen at P21 in the DKOs, when regression and blood flow is 
established. As well as the presence of AVMs in the DKOs at P21, highly tortuous vascular 
beds and the overlay of veins and arteries, where the normal spacing between the two was 
lost, were also observed. Previous studies showed that hypoxia can lead to an increase in 
overall APLNR expression throughout the network, where normally it is an early and specific 
venous marker, which resulted in expansion of venous capillaries while the spatial distance 
between arterial and venous networks was compromised 236,237. These results can be 
explained by the fact that loss of BMP9 and BMP10 leads to an increase in APLNR 
expression, indicating towards an increase in APLN signalling and potentially a hypoxic 
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environment. Along with the known fact that loss of Alk1 and Eng leads to AVMs, tortuous 
vascular beds and loss of distance between arteries and veins, the retina assay clearly 
showed the presence of these vascular abnormalities in the DKO retinas, although at a lower 
rate that the receptors KO mice, confirming BMP9 and BMP10 are important to preventing 
the development of these vascular abnormalities.  
Once it had been determined that within the retinas there were changes in PECAM and 
αSMA expression, qRT-PCR of heart samples at different time points was performed. In 
conjunction with the retinas results, αSMA levels showed a significant reduction in 
expression at both 1 and 2 months while PECAM levels were only slightly elevated at 1 
month of age in the DKO hearts. These results confirmed that the vascular phenotype was a 
global problem that displays it’s most significant phenotype not long after birth where other 
mechanisms appear to compensate for the loss of BMP9 and BMP10 and maintain a 
functioning system throughout adult life. As mentioned previously when the DKO animals 
had been challenged with L-NAME and there was only a slight change in vasoconstriction, 
EM imaging gave an insight into the possible explanation for this response. EM images 
showed that large vessels in the DKO samples had fewer SMCs and these few SMCs were 
stretched tightly around the vessel for support. These SMCs in the DKO mice had lost their 
shape and volume as a result of the SMCs being stretched around the vessel, resulting in a 
thinner SMC layer. GSEA analysis of DKO aortas versus control aortas showed an 
upregulation of genes involved in respiration, which could be due to the loss of SMCs as a 
way to maintain normal function. Not much is currently known about mitochondria in smooth 
muscle cells although some studies have shown mitochondrial function to be involved in 
maintaining vascular tone, transport and vascular energy production 238. Interestingly genes 
downregulated in the DKO aortas were related to cell division and maturation, meaning 
SMCs absent of BMP9 and BMP10 are not recruited properly or do not mature efficiently. 
EFNB2, a marker for defining arteries, has been shown to be dramatically reduced in Alk1 
KO mice and that BMP9 is able to induce EFNB2 expression in ECs 134,239. Interestingly in 
the DKO aortas, EFNB2 expression was significantly upregulated, although BMP9 is absent, 
but is explained by the discovery that Notch signalling is able to compensate for this loss 239. 
Overall it is important to comprehend the direct effects BMP9 and BMP10 have on ECs and 
SMCs as well as cross talk signalling pathways between the two and results here would 
suggest a possible direct interaction with BMP9 and BMP10 with SMCs but that secreted 
factors play a role with other signalling pathways being involved too. 
The role BMP9, BMP10 and TGFβ have in the vasculature and how they work in 
concert or in opposition to each other is still highly controversial 140,208. It is well understood 
that TGFβ signals via TGFBR2 and ALK5 while BMP9 and BMP10 signal via BMPR2 and 
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ALK1, however what is not well understood is the balance these two signalling pathways 
manage and how alterations in either of these signals can change vascular homeostasis. 
Singularly BMP9 and BMP10 are able to inhibit HUVEC proliferation and have a more 
dramatic effect when combined, reiterating their quiescent potential. Under these conditions 
TGFβ does not inhibit proliferation as strongly as BMP9 and BMP10, possibly due to the fact 
that ALK5 is not expressed on ECs 140,240,241. However when all three compounds are added 
together, TGFβ is able to alleviate the degree of cellular inhibition that BMP9 and BMP10 
oppose suggesting a crosstalk between these two signalling cascades. The differences in 
results could be due to different cell culture setups, different cell lines or the type of ligand 
competitive environment. One publication showed that loss of EC Smad1 and complete 
Smad5 in the embryo lead to a reduction in pericytes coverage resulting in the fusion of 
vessels into large cavities 183. These embryos also addressed the question of SMAD 1/5/ - 
Notch signalling crosstalk, where the absence of SMAD 1/5 in ECs showed alterations in 
Notch signalling that resulted in an increase in protruding filopodia and a reduction in stalk 
cell markers, such as HEY1 183. This was clearing shown in the BMP9 and BMP10 DKO 
retinas where reduced SMAD 1/5/8 saw an increase in ERG positive cells at the angiogenic 
front. Therefore stimulation of HUVECS with BMP9 and BMP10 that result in a significant 
increase in stalk cell markers like HEY1, mentioned previously, shows that these two BMPs 
are important in the tip cell-stalk cell switch that regulates cellular proliferation and vessel 
maturation. GO analysis of these stimulated HUVECs confirmed these findings where genes 
highly involved in blood vessel morphogenesis and cellular differentiation were the most 
upregulated biological processes in the presence of BMP9 and BMP10. In line with other 
publications, GO analysis showed the genes involved in cell division and cell cycle were 
most downregulated when stimulated with BMP9 and BMP10 119,120. Under normal 
conditions vascular quiescence is achieved by the reduction of sprouting tip cells, the 
presence of stalk cells and the coverage of the vessel with SMCs 242.Taken together BMP9 
and BMP10 could induce vascular quiescence by increasing the expression of stalk cell 
markers while reducing proliferation of tip cells, which would then allow for the proper recruit 
of SMCs and induce vascular quiescence and stability.  
Till now it has not been discovered as to whether BMP9 and BMP10 are able to recruit 
SMCs directly or whether they control the release of signalling cues from quiescence ECs, 
like Apelin,  that in turn recruit SMCs. To address the question of the direct effects BMP9 
and BMP10 have on mSMCs, SMCs were isolated from rat and mouse aortas and directly 
stimulated with BMP9, BMP10 and Apelin-13. To answer the question in vivo, an Alk1-/- 
specific for SMCs needs to be generated. In vitro stimulation of mSMCs with BMP9 and 
BMP10, both individually as well as combined, saw a stark re-expression of αSMA with a 
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higher expression level in double stimulated cells both via immunofluorescence and qRT-
PCR. Under normal culture conditions SMCs loss their contractile markers and express 
synthetic markers 193. Therefore re-expression of αSMA in mSMCs would suggest that 
BMP9 and BMP10 can have a direct effect on SMCs and help them maintain their contractile 
state as well as proliferation and migration. To determine the potency of these two factors, 
heterozygous mice for mir143 and mir145 (mir143+/-, mir145+/-) were used and mSMCs were 
isolated. These mice were used because loss of mir143 and mir145 results in loss of 
contractility markers in SMCs where they are unable to re-express them 194. Although not as 
dramatic as stimulation of WT mSMCs, stimulation of mir143+/-, mir145+/- SMCs with BMP9 
and BMP10 together resulted in an increase in αSMA showing their potency as SMC 
phenotypic modulators. Direct stimulation of mSMCs with BMP9 and BMP10 also showed a 
downregulation of Apln and Aplnr, the same result seen in HUVECs, strengthening the 
theory that BMP9 and BMP10 are able to target the Apelin signalling pathway. As well as 
direct inhibition of APLN expression, when in combination BMP9 and BMP10 are able to 
reduce the proliferative effects of apelin-13in in HUVECs again arguing for their ability to 
repress APLN expression and function. Loss of Pdgfβ and its receptor leads to embryonic 
lethality in mice due to defective SMC recruitment and are well known growth factors that are 
secreted from ECs and effect SMC migration and recruitment, however in our stimulated 
HUVEC array they are unchanged 195,243,244. HB-EGF, also implicated in EC-SMC 
communication, is expressed by HUVEC’s and stimulates migration in numerous SMC lines 
244. In vitro array data of BMP9 and BMP10 stimulated HUVECs showed increased HB-
EGF’s secretion meaning these BMPs are involved in EC-SMC communication. Many 
factors are secreted from ECs and loss of factors or higher secretion of factors may be the 
cause of the problems for the SMCs, therefore co-culture experiments were performed. 
Results were similar for APLN and αSMA, though not as dramatic, when HUVECs were 
stimulated with BMP9 and BMP10 and this media was added to SMCs concluding that 
factors secreted from ECs, or inhibition of factors, can directly affect SMC maturation and 
contractile phenotype. These results suggest that factors secreted from ECs, such as APLN, 
can effect phenotypic modulation of SMCs but that direct stimulation with BMP9 and BMP10 
has a more dramatic effect.  
Since the APLNR is known to be expressed on EC, SMCs and CMs eliciting various 
effects on them, it was hypothesised that Apelin signalling could account for the phenotypes 
seen in the DKO mice, where all these cell types are effected 245–247. Upon direct stimulation 
of HUVECs and mSMCs with BMP9 and BMP10, Apln and Aplnr, were dramatically 
downregulated while loss of BMP9 and BMP10 in the heart saw an increase in both, making 
this a candidate gene of interest 247. This lead to the theory that reduction of APLN levels in 
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our DKO mice could restore SMC coverage and reduce the hypertrophic response. Apln-/- 
mice were then bred with the DKO mice to generate a TKO mouse line, where loss of Apln 
was confirmed by qRT-PCR. Three criteria were used to determine if these TKO mice were 
a rescue; reduced cardiac hypertrophy, reduced vascular dilation and the return of proper 
SMC coverage. At 2 months of age these mice still had a high heart:tibia ratio, increase in 
aorta diameter, reduced aortic wall thickness and a lower expression of αSMA compared to 
WT mice. Taken together the loss of APLN in the DKO background does not rescue these 
animals but still displays the same phenotype.  
 
Figure 24: General overview of the role of BMP9 and BMP10 in cardiovascular 
homeostasis 
(A) Under normal conditions BMP9 and BMP10 block EC proliferation via ALK1. BMP9 and BMP10 
can work in opposition to TGFβ that also reduces signals inducing EC proliferation. This allows for the 
quiescence of a vessel that recruits SMCs to stabilize the network. Once vascular stability is achieved 
pathological stresses are not put on the heart allowing for normal cardiac function. (B) Loss of BMP9 
and BMP10 does not lead to lethality like the ALK1 receptor which may be explained by other factors 
singling via or in conjunction with ALK1, like TGFβ. Loss of BMP9 and BMP10 results in an increase 
in EC proliferation, causing an active angiogenic and immature state. This results in the loss of a 
quiescent phase where SMCs are not recruited or proliferate and those that are present loss their 
contractile, mature phenotype. Losing SMCs ends in vascular instability where vasodilation occurs. 
This can be due to upregulation of numerous factors such as ET-1, eNOS and APLN. Vascular 
instability puts pressure on the heart which must remodel to deal with these stresses and it results in 
cardiac hypertrophy and various hemodynamic changes. Vessels themselves are able to secrete 
factors that cause the heart to hypertrophy such as ANP, BNP, ET-1 and APLN.  
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9.2  BMP9 and BMP10 as potential therapeutic targets for cardiac 
and vascular diseases 
Pulmonary hypertension (PH) occurs when BF through the pulmonary vasculature is 
restricted and results in increased pressure. Increased pressure then causes a rise in right 
ventricle (RV) afterload, initiating an adaptive response, followed by maladaptive RV 
hypertrophy (RVH) because the right side of the heart must force blood through small 
arteries and arterioles of the lung to compensate. This condition is characterized by an 
imbalance in vascular tone, due to an increase in proliferation of SMCs, adventitial 
fibroblasts and ECs 248. Maladaptive remodelling leads to changes in gene transcription in 
the right ventricle inflicting regional ischemia upon the heart where dedifferentiation of CMs 
then occurs alongside the accumulation of inflammatory cells all which contribute to the 
further decline in RV function 249–251. However to date the mechanisms underlying PH are still 
not well understood due to the heterogeneous conditions this disease presents. In healthy 
individuals the endothelium releases numerous different growth factors and vasoactive 
mediators, which keep a balance between the different responses of these factors to 
maintain a low basal vascular tone and vascular homeostasis via vascular cell contractility 
and growth 248. Currently it is thought that EC dysfunction results in a change in this 
important balance, where endothelium-derived vasodilators are decreased and 
vasoconstrictors are upregulated, which leads to severe vasoconstriction seen in patients 
with PH and also contributes to SMC and adventitial hypertrophy 194.  
Patients with heritable forms of PH have mutations in genes encoding receptors of the 
TGF receptor superfamily, the majority of cases having mutations in BMPR2 but other cases 
also having them in the receptors for ALK1 and ENG although less frequently 252. Patients 
who suffer from HHT due to mutations in Alk1 also have an increased likelihood of displaying 
associated PH 253. Patients who are haploinsufficent for BMPR2 develop PH and mice 
models also recapitulate this condition where Bmpr2+/- mice show an increase in pulmonary 
arterial pressure and vascular resistance along with an increase in wall thickness of 
muscularised arteries and under hypoxic conditions were not able to remodel 254. A link 
between PH and HHT has been discovered by Rigelsky et al. where a patient who was 
diagnosed with PH was then later diagnosed with HHT after multiple pulmonary AVMs 
although they did not have any mutations in any of the HHT associated genes, Alk1, Eng, 
and Smad4 131. Mouse models for both ALK1 and ENG show a development of PH, where 
there are signs of increased RVSP, RVH and a decrease in pulmonary density in adult mice 
over time due to oxidative stress 255,256. Taken together these results show the importance 
this signalling pathway and the TGFβ receptors have in the development of PH and 
therefore one could speculate that BMP9 and BMP10 could play an important role in PH. 
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Recently a publication from Long et al. suggest conflicting results with this hypothesis where 
they demonstrated a beneficial role of enhanced BMP9 signalling during vascular 
remodelling in a new mouse model. This model shows mice with a heterozygous knock-in 
allele of a human BMPR2 mutation (Bmpr2+/R899X) which spontaneously developed PH, and 
injection of BMP9 can prevent apoptosis and enhance EC layer integrity having therefore a 
beneficial role in preventing adverse vascular remodelling during PH 257. 
Our preliminary data showed that the loss of both BMP9 and BMP10 leads to dramatic 
changes in blood vessel integrity where EC number is slightly increased but SMC coverage 
is significantly reduced leading to an increased vessel diameter. BP measurements also 
showed the DKO mice had a lower basal BP and administration of L-NAME failed to 
increase BP in these mice suggesting impaired vasoconstriction. These findings are 
interesting as current therapies for PH mainly target drugs with vasodilative properties and 
our results would suggest that antagonizing BMP9 and BMP10 may represent a therapeutic 
approach to treat PH patients. Gene array data from the DKO mice or stimulated HUVECs 
revealed the changes in gene expression of key factors, including eNOS, KDR, EDN1, 
thrombospondin1 (THBS1) and APLN which are regulated by TGFβ signalling, that regulate 
angiogenesis, inflammation and SMC proliferation; all of which are known to be involved in 
the development of PH. Since ALK1 was shown to antagonize the activities of TGFβ by 
controlling of EC function and ALK5 mediates proliferation of SMCs from patients with PH 
this raises the possibility that BMP9 and BMP10 induces vascular quiescence by 
antagonizing TGFβ signalling via cross-talk between ALK1 and ALK5 receptors 66. An 
explanation of these controversial and opposing results might be due to the differences in 
the mouse models used or the differences in time where we use a model with persistent loss 
of BMP9 and BMP10 and where they administer BMP9 over a short space of time. Taken 
together it is known that BMP9 and BMP10, via ALK1, are critical for vascular development 
and that changes in this signalling pathway leads to changes in vascular homeostasis and in 
some cases could be involved in the vascular pathogenesis of PH while could also be new 
potential therapeutic targets for the treatment of PH.  
During HF or MI, CMs undergo cell death due to lack of blood flow in a certain region 
of the heart resulting in an acute imbalance between oxygen supply and demand causing 
damage to the heart muscle 258. As mentioned previously MIs normally occur due to 
coronary artery disease where a blockage of a coronary artery could be a result of a 
ruptured atherosclerotic plaque or due to other obstructions. Numerous risk factors are 
involved which can include elevated BP, high blood cholesterol, side effect of diabetes, or 
life style choices like smoking, lack of exercise, obesity, poor diet, and excessive alcohol 
consumption 259. After MI, reperfusion is performed as an attempt to re-establish blood flow 
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to the damaged area, although during the early phase this may cause further injury as the 
recruitment and activation of inflammatory cells is needed for cardiac healing 251. The extent 
of post infarction remodelling depends largely on the size of the initial infarct and the quality 
of cardiac repair. A major issue to overcome after MI is the fact that CMs have a low 
regenerative capacity and after MI there is a loss of a large number of CMs, hence why scar 
formation is essential. The cardiac repair program is needed to clear the wound of dead cells 
and ECM debris, as well as providing molecular signals for activation of reparative cells 260. 
Incorrect timing or too long a duration can have fatal effects; while an increase in early 
inflammation can lead to ECM degradation resulting in cardiac rupturing, prolonged 
inflammation can impair collagen deposition leading to weak scar formation resulting in 
chamber dilation. Enhanced severe inflammation activates proapoptotic signalling increasing 
the loss of CMs and lastly defective containment of the inflammation response results in an 
expansion into the non-infarcted area which enhances fibrosis and decreases cardiac 
performance 260. Numerous different cell groups are vital for the initial response however 
evidence also supports the theory that other cells, such as neutrophils, mononuclear cells, 
ECs, and pericytes, also contribute to the suppression and resolution phase of the 
inflammatory reaction 260. Here the importance of vascular cells, ECs and SMCs, and the 
role the vasculature is seen where ECs synthesize and present chemokines and adhesion 
molecules to allow for adhesion of inflammatory cells. An increase in angiogenesis is 
necessary to provide oxygen and nutrients to areas of damage to allow for healing and a 
reduction in infarct size and it has been shown that there is a high increase in EC number a 
few hours after infarction as these new vessels are highly permeable due to the lack of SMC 
coverage 261. Work by Ren et al. demonstrates that maturation of scar formation depends on 
the recruitment of mural cells which give stability to the scar and are also able to promote 
resolution as they repress granulation tissue formation 262.  
To date extensive work on the role of ALK1 has not been carried out although there is 
some evidence for its potential role in cardiac remodelling after MI. The main argument for 
this hypothesis is the known role that ALK1 plays in ECM expression and production in 
various cell types, such as myoblasts, fibroblasts and ECs, although ALK1’s role and effect 
is context dependent 263–265. No studies have been performed to understand the role of ALK1 
on cardiac fibroblasts and MI. However the role of ENG during cardiac remodelling has been 
studied. Mice heterozygous for Eng (Eng+/-) underwent thoracic aortic constriction (TAC), 
where a knot is tied around the transverse aorta to induce pressure overload HF, and were 
shown to have reduced cardiac fibrosis 266,267. Knowing that ALK1 and ENG work closely 
together to regulate gene expression indicates ALK1 could also regulate cardiac fibrosis. 
Again not much is known about ALK1 and the immune response but it has been shown that 
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ALK1 is expressed by macrophages and monocytes 268,269. Eng+/- mice that underwent renal 
ischaemia–reperfusion showed less signs of injury concluding that these mice may be 
protected from injury due to reduced endothelial activation and macrophage maturation 270. 
Recent reports have suggested the BMP9 plays a role in fibrosis in vitro where they 
demonstrated that BMP9 is a profibrotic factor in fibroblasts by promoting ECM protein 
expression through both, ALK1 and ALK5 receptors 172. Although in depths studies into 
BMP10 and its fibrotic potential have not been carried out, overexpression of BMP10 in a 
murine model was not associated with cardiac fibrosis but disrupted post-natal hypertrophic 
growth 189. 
After the initial response of ECM deposit and immune cell infiltration to ensure the 
least amount of damage, angiogenesis is needed in the damage area to ensure survival of 
the tissue. As a model of MI normally a permanent ligation of the left anterior descending 
artery (LAD) is carried out. The LAD is ligated with one single stitch, forming an ischemia 
that can be seen almost immediately. By closing the LAD, no further blood flow is permitted 
in that area, while the surrounding myocardial tissue is nearly not affected 271. Reperfusion of 
the ischemic area is essential in salvaging damaged tissue; therefore angiogenesis plays a 
major role in this process.  There are a number of important signalling pathways that are 
involved in myocardial angiogenesis after an infarction has occurred. One pathway involved 
is HIF1α that is activated under hypoxic conditions and can activate a number of target 
genes such as Vegf or Cxcl12, which are important for the angiogenic response and 
chemokine response of progenitor cells respectively 272. Two HIF isoforms, HIF1α and 
HIF2α, have been shown to be expressed in the early stages after MI in ECs, CMs and 
inflammatory cells, where mice that constantly express HIF1α in CMs have an improved 
cardiac performance which has been correlated to increased levels of VEGF and 
angiogenesis 273,274. Data from the gene array of stimulated HUVECs with BMP9 and BMP10 
showed that there was an increase in HIF1α expression while the gene array of the DKO 
hearts showed with a slight reduction in HIF1α levels. Studies in different cell culture 
conditions, such as mesenchymal stromal progenitor cells, have shown that BMP9 is able to 
induce HIF1α expression via SMAD1/5/8 and is important for angiogenic signalling 275. 
CXCR4, the receptor for CXCL12, was shown to protect mice after MI where Cxcr4 +/- mice 
had a smaller but more fibrotic scar that underwent an acute inflammatory response and an 
improved adaptation of cardiomyocytes 276. This response in these mice however was 
counter balanced by an impaired outgrowth of cells, myocardial neovascularization and 
coronary flow recovery after MI which ultimately resulted in a defective ventricular function 
276. Loss of BMP9 and BMP10 in the heart showed a dramatic decrease in Cxcl12 
expression while stimulated HUVECs saw a 2 fold increase in CXCL12 expression, 
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suggesting a role for BMP9 and BMP10 in cardiac remodelling after MI. Taken together 
these results show the BMP9 and BMP10 are able to regulate target genes important in the 
angiogenic processes needed after MI. 
VEGF family members also play a major role in post MI angiogenesis and are known 
to be rapidly expressed in the heart of humans and rodents following MI due to the hypoxic 
environment but also due to mechanical stress 277–279. Interactions between these family 
members are essential during different phases as VEGFA is able to initiate the formation of 
immature vessels but if the signalling is not switched off these vessels become leaky and 
disorganized as VEGFA can inhibit PDGFB signalling, altering mural cell recruitment, which 
is essential for vessel maturation 280–282. Another family member that is able to bind VEGFR1 
is Placental Growth Factor (PlGF) which activates angiogenesis after MI 283,284. Other family 
members such as VEGFB or VEGFC do not have such a clear role in angiogenesis after MI 
as other family members do. Rather than having a direct effect and role on angiogenesis 
VEGF-B could be more responsible for its prosurvival actions that may allow newly formed 
vessels to survive and mature in the damaged area allowing for the return of blood flow and 
preventing long term adverse remodelling 285. In the case of VEGFC it is known to play a role 
in lymphangiogenesis via VEGFR3 and early findings have suggested it may play a role in 
promoting angiogenesis in an indirect manner by promoting PDGFB expression which would 
allow for vessel maturation 285. Stimulation of HUVECs with BMP9 and BMP10 showed 
regulation of VEGFA, VEGFB and VEGFC, again implying the cross-talk that occurs 
between these two signalling pathways and the important role angiogenesis has in reducing 
damaged tissue after MI 208. Taken together this data could suggest that BMP9 and BMP10 
are involved in the repair response after MI seeing as other members of this super protein 
family have been reported to also be involved.  
Overall these results show the importance of a mature and stable vascular network for 
systemic vascular homeostasis but also how essential homeostasis is to prevent disease 
conditions and especially during remodelling and prevention of damage to an already 
deteriorating area. The role of BMP9 and BMP10 is clear in maintaining vascular quiescence 
in a normal situation where active angiogenesis is not needed. Loss of these two proteins 
under basal conditions leads to an increase in vessel dilation due to active ECs and a lack of 
SMC coverage which results in lower basal BP. This is turn increases blood volume within 
the vascular system which puts extra pressure on the heart causing the ventricles to 
increase in size. However under these circumstances the ventricular wall does not dilate and 
fibrosis does not occur therefore suggesting this is not a pathological response. Hypertrophy 
is due to the CMs increasing in size in response to the pressure of the extra blood within the 
system and lethality does not occur as cardiac function still remains with contracting, 
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functioning CMs. One possible downstream target that could have explained the different 
changes seen was Apln, as Apln expression increases when BMP9 and BMP10 are lost and 
in vitro stimulation of HUVECs with BMP9 and BMP10 leads to a drastic decrease in APLN 
levels. APLN has been shown to inhibit apoptosis in ECs which allows for an increase in 
angiogenic potential along with an increase in eNOS secretion, higher levels of eNOS signal 
to SMCs to allow for vasodilation but also an increase in APLN in SMCs directly blocks 
proliferation and recruitment of SMCs. APLN affects CMs by inducing hypertrophy but also 
keeping them contractile while preventing fibrosis and apoptosis. Taken together this could 
have explained much of what was seen in these DKO mice. Preliminary data in the TKO 
mice generated shows that loss of Apln in the DKO mice does not rescue them. This could 
be due to the fact that one gene cannot account for everything because multiple factors and 
signalling pathways are also known to play important roles in this hypertrophic response. 
Loss of BMP9 and BMP10 in a disease model may possess beneficial aspects. For example 
in PH where SMCs are affected and blood vessels are constricted causing elevation in BP 
and therefore RV hypertrophy and failure loss of these two proteins won’t allow for vascular 
constriction due to loss of SMC coverage and therefore may not develop severe cases of 
PH. Or even in MI where tissue damage has occurred, CMs may be protected from 
apoptosis and there hypertrophic response may allow for a reduction in scar formation, 
seeing as BMP9 has been proposed as a pro-fibrotic factor, but also due to the increase in 
vascular dilation and increase in angiogenesis allowing for better perfusion and access of 
nutrients to prevent tissue death.  
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9.3  Thesis perspective 
To date the direct role of BMP9 and BMP10 in maintaining cardiovascular homeostasis 
has not been addressed. In this thesis the first conditional BMP10 KO mouse and BMP9 and 
10 DKO mice were generated and used to answer essential questions regarding the function 
of BMP9 and BMP10 in angiogenesis and cardiac function as well as their overlapping roles. 
Loss of BMP9 and BMP10 leads to alterations in vascular structure characterised by an 
increase in active ECs and a reduction in SMC coverage, resulting in dilation of blood 
vessels. Changes in the vascular structure also lead to alterations in vascular 
hemodynamics, with a significantly reduced basal BP and an increased BF and BV. Global 
gene transcription analysis of DKO hearts and aortas showed an increase in genes involved 
in angiogenesis and epithelial cell migration while genes governing cell maturation and SMC 
division were reduced. In vitro data demonstrated that HUVECs stimulated with BMP9 and 
BMP10 resulted in a global upregulation of genes that are essential for vascular 
morphogenesis and EC differentiation while genes involved in cell cycle regulation and 
division were downregulated. Overall these results clearly show that BMP9 and BMP10 play 
an important role in adult vascular morphogenesis and in maintaining vascular stability. 
Further, it is very likely that this disruption to vascular homeostasis is responsible for the 
cardiac defects observed in DKO mice, namely; a significant decrease in EF and an increase 
in SV and LVM. Increased pre-load as a result of higher blood volume and flow leads to an 
overall hypertrophic response, essentially an adaptation to the changes in vascular 
hemodynamics.  
These results show how BMP9 and BMP10 function to mediate the intrinsic relationship 
between the cardiovascular system and cardiac remodelling and function. This new DKO 
model will be extremely useful for understanding the molecular mechanisms responsible for 
the development of vascular diseases such as HHT, atherosclerosis and vascular 
calcification as well as other diseases such as in PH or MI. Future development of agonists 
or antagonists for BMP9 and BMP10 may serve as a novel therapeutic approach to target 
this group of diseases.   
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11 Supplementary Figures 
 
11.1  Biological processes upregulated in stimulated HUVECs 
 
(A) GO analysis for biological processes upregulated in HUVECs stimulated with BMP9 and BMP10 have changes in blood vessel 
morphogenesis, SMAD signalling and cell differentiation.  
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11.2  Biological processes downregulated in stimulated HUVECs 
(B) GO analysis for biological processes downregulated in HUVECs stimulated with BMP9 and BMP10 included regulation of cell cycle and cell 
division. 
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11.3  Biological processes upregulated in DKO hearts 
 
(C) GO analysis for biological processes upregulated in DKO hearts compared to WT at 2 months of age, where genes involved in GPCR 
signalling, angiogenesis and epithelial cell migration were upregulated. 
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11.4  Biological processes upregulated in DKO hearts and downregulated in stimulated HUVECs 
 
(D) GO analysis of genes highly expressed in DKO hearts but have low expression in stimulated HUVECs shows changes in genes mainly 
involved in cell division and cycle.
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